



HU000026280T2

(19) **HU****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala(11) Lajstromszám: **E 026 280**(13) **T2**

EURÓPAI SZABADALOM

SZÖVEGÉNEK FORDÍTÁSA

- (21) Magyar ügyszám: **E 10 741789**
(22) A bejelentés napja: **2010. 02. 12.**
(96) Az európai bejelentés bejelentési száma:
EP 20100741789
(97) Az európai bejelentés közzétételi adatai:
EP 2396038 A2 **2010. 08. 19.**
(97) Az európai szabadalom megadásának meghirdetési adatai: **EP 2396038 B1** **2015. 10. 21.**
(51) Int. Cl.: **C12N 151/13** (2006.01)
A61K 3170/88 (2006.01)
A61K 317/12 (2006.01)
A61P 25/00 (2006.01)
A61P 25/16 (2006.01)
A61P 25/28 (2006.01)
(86) A nemzetközi (PCT) bejelentési szám: **PCT/US 10/024075**
(87) A nemzetközi közzétételi szám: **WO 10093904**

(30) Elsőbbségi adatok: 152132 P 2009. 02. 12. US	(73) Jogosult(ak): CuRNA, Inc., Miami, FL 33137 (US)
(72) Feltaláló(k): COLLARD, Joseph, Delray Beach, FL 33483 (US) KHORKOVA SHERMAN, Olga, Tequesta, FL 33469 (US) COITO, Carlos, West Palm Beach, FL 33417 (US)	(74) Képviselő: KOVÁRI ÉS TÁRSAI Szabadalmi és Védjegy Iroda Kft., Budapest

- (54) **Agyi eredetű neurotróf faktorról (brain-derived neurotrophic factor, BDNF) összefüggő betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11)

EP 2 396 038 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
21.10.2015 Bulletin 2015/43

(51) Int Cl.:
C12N 15/113 ^(2010.01) **A61K 31/7088** ^(2006.01)
A61K 31/712 ^(2006.01) **A61P 25/16** ^(2006.01)
A61P 25/28 ^(2006.01) **A61P 25/00** ^(2006.01)

(21) Application number: **10741789.1**

(86) International application number:
PCT/US2010/024075

(22) Date of filing: **12.02.2010**

(87) International publication number:
WO 2010/093904 (19.08.2010 Gazette 2010/33)

(54) **TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF**

BEHANDLUNG VON ERKRANKUNGEN IM ZUSAMMENHANG MIT DEM BRAIN-DERIVED NEUROTROPHEN FAKTOR (BDNF) MITTELS HEMMUNG DES NATÜRLICHEN ANTISENSE-TRANSKRIPTS GEGEN BDNF

TRAITEMENT DES MALADIES ASSOCIÉES AU FACTEUR NEUROTROPHIQUE DÉRIVÉ DU CERVEAU (BDNF) PAR INHIBITION DU PRODUIT ANTISENS NATUREL DE LA TRANSCRIPTION EN BDNF

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK SM TR**

US-A1- 2002 193 335

(30) Priority: **12.02.2009 US 152132 P**

(43) Date of publication of application:
21.12.2011 Bulletin 2011/51

(73) Proprietor: **CuRNA, Inc.
Miami, FL 33137 (US)**

(72) Inventors:
• **COLLARD, Joseph**
Delray Beach, FL 33483 (US)
• **KHORKOVA SHERMAN, Olga**
Tequesta, FL 33469 (US)
• **COITO, Carlos**
West Palm Beach, FL 33417 (US)

(74) Representative: **Evenson, Jane Harriet et al
Mathys & Squire LLP
The Shard
32 London Bridge Street
London SE1 9SG (GB)**

(56) References cited:
WO-A1-98/01573 WO-A2-2006/072005

- **PRUUNSILDE ET AL:** "Dissecting the human BDNF locus: Bidirectional transcription, complex splicing, and multiple promoters", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 90, no. 3, 1 August 2007 (2007-08-01), pages 397-406, XP022182854, ISSN: 0888-7543, DOI: 10.1016/J.YGENO.2007.05.004
- **BEITER T ET AL:** "Antisense transcription: A critical look in both directions", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHÄUSER-VERLAG, BA, vol. 66, no. 1, 15 September 2008 (2008-09-15), pages 94-112, XP019700754, ISSN: 1420-9071
- **LIU ET AL:** "Rodent BDNF genes, novel promoters, novel splice variants, and regulation by cocaine", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1067, no. 1, 5 January 2006 (2006-01-05), pages 1-12, XP005263562, ISSN: 0006-8993, DOI: 10.1016/J.BRAINRES. 2005.10.004

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 396 038 B1

- QING-RONG LIU ET AL: "Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease", AMERICAN JOURNAL OF MEDICAL GENETICS. PART B: NEUROPSYCHIATRIC GENETICS, JOHN WILEY & SONS, INC, US, vol. 134B, no. 1, 1 January 2005 (2005-01-01), pages 93-103, XP008129266, ISSN: 1552-485X, DOI: 10.1002/AJMG.B.30109
- LIU Q R ET AL: "Differential regulation of sense and antisense human BDNF/BDNFOS genes and rodent BDNF gene: Possible roles in Alzheimer's disease and addictions", INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, PERGAMON, OXFORD, GB, vol. 24, no. 8, 1 December 2006 (2006-12-01), page 559, XP028007780, ISSN: 0736-5748, DOI: 10.1016/J.IJDEVNEU.2006.09.208 [retrieved on 2006-12-01]
- TAMURA MAKOTO ET AL: "Influence of brain-derived neurotrophic factor on pathfinding of dentate granule cell axons, the hippocampal mossy fibers", MOLECULAR BRAIN, BIOMED CENTRAL LTD, LONDON UK, vol. 2, no. 1, 31 January 2009 (2009-01-31), page 2, XP021052896, ISSN: 1756-6606, DOI: 10.1186/1756-6606-2-2
- CHIKAR J A ET AL: "Over-expression of BDNF by adenovirus with concurrent electrical stimulation improves cochlear implant thresholds and survival of auditory neurons", HEARING RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 245, no. 1-2, 1 November 2008 (2008-11-01), pages 24-34, XP025627566, ISSN: 0378-5955, DOI: 10.1016/J.HEARES.2008.08.005 [retrieved on 2008-08-19]
- KUSUMIKA GHARAMI ET AL: "Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice", JOURNAL OF NEUROCHEMISTRY, vol. 105, no. 2, 1 April 2008 (2008-04-01), pages 369-379, XP055054048, ISSN: 0022-3042, DOI: 10.1111/j.1471-4159.2007.05137.x
- N. MELLIOS ET AL: "A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex", HUMAN MOLECULAR GENETICS, vol. 17, no. 19, 1 January 2008 (2008-01-01), pages 3030-3042, XP055053999, ISSN: 0964-6906, DOI: 10.1093/hmg/ddn201
- FARZANEH MODARRESI ET AL: "Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation", NATURE BIOTECHNOLOGY, vol. 30, no. 5, 1 January 2012 (2012-01-01), pages 453-459, XP055052745, ISSN: 1087-0156, DOI: 10.1038/nbt.2158
- PLOUGHMAN, M. ET AL.: 'Brain-Derived Neurotrophic Factor contributes to recovery of skilled reaching after focal Ischemia in rats.' STROKE. vol. 40, 22 January 2009, pages 1490 - 1495, XP055050855
- KANDIMALLA, E. R. ET AL.: 'Design, biochemical, biophysical and biological properties of cooperative antisense oligonucleotides.' NUCLEIC ACIDS RESEARCH vol. 23, no. 17, 1995, pages 3578 - 3584, XP002037285
- CHAN, J. H. P. ET AL.: 'Antisense oligonucleotides: from design to therapeutic application.' CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY. vol. 33, 2006, pages 533 - 540, XP008158920
- BRAASCH, D. A. ET AL.: 'Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression.' BIOCHEMISTRY vol. 41, no. 14, 09 April 2002, pages 4503 - 4510, XP002975681
- Y. Zhang ET AL: "NATsDB: Natural Antisense Transcripts DataBase", Nucleic Acids Research, vol. 35, no. Database, 3 January 2007 (2007-01-03), pages D156-D161, XP055069289, ISSN: 0305-1048, DOI: 10.1093/nar/gkl782
- Bradley W. Kesser ET AL: "Gene Transfer in Human Vestibular Epithelia and the Prospects for Inner Ear Gene Therapy", The Laryngoscope, vol. 118, no. 5, 1 May 2008 (2008-05-01), pages 821-831, XP055155006, ISSN: 0023-852X, DOI: 10.1097/MLG.0b013e318164d0aa
- CHANG QIANG ET AL: "The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression", NEURON, CELL PRESS, US, vol. 49, no. 3, 2 February 2006 (2006-02-02), pages 341-348, XP002510445, ISSN: 0896-6273, DOI: 10.1016/J.NEURON.2005.12.027
- Shih-Jen Tsai: "Brain-derived neurotrophic factor: a bridge between major depression and Alzheimer's disease?", Medical Hypotheses, vol. 61, no. 1, 1 July 2003 (2003-07-01), pages 110-113, XP055155017, ISSN: 0306-9877, DOI: 10.1016/S0306-9877(03)00141-5
- TAKEBAYASHI MINORU ET AL: "Decreased levels of whole blood glial cell line-derived neurotrophic factor (GDNF) in remitted patients with mood disorders", INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, CAMBRIDGE UNIV. PRESS, CAMBRIDGE, vol. 9, no. 5, 1 October 2006 (2006-10-01), pages 607-612, XP008173605, ISSN: 1461-1457, DOI: 10.1017/S1461145705006085 [retrieved on 2005-09-28]

- GUIARD BRUNO P ET AL: "Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype", INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, CAMBRIDGE UNIV. PRESS, CAMBRIDGE, vol. 11, no. 1, 1 February 2008 (2008-02-01), pages 79-92, XP008173607, ISSN: 1461-1457, DOI: 10.1017/S1461145707007857 [retrieved on 2007-06-11]
- Lioudmila Novikova ET AL: "Effects of Neurotransplants and BDNF on the Survival and Regeneration of Injured Adult Spinal Motoneurons", European Journal of Neuroscience, vol. 9, no. 12, 1 December 1997 (1997-12-01), pages 2774-2777, XP055155014, ISSN: 0953-816X, DOI: 10.1111/j.1460-9568.1997.tb01706.x
- I Kiprianova: "Brain-Derived Neurotrophic Factor Improves Long-Term Potentiation and Cognitive Functions after Transient Forebrain Ischemia in the Rat", Experimental Neurology, vol. 159, no. 2, 1 October 1999 (1999-10-01), pages 511-519, XP055155016, ISSN: 0014-4886, DOI: 10.1006/exnr.1999.7109

- Joan C. Han ET AL: "Brain-Derived Neurotrophic Factor and Obesity in the WAGR Syndrome", New England Journal of Medicine, vol. 359, no. 9, 28 August 2008 (2008-08-28), pages 918-927, XP055155011, ISSN: 0028-4793, DOI: 10.1056/NEJMoa0801119

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Description**CROSS REFERENCE**

5 [0001] This application claims the benefit of U.S. Provisional Application No. 61/152,132 filed February 12, 2009.

FIELD OF THE DISCLOSURE

10 [0002] Instances of the disclosure comprise oligonucleotides modulating expression and/or function of BDNF and associated molecules.

BACKGROUND

15 [0003] DNA-RNA and RNA-RNA hybridization are important to many aspects of nucleic acid function including DNA replication, transcription, and translation. Hybridization is also central to a variety of technologies that either detect a particular nucleic acid or alter its expression. Antisense nucleotides, for example, disrupt gene expression by hybridizing to target RNA, thereby interfering with RNA splicing, transcription, translation, and replication. Antisense DNA has the added feature that DNA-RNA hybrids serve as a substrate for digestion by ribonuclease H, an activity that is present in most cell types. Antisense molecules can be delivered into cells, as is the case for oligodeoxynucleotides (ODNs), or they can be expressed from endogenous genes as RNA molecules. The FDA recently approved an antisense drug, VITRAVENE™ (for treatment of cytomegalovirus retinitis), reflecting that antisense has therapeutic utility.

20 Pruunsild et al. 2007 (Genomics, vol.90(3):397-406) describe dissecting the human BDNF locus: bidirectional transcription, complex splicing and multiple promoters.

25 Beiter et al. 2008 (Cellular and Molecular Life Sciences, vol. 66(1):94-112) describe antisense transcription: a critical look in both directions.

Liu et al. 2006 (Brain Research, vol. 1067(1):1-12) describe rodent BDNF genes, novel promoters, splice variants and regulation by cocaine.

30 Qing-Rong Liu et al. 2005 (American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, vol. 134B(1):93-103) describe human BDNF genes, splicing patterns and assessments of associations with substance abuse and Parkinson's disease.

Liu et al. 2006 (International Journal of Developmental Neuroscience, vol. 24(8):559) describe differential regulation of sense and antisense human BDNF/BDNFOS genes and rodent BDNF gene: possible roles in Alzheimer's disease and addictions.

WO 98/01573 describes transformation-associated recombinant cloning.

35 WO 2006/072005 describes methods for high efficiency survival/proliferation of human embryonic stem cells and human embryo survival in culture.

SUMMARY OF THE INVENTION

40 [0004] The invention is defined by the claims. Those aspects/ instances of the present disclosure which constitute the invention are defined by the claims.

SUMMARY OF THE DISCLOSURE

45 [0005] This Summary is provided to present a summary of the disclosure to briefly indicate the nature and substance of the disclosure.

[0006] In one instance, the disclosure provides methods for inhibiting the action of a natural antisense transcript by using antisense oligonucleotide(s) targeted to any region of the natural antisense transcript resulting in up-regulation of the corresponding sense gene. It is also contemplated herein that inhibition of the natural antisense transcript can be achieved by siRNA, ribozymes and small molecules, which are considered to be within the scope of the present disclosure.

50 [0007] One instance provides a method of modulating function and/or expression of an BDNF polynucleotide in patient cells or tissues *in vivo* or *in vitro* comprising contacting said cells or tissues with an antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 3175 of SEQ ID NO: 2 (Figure 3) thereby modulating function and/or expression of the BDNF polynucleotide in patient cells or tissues *in vivo* or *in vitro*.

55 [0008] In another preferred instance, an oligonucleotide targets a natural antisense sequence of BDNF polynucleotides, for example, nucleotides set forth in SEQ ID NO: 2, and any variants, alleles, homo logs, mutants, derivatives, fragments and complementary sequences thereto. Examples of antisense oligonucleotides are set forth as SEQ ID NOS: 3 to 8

(Figure 4).

[0009] Another instance provides a method of modulating function and/or expression of an BDNF polynucleotide in patient cells or tissues in vivo or in vitro comprising contacting said cells or tissues with an antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to a reverse complement of the an antisense of the BDNF polynucleotide; thereby modulating function and/or expression of the BDNF polynucleotide in patient cells or tissues in vivo or in vitro.

[0010] Another instance provides a method of modulating function and/or expression of an BDNF polynucleotide in patient cells or tissues in vivo or in vitro comprising contacting said cells or tissues with an antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to an antisense oligonucleotide to an BDNF antisense polynucleotide; thereby modulating function and/or expression of the BDNF polynucleotide in patient cells or tissues in vivo or in vitro.

[0011] In a preferred instance, a composition comprises one or more antisense oligonucleotides which bind to sense and/or antisense BDNF polynucleotides.

[0012] In another preferred instance, the oligonucleotides comprise one or more modified or substituted nucleotides.

[0013] In another preferred instance, the oligonucleotides comprise one or more modified bonds.

[0014] In yet another instance, the modified nucleotides comprise modified bases comprising phosphorothioate, methylphosphonate, peptide nucleic acids, 2'-O-methyl, fluoro- or carbon, methylene or other locked nucleic acid (LNA) molecules. Preferably, the modified nucleotides are locked nucleic acid molecules, including α -L-LNA.

[0015] In another preferred instance, the oligonucleotides are administered to a patient subcutaneously, intramuscularly, intravenously or intraperitoneally.

[0016] In another preferred instance, the oligonucleotides are administered in a pharmaceutical composition. A treatment regimen comprises administering the antisense compounds at least once to patient; however, this treatment can be modified to include multiple doses over a period of time. The treatment can be combined with one or more other types of therapies.

[0017] In another preferred instance, the oligonucleotides are encapsulated in a liposome or attached to a carrier molecule (e.g. cholesterol, TAT peptide).

[0018] Other aspects are described *infra*.

BRIEF DESCRIPTION OF THE DRAWINGS

[0019]

Figure 1

Figure 1 A: is a graph of real time PCR results showing the fold change + standard deviation in BDNF mRNA after treatment of HepG2 cells with LNA gapmer phosphorothioate oligonucleotides introduced using Lipofectamine 2000, as compared to control. Real time PCR results show that the levels of the BDNF mRNA in HepG2 cells are significantly increased 48 h after treatment with two of the LNA gapmers with fully phosphothioated backbone designed to BDNF antisense NM_170735 (CUR-0071, P=0.04, CUR-0073, P=0.07, CUR-0075, P=0.03). Bars denoted as CUR-0071, CUR-0072, CUR-0073, CUR-0074, CUR-0075 and CUR-0076 correspond to samples treated with SEQ ID NOS: 6, 7, 8, 3, 4 and 5, respectively.

Figure 1 B: is a graph of real time PCR results showing the fold change + standard deviation in BDNF mRNA after treatment of HepG2 cells with phosphorothioate oligonucleotides introduced using Lipofectamine 2000, as compared to control. Real time PCR results show that the levels of BDNF antisense were significantly decreased after treatment with all oligos except CUR-0072, which is possibly due to different oligos affecting different splice variants of BDNF and/or BDNF antisense NM_170735. Bars denoted as CUR-0071, CUR-0072, CUR-0073, CUR-0074, CUR-0075 and CUR-0076 correspond to samples treated with SEQ ID NOS: 6, 7, 8, 3, 4 and 5, respectively.

Figure 1 C: is a graph of real time PCR results showing the fold change + standard deviation in BDNF mRNA after treatment of CHP212 cells with LNA gapmer-phosphorothioate oligonucleotides introduced using Lipofectamine 2000, as compared to control. Real time PCR results show that the levels of the BDNF mRNA in CHP212 cells are significantly increased 48 h after treatment with two of the LNA gapmers with fully phosphothioated backbone designed to BDNF antisense NM_170735. Bars denoted as CUR-0071, CUR-0072, and CUR-0076 correspond to samples treated with SEQ ID NOS: 6, 7, and 3, respectively.

Figure 2 shows SEQ ID NO: 1: Homo sapiens brain-derived neurotrophic factor (BDNF), transcript variant 1, mRNA.

(NCBI Accession No.: NM_170735) and SEQ ID NO: 11 shows the genomic sequence of BDNF (exons are shown in capital letters, introns in small).

Figure 3 shows SEQ ID NO: 2: Natural BDNF antisense sequence (NR_002832.1) Homo sapiens BDNF opposite strand (non-protein coding) (BDNFOS), non-coding RNA.

Figure 4 shows the antisense oligonucleotides, SEQ ID NOS: 3 to 8. * indicates phosphothioate bond and + indicates LNA modification.

Figure 5 shows SEQ ID NOS: 9 and 10.

DETAILED DESCRIPTION OF THE DISCLOSURE

[0020] Several aspects of the disclosure are described below with reference to example applications for illustration. It should be understood that numerous specific details, relationships, and methods are set forth to provide a full understanding of the disclosure. One having ordinary skill in the relevant art, however, will readily recognize that the disclosure can be practiced without one or more of the specific details or with other methods. The present disclosure is not limited by the ordering of acts or events, as some acts may occur in different orders and/or concurrently with other acts or events. Furthermore, not all illustrated acts or events are required to implement a methodology in accordance with the present disclosure.

[0021] All genes, gene names, and gene products disclosed herein are intended to correspond to homologs from any species for which the compositions and methods disclosed herein are applicable. Thus, the terms include, but are not limited to genes and gene products from humans and mice. It is understood that when a gene or gene product from a particular species is disclosed, this disclosure is intended to be exemplary only, and is not to be interpreted as a limitation unless the context in which it appears clearly indicates. Thus, for example, for the genes disclosed herein, which in some instances relate to mammalian nucleic acid and amino acid sequences are intended to encompass homologous and/or orthologous genes and gene products from other animals including, but not limited to other mammals, fish, amphibians, reptiles, and birds. In preferred instances, the genes or nucleic acid sequences are human.

Definitions

[0022] The terminology used herein is for the purpose of describing particular instances only and is not intended to be limiting of the disclosure. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms "including", "includes", "having", "has", "with", or variants thereof are used in either the detailed description and/or the claims, such terms are intended to be inclusive in a manner similar to the term "comprising."

[0023] The term "about" or "approximately" means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, "about" can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and more preferably still up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term "about" meaning within an acceptable error range for the particular value should be assumed.

[0024] As used herein, the term "mRNA" means the presently known mRNA transcript(s) of a targeted gene, and any further transcripts which may be elucidated.

[0025] By "antisense oligonucleotides" or "antisense compound" is meant an RNA or DNA molecule that binds to another RNA or DNA (target RNA, DNA). For example, if it is an RNA oligonucleotide it binds to another RNA target by means of RNA-RNA interactions and alters the activity of the target RNA (Eguchi et al., (1991) Ann. Rev. Biochem. 60, 631-652). An antisense oligonucleotide can upregulate or downregulate expression and/or function of a particular polynucleotide. The definition is meant to include any foreign RNA or DNA molecule which is useful from a therapeutic, diagnostic, or other viewpoint. Such molecules include, for example, antisense RNA or DNA molecules, interference RNA (RNAi), micro RNA, decoy RNA molecules, siRNA, enzymatic RNA, therapeutic editing RNA and agonist and antagonist RNA, antisense oligomeric compounds, antisense oligonucleotides, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other oligomeric compounds that hybridize to at least a portion of the target nucleic acid. As such, these compounds may be introduced in the form of single-stranded, double-stranded, partially single-stranded, or circular oligomeric compounds.

[0026] In the context of this disclosure, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid

(RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. The term "oligonucleotide", also includes linear or circular oligomers of natural and/or modified monomers or linkages, including deoxyribonucleosides, ribonucleosides, substituted and alpha-anomeric forms thereof, peptide nucleic acids (PNA), locked nucleic acids (LNA), phosphorothioate, methylphosphonate, and the like. Oligonucleotides are capable of specifically binding to a target polynucleotide by way of a regular pattern of monomer-to-monomer interactions, such as Watson-Crick type of base pairing, Hoogsteen or reverse Hoogsteen types of base pairing, or the like.

[0027] The oligonucleotide may be "chimeric", that is, composed of different regions. In the context of this disclosure "chimeric" compounds are oligonucleotides, which contain two or more chemical regions, for example, DNA region(s), RNA region(s), PNA region(s) etc. Each chemical region is made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotides compound. These oligonucleotides typically comprise at least one region wherein the oligonucleotide is modified in order to exhibit one or more desired properties. The desired properties of the oligonucleotide include, but are not limited, for example, to increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. Different regions of the oligonucleotide may therefore have different properties. The chimeric oligonucleotides of the present disclosure can be formed as mixed structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide analogs as described above.

[0028] The oligonucleotide can be composed of regions that can be linked in "register", that is, when the monomers are linked consecutively, as in native DNA, or linked via spacers. The spacers are intended to constitute a covalent "bridge" between the regions and have in preferred cases a length not exceeding about 100 carbon atoms. The spacers may carry different functionalities, for example, having positive or negative charge, carry special nucleic acid binding properties (intercalators, groove binders, toxins, fluorophores etc.), being lipophilic, inducing special secondary structures like, for example, alanine containing peptides that induce alpha-helices.

[0029] As used herein "BDNF" and "Brain derived neurotrophic factor" are inclusive of all family members, mutants, alleles, fragments, species, coding and noncoding sequences, sense and antisense polynucleotide strands, etc.

[0030] As used herein, the words 'Brain derived neurotrophic factor', 'Brain-derived neurotrophic factor' and BDNF, are used interchangeably in the present application.

[0031] As used herein, the term "oligonucleotide specific for" or "oligonucleotide which targets" refers to an oligonucleotide having a sequence (i) capable of forming a stable complex with a portion of the targeted gene, or (ii) capable of forming a stable duplex with a portion of a mRNA transcript of the targeted gene. Stability of the complexes and duplexes can be determined by theoretical calculations and/or in vitro assays. Exemplary assays for determining stability of hybridization complexes and duplexes are described in the Examples below.

[0032] As used herein, the term "target nucleic acid" encompasses DNA, RNA (comprising premRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA, coding, noncoding sequences, sense or antisense polynucleotides. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds, which specifically hybridize to it, is generally referred to as "antisense". The functions of DNA to be interfered include, for example, replication and transcription. The functions of RNA to be interfered, include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of an encoded product or oligonucleotides.

[0033] RNA interference "RNAi" is mediated by double stranded RNA (dsRNA) molecules that have sequence-specific homology to their "target" nucleic acid sequences (Caplen, N. J., et al. (2001) Proc. Natl. Acad. Sci. USA 98:9742-9747). In certain instances of the present disclosure, the mediators are 5-25 nucleotide "small interfering" RNA duplexes (siRNAs). The siRNAs are derived from the processing of dsRNA by an RNase enzyme known as Dicer (Bernstein, E., et al. (2001) Nature 409:363-366). siRNA duplex products are recruited into a multi-protein siRNA complex termed RISC (RNA Induced Silencing Complex). Without wishing to be bound by any particular theory, a RISC is then believed to be guided to a target nucleic acid (suitably mRNA), where the siRNA duplex interacts in a sequence-specific way to mediate cleavage in a catalytic fashion (Bernstein, E., et al. (2001) Nature 409:363-366; Boutla, A., et al. (2001) Curr. Biol. 11:1776-1780). Small interfering RNAs that can be used in accordance with the present disclosure can be synthesized and used according to procedures that are well known in the art and that will be familiar to the ordinarily skilled artisan. Small interfering RNAs for use in the methods of the present disclosure suitably comprise between about 1 to about 50 nucleotides (nt). In examples of non limiting instances, siRNAs can comprise about 5 to about 40 nt, about 5 to about 30 nt, about 10 to about 30 nt, about 15 to about 25 nt, or about 20-25 nucleotides.

[0034] Selection of appropriate oligonucleotides is facilitated by using computer programs that automatically align nucleic acid sequences and indicate regions of identity or homology. Such programs are used to compare nucleic acid sequences obtained, for example, by searching databases such as GenBank or by sequencing PCR products. Comparison of nucleic acid sequences from a range of species allows the selection of nucleic acid sequences that display an appropriate degree of identity between species. In the case of genes that have not been sequenced, Southern blots

are performed to allow a determination of the degree of identity between genes in target species and other species. By performing Southern blots at varying degrees of stringency, as is well known in the art, it is possible to obtain an approximate measure of identity. These procedures allow the selection of oligonucleotides that exhibit a high degree of complementarity to target nucleic acid sequences in a subject to be controlled and a lower degree of complementarity to corresponding nucleic acid sequences in other species. One skilled in the art will realize that there is considerable latitude in selecting appropriate regions of genes for use in the present disclosure.

[0035] By "enzymatic RNA" is meant an RNA molecule with enzymatic activity (Cech, (1988) J. American. Med. Assoc. 260, 3030-3035). Enzymatic nucleic acids (ribozymes) act by first binding to a target RNA. Such binding occurs through the target binding portion of an enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through base pairing, and once bound to the correct site, acts enzymatically to cut the target RNA.

[0036] By "decoy RNA" is meant an RNA molecule that mimics the natural binding domain for a ligand. The decoy RNA therefore competes with natural binding target for the binding of a specific ligand. For example, it has been shown that over-expression of HIV trans-activation response (TAR) RNA can act as a "decoy" and efficiently binds HIV tat protein, thereby preventing it from binding to TAR sequences encoded in the HIV RNA (Sullenger et al. (1990) Cell, 63, 601- 608). This is meant to be a specific example. Those in the art will recognize that this is but one example, and other instances can be readily generated using techniques generally known in the art.

[0037] As used herein, the term "monomers" typically indicates monomers linked by phosphodiester bonds or analogs thereof to form oligonucleotides ranging in size from a few monomeric units, e.g., from about 3-4, to about several hundreds of monomeric units. Analogs of phosphodiester linkages include: phosphorothioate, phosphorodithioate, methylphosphonates, phosphoroselenoate, phosphoramidate, and the like, as more fully described below.

[0038] The term "nucleotide" covers naturally occurring nucleotides as well as nonnaturally occurring nucleotides. It should be clear to the person skilled in the art that various nucleotides which previously have been considered "non-naturally occurring" have subsequently been found in nature. Thus, "nucleotides" includes not only the known purine and pyrimidine heterocycles-containing molecules, but also heterocyclic analogues and tautomers thereof. Illustrative examples of other types of nucleotides are molecules containing adenine, guanine, thymine, cytosine, uracil, purine, xanthine, diaminopurine, 8-oxo- N6-methyladenine, 7-deazaxanthine, 7-deazaguanine, N4,N4-ethanocytosin, N6,N6-ethano-2,6-diaminopurine, 5-methylcytosine, 5-(C3-C6)-alkynylcytosine, 5-fluorouracil, 5-bromouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridin, isocytosine, isoguanin, inosine and the "non-naturally occurring" nucleotides described in Benner et al., U.S. Pat No. 5,432,272. The term "nucleotide" is intended to cover every and all of these examples as well as analogues and tautomers thereof. Especially interesting nucleotides are those containing adenine, guanine, thymine, cytosine, and uracil, which are considered as the naturally occurring nucleotides in relation to therapeutic and diagnostic application in humans. Nucleotides include the natural 2'-deoxy and 2'-hydroxyl sugars, e.g., as described in Kornberg and Baker, DNA Replication, 2nd Ed. (Freeman, San Francisco, 1992) as well as their analogs.

[0039] "Analog" in reference to nucleotides includes synthetic nucleotides having modified base moieties and/or modified sugar moieties (see e.g., described generally by Scheit, Nucleotide Analogs, John Wiley, New York, 1980; Freier & Altmann, (1997) Nucl. Acid. Res., 25(22), 4429- 4443, Toulmé, J.J., (2001) Nature Biotechnology 19:17-18; Manoharan M., (1999) Biochemica et Biophysica Acta 1489:117-139; Freier S. M., (1997) Nucleic Acid Research, 25:4429-4443, Uhlman, E., (2000) Drug Discovery & Development, 3: 203-213, Herdewin P., (2000) Antisense & Nucleic Acid Drug Dev., 10:297-310); 2'-O, 3'-C-linked [3.2.0] bicycloarabinonucleosides (see e.g. N.K Christensen., et al, (1998) J. Am. Chem. Soc., 120: 5458-5463; Prakash TP, Bhat B. (2007) Curr Top Med Chem. 7(7):641-9; Cho EJ, et al. (2009) Annual Review of Analytical Chemistry, 2, 241-264). Such analogs include synthetic nucleotides designed to enhance binding properties, e.g., duplex or triplex stability, specificity, or the like.

[0040] As used herein, "hybridization" means the pairing of substantially complementary strands of oligomeric compounds. One mechanism of pairing involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases (nucleotides) of the strands of oligomeric compounds. For example, adenine and thymine are complementary nucleotides which pair through the formation of hydrogen bonds. Hybridization can occur under varying circumstances.

[0041] An antisense compound is "specifically hybridizable" when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a modulation of function and/or activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and under conditions in which assays are performed in the case of in vitro assays.

[0042] As used herein, the phrase "stringent hybridization conditions" or "stringent conditions" refers to conditions under which a compound of the disclosure will hybridize to its target sequence, but to a minimal number of other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances and in the context of this disclosure, "stringent conditions" under which oligomeric compounds hybridize to a target sequence are determined by the nature and composition of the oligomeric compounds and the assays in which they are being inves-

5 titated. In general, stringent hybridization conditions comprise low concentrations ($<0.15\text{M}$) of salts with inorganic cations such as Na^{++} or K^{++} (i.e., low ionic strength), temperature higher than 20°C - 25°C below the T_m of the oligomeric compound:target sequence complex, and the presence of denaturants such as formamide, dimethylformamide, dimethyl sulfoxide, or the detergent sodium dodecyl sulfate (SDS). For example, the hybridization rate decreases 1.1% for each

10 **[0043]** "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides on one or two oligomeric strands. For example, if a nucleobase at a certain position of an antisense compound is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, said target nucleic acid being a DNA, RNA, or oligonucleotide molecule, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be a complementary position. The oligomeric compound and the further DNA, RNA, or oligonucleotide molecule are complementary to each other when a sufficient number of complementary positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of precise pairing or complementarity over a

15 sufficient number of nucleotides such that stable and specific binding occurs between the oligomeric compound and a target nucleic acid.
[0044] It is understood in the art that the sequence of an oligomeric compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. Moreover, an oligonucleotide may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure, mismatch or hairpin structure). The oligomeric compounds of the present disclosure comprise at least about 20 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 99% sequence complementarity to a target region within the target nucleic acid sequence to which they are targeted. For example, an antisense compound in which 18 of 20 nucleotides of the antisense compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining noncomplementary nucleotides may be clustered or interspersed with complementary nucleotides and need not be contiguous to each other or to complementary nucleotides. As such, an antisense compound which is 18 nucleotides in length having 4 (four) noncomplementary nucleotides which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would thus fall within the scope of the present disclosure. Percent complementarity of an antisense 30 compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul et al., (1990) J. Mol. Biol., 215, 403-410; Zhang and Madden, (1997) Genome Res., 7, 649-656). Percent homology, sequence identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., (1981) 2, 482-489).

35 **[0045]** As used herein, the term "Thermal Melting Point (T_m)" refers to the temperature, under defined ionic strength, pH, and nucleic acid concentration, at which 50% of the oligonucleotides complementary to the target sequence hybridize to the target sequence at equilibrium. Typically, stringent conditions will be those in which the salt concentration is at least about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 40 30°C for short oligonucleotides (e.g., 10 to 50 nucleotide). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.

[0046] As used herein, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene.

45 **[0047]** The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to a wild type gene. This definition may also include, for example, "allelic," "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. Of particular utility in the disclosure are variants of wild 50 type gene products. Variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes that give rise to variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

55 **[0048]** The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs,) or single base mutations in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain

population with a propensity for a disease state, that is susceptibility versus resistance.

[0049] Derivative polynucleotides include nucleic acids subjected to chemical modification, for example, replacement of hydrogen by an alkyl, acyl, or amino group. Derivatives, e.g., derivative oligonucleotides, may comprise non-naturally-occurring portions, such as altered sugar moieties or inter-sugar linkages. Exemplary among these are phosphorothioate and other sulfur containing species which are known in the art. Derivative nucleic acids may also contain labels, including radionucleotides, enzymes, fluorescent agents, chemiluminescent agents, chromogenic agents, substrates, cofactors, inhibitors, magnetic particles, and the like.

[0050] A "derivative" polypeptide or peptide is one that is modified, for example, by glycosylation, pegylation, phosphorylation, sulfation, reduction/alkylation, acylation, chemical coupling, or mild formalin treatment. A derivative may also be modified to contain a detectable label, either directly or indirectly, including, but not limited to, a radioisotope, fluorescent, and enzyme label.

[0051] As used herein, the term "animal" or "patient" is meant to include, for example, humans, sheep, elks, deer, mule deer, minks, mammals, monkeys, horses, cattle, pigs, goats, dogs, cats, rats, mice, birds, chicken, reptiles, fish, insects and arachnids.

[0052] "Mammal" covers warm blooded mammals that are typically under medical care (e.g., humans and domesticated animals). Examples include feline, canine, equine, bovine, and human, as well as just human.

[0053] "Treating" or "treatment" covers the treatment of a disease-state in a mammal, and includes: (a) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease-state but has not yet been diagnosed as having it; (b) inhibiting the disease-state, e.g., arresting its development; and/or (c) relieving the disease-state, e.g., causing regression of the disease state until a desired endpoint is reached. Treating also includes the amelioration of a symptom of a disease (e.g., lessen the pain or discomfort), wherein such amelioration may or may not be directly affecting the disease (e.g., cause, transmission, expression, etc.).

[0054] As used herein, the term "cancer" refers to any malignant tumor, particularly arising in the lung, kidney, or thyroid. The cancer manifests itself as a "tumor" or tissue comprising malignant cells of the cancer. Examples of tumors include sarcomas and carcinomas such as, but not limited to: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma. As noted above, the disclosure specifically permits differential diagnosis of lung, kidney, and thyroid tumors.

Polynucleotide and Oligonucleotide Compositions and Molecules

[0055] *Targets:* In one instance, the targets comprise nucleic acid sequences of Brain derived neurotrophic factor (BDNF), including without limitation sense and/or antisense noncoding and/or coding sequences associated with BDNF.

[0056] Neurotrophins are a class of structurally related growth factors that promote neural survival and differentiation. They stimulate neurite outgrowth, suggesting that they can promote regeneration of injured neurons, and act as target-derived neurotrophic factors to stimulate collateral sprouting in target tissues that produce the neurotrophin (Korsching., (1993) J. Neurosci., 13: 2739). Brain-derived neurotrophic factor (BDNF) was initially characterized as a basic protein present in brain extracts and capable of increasing the survival of dorsal root ganglia (Leibrock., et al., (1989) Nature, 341:149). When axonal communication with the cell body is interrupted by injury, Schwann cells produce neurotrophic factors such as nerve growth factor (NGF) and BDNF. Neurotrophins are released from the Schwann cells and dispersed diffusely in gradient fashion around regenerating axons, which then extend distally along the neurotrophins' density gradient (Ide., (1996) Neurosci. Res., 25:101). Local application of BDNF to transected nerves in neonatal rats has been shown to prevent massive death of motor neurons that follows axotomy (DiStefano., et al., (1992) Neuron, 8:983; Oppenheim., et al., (1992) Nature, 360:755; Yan., et al., (1992) Nature, 360:753). The mRNA titer of BDNF increases to several times the normal level four days after axotomy and reaches its maximum at 4 weeks (Meyer., et al., (1992) J. Cell Biol. 119:45). Moreover, BDNF has been reported to enhance the survival of cholinergic neurons in culture (Nonomura, et al., (1995) Brain Res. 683:129).

[0057] Exemplary Brain derived neurotrophic factor (BDNF) mediated diseases and disorders which can be treated with cell/tissues regenerated from stem cells obtained using the antisense compounds comprise: a disease or a disorder associated with defective neurogenesis; a neurodegenerative disease or disorder (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis etc.); a neuropsychiatric disorder (depression, schizophre-

nia, schizofreniform disorder, schizoaffective disorder, and delusional disorder; anxiety disorders such as panic disorder, phobias (including agoraphobia), an obsessive-compulsive disorder, a posttraumatic stress disorder, a bipolar disorder, anorexia nervosa, bulimia nervosa, an autoimmune disorder (e.g., multiple sclerosis) of the central nervous system, memory loss, a long term or a short term memory disorder, benign forgetfulness, a childhood learning disorder, close head injury, an attention deficit disorder, neuronal reaction to viral infection, brain damage, narcolepsy, a sleep disorder (e.g., circadian rhythm disorders, insomnia and narcolepsy); severance of nerves or nerve damage, severance of cerebrospinal nerve cord (CNS) and a damage to brain or nerve cells, a neurological deficit associated with AIDS, a motor and tic disorder characterized by motor and/or vocal tics (e.g., Tourette's disorder, chronic motor or vocal tic disorder, transient tic disorder, and stereotypic movement disorder), a substance abuse disorder (e.g., substance dependence, substance abuse and the sequelae of substance abuse/dependence, such as substance-induced psychological disorder, substance withdrawal and substance-induced dementia or amnesic disorder), traumatic brain injury, tinnitus, neuralgia (e.g., trigeminal neuralgia) pain (e.g chronic pain, chronic inflammatory pain, pain associated with arthritis, fibromyalgia, back pain, cancer-associated pain, pain associated with digestive disease, pain associated with Crohn's disease, pain associated with autoimmune disease, pain associated with endocrine disease, pain associated with diabetic neuropathy, phantom limb pain, spontaneous pain, chronic post-surgical pain, chronic temporomandibular pain, causalgia, post-herpetic neuralgia, AIDS-related pain, complex regional pain syndromes type I and II, trigeminal neuralgia, chronic back pain, pain associated with spinal cord injury, pain associated with drug intake and recurrent acute pain, neuropathic pain), inappropriate neuronal activity resulting in neurodysesthesias in a disease such as diabetes, an MS and a motor neuron disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, Reward deficiency syndrome (RDS), neurotoxicity caused by alcohol or substance abuse (e.g., ecstasy, methamphetamine etc.), mental retardation or cognitive impairment (e.g., nonsyndromic X-linked mental retardation, fragile X syndrome, Down's syndrome, autism), aphasia, Bell's palsy, Creutzfeldt-jacob disease, encephalitis, age related macular degeneration, Ondine syndrome, WAGR syndrome, hearing loss, Rett syndrome, epilepsy, spinal cord injury, stroke, hypoxia, ischemia, brain injury, optic nerve injury, diabetic neuropathy, peripheral neuropathy, nerve transplantation complications, motor neuron disease, peripheral nerve injury, obesity, a metabolic syndrome, cancer, asthma, an atopic disease, an allergic inflammation, eczema, a neuro-oncological disease or disorder, neuro-immunological disease or disorder and neuro-otological disease or disorder; and a disease or disorder associated with aging and senescence.

[0058] In a preferred instance, the oligonucleotides are specific for polynucleotides of BDNF, which includes, without limitation noncoding regions. The BDNF targets comprise variants of BDNF or BDNFOS; mutants of BDNF or BDNFOS, including SNPs; noncoding sequences of BDNF; alleles, fragments and the like. Preferably the oligonucleotide is an antisense RNA molecule.

[0059] In accordance with instances of the disclosure, the target nucleic acid molecule is not limited to BDNF polynucleotides alone but extends to any of the isoforms, receptors, homologs, non-coding regions and the like of BDNF.

[0060] In another preferred instance, an oligonucleotide targets a natural antisense sequence (natural antisense to the coding and non-coding regions) of BDNF targets, including, without limitation, variants, alleles, homologs, mutants, derivatives, fragments and complementary sequences thereto. Preferably the oligonucleotide is an antisense RNA or DNA molecule.

[0061] In another preferred instance, the oligomeric compounds of the present disclosure also include variants in which a different base is present at one or more of the nucleotide positions in the compound. For example, if the first nucleotide is an adenine, variants may be produced which contain thymidine, guanosine, cytidine or other natural or unnatural nucleotides at this position. This may be done at any of the positions of the antisense compound. These compounds are then tested using the methods described herein to determine their ability to inhibit expression of a target nucleic acid.

[0062] In some instances, homology, sequence identity or complementarity, between the antisense compound and target is from about 50% to about 60%. In some instances, homology, sequence identity or complementarity, is from about 60% to about 70%. In some instances, homology, sequence identity or complementarity, is from about 70% to about 80%. In some instances, homology, sequence identity or complementarity, is from about 80% to about 90%. In some instances, homology, sequence identity or complementarity, is about 90%, about 92%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100%.

[0063] An antisense compound is specifically hybridizable when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions in which specific binding is desired. Such conditions include, i.e., physiological conditions in the case of in vivo assays or therapeutic treatment, and conditions in which assays are performed in the case of in vitro assays.

[0064] An antisense compound, whether DNA, RNA, chimeric, substituted etc, is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological con-

ditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

[0065] In another preferred instance, targeting of BDNF including without limitation, antisense sequences which are identified and expanded, using for example, PCR, hybridization etc., one or more of the sequences set forth as SEQ ID NO: 2, and the like, modulate the expression or function of BDNF. In one instance, expression or function is up-regulated as compared to a control. In another preferred instance, expression or function is down-regulated as compared to a control.

[0066] In another preferred instance, oligonucleotides comprise nucleic acid sequences set forth as SEQ ID NOS: 3 to 8 including antisense sequences which are identified and expanded, using for example, PCR, hybridization etc. These oligonucleotides can comprise one or more modified nucleotides, shorter or longer fragments, modified bonds and the like. Examples of modified bonds or internucleotide linkages comprise phosphorothioate, phosphorodithioate or the like. In another preferred instance, the nucleotides comprise a phosphorus derivative. The phosphorus derivative (or modified phosphate group) which may be attached to the sugar or sugar analog moiety in the modified oligonucleotides of the present disclosure may be a monophosphate, diphosphate, triphosphate, alkylphosphate, alkanephosphate, phosphorothioate and the like. The preparation of the above-noted phosphate analogs, and their incorporation into nucleotides, modified nucleotides and oligonucleotides, *per se*, is also known and need not be described here.

[0067] The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

[0068] In instances of the present disclosure oligomeric antisense compounds, particularly oligonucleotides, bind to target nucleic acid molecules and modulate the expression and/or function of molecules encoded by a target gene. The functions of DNA to be interfered comprise, for example, replication and transcription. The functions of RNA to be interfered comprise all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The functions may be up-regulated or inhibited depending on the functions desired.

[0069] The antisense compounds, include, antisense oligomeric compounds, antisense oligonucleotides, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other oligomeric compounds that hybridize to at least a portion of the target nucleic acid. As such, these compounds may be introduced in the form of single-stranded, double-stranded, partially single-stranded, or circular oligomeric compounds.

[0070] Targeting an antisense compound to a particular nucleic acid molecule, in the context of this disclosure, can be a multistep process. The process usually begins with the identification of a target nucleic acid whose function is to be modulated. This target nucleic acid may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present disclosure, the target nucleic acid encodes Brain derived neurotrophic factor (BDNF).

[0071] The targeting process usually also includes determination of at least one target region, segment, or site within the target nucleic acid for the antisense interaction to occur such that the desired effect, e.g., modulation of expression, will result. Within the context of the present disclosure, the term "region" is defined as a portion of the target nucleic acid having at least one identifiable structure, function, or characteristic. Within regions of target nucleic acids are segments. "Segments" are defined as smaller or sub-portions of regions within a target nucleic acid. "Sites," as used in the present disclosure, are defined as positions within a target nucleic acid.

[0072] In a preferred instance, the antisense oligonucleotides bind to the natural antisense sequences of Brain derived neurotrophic factor (BDNF) and modulate the expression and/or function of Brain derived neurotrophic factor (BDNF) (SEQ ID NO: 1). Examples of antisense sequences include SEQ ID NOS: 2 to 8.

[0073] In another preferred instance, the antisense oligonucleotides bind to one or more segments of Brain derived neurotrophic factor (BDNF) polynucleotides and modulate the expression and/or function of Brain derived neurotrophic factor (BDNF). The segments comprise at least five consecutive nucleotides of the Brain derived neurotrophic factor (BDNF) sense or antisense polynucleotides.

[0074] In another preferred instance, the antisense oligonucleotides are specific for natural antisense sequences of Brain derived neurotrophic factor (BDNF) wherein binding of the oligonucleotides to the natural antisense sequences of Brain derived neurotrophic factor (BDNF) modulate expression and/or function of Brain derived neurotrophic factor (BDNF).

[0075] In another preferred instance, oligonucleotide compounds comprise sequences set forth as SEQ ID NOS: 3 to 8, antisense sequences which are identified and expanded, using for example, PCR, hybridization etc. These oligonucleotides can comprise one or more modified nucleotides, shorter or longer fragments, modified bonds and the like. Examples of modified bonds or internucleotide linkages comprise phosphorothioate, phosphorodithioate or the like. In another preferred instance, the nucleotides comprise a phosphorus derivative. The phosphorus derivative (or modified

phosphate group) which may be attached to the sugar or sugar analog moiety in the modified oligonucleotides of the present disclosure may be a monophosphate, diphosphate, triphosphate, alkylphosphate, alkanephosphate, phosphorothioate and the like. The preparation of the above-noted phosphate analogs, and their incorporation into nucleotides, modified nucleotides and oligonucleotides, per se, is also known and need not be described here.

5 **[0076]** Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes has a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG; and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino
10 acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). Eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the disclosure, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA transcribed from a gene encoding Brain derived neurotrophic factor (BDNF), regardless of the sequence(s) of
15 such codons. A translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively).

[0077] The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to
20 a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon. Consequently, the "start codon region" (or "translation initiation codon region") and the "stop codon region" (or "translation termination codon region") are all regions that may be targeted effectively with the antisense compounds of the present disclosure.

[0078] The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively.
25 Within the context of the present disclosure, a targeted region is the intragenic region encompassing the translation initiation or termination codon of the open reading frame (ORF) of a gene.

[0079] Another target region includes the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA (or corresponding nucleotides on the gene). Still another target region includes
30 the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA (or corresponding nucleotides on the gene). The 5' cap site of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap site. Another target
35 region for this disclosure is the 5' cap region.

[0080] Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. In one instance, targeting splice
40 sites, i.e., intron-exon junctions or exon-intron junctions, is particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular splice product is implicated in disease. An aberrant fusion junction due to rearrangement or deletion is another instance of a target site. mRNA transcripts produced via the process of splicing of two (or more) mRNAs from different gene sources are known as "fusion transcripts". Introns can be effectively targeted using antisense compounds targeted to, for example, DNA or pre-mRNA.

45 **[0081]** In another preferred instance, the antisense oligonucleotides bind to coding and/or non-coding regions of a target polynucleotide and modulate the expression and/or function of the target molecule.

[0082] In another preferred instance, the antisense oligonucleotides bind to natural antisense polynucleotides and modulate the expression and/or function of the target molecule.

50 **[0083]** In another preferred instance, the antisense oligonucleotides bind to sense polynucleotides and modulate the expression and/or function of the target molecule.

[0084] Alternative RNA transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as "variants". More specifically, "pre-mRNA variants" are transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in either their start or stop position and contain both intronic and exonic sequence.

55 **[0085]** Upon excision of one or more exon or intron regions, or portions thereof during splicing, pre-mRNA variants produce smaller "mRNA variants". Consequently, mRNA variants are processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as "alternative splice variants". If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical

to the mRNA variant.

[0086] Variants can be produced through the use of alternative signals to start or stop transcription. Pre-mRNAs and mRNAs can possess more than one start codon or stop codon. Variants that originate from a pre-mRNA or mRNA that use alternative start codons are known as "alternative start variants" of that pre-mRNA or mRNA. Those transcripts that use an alternative stop codon are known as "alternative stop variants" of that pre-mRNA or mRNA. One specific type of alternative stop variant is the "polyA variant" in which the multiple transcripts produced result from the alternative selection of one of the "polyA stop signals" by the transcription machinery, thereby producing transcripts that terminate at unique polyA sites. Within the context of the disclosure, the types of variants described herein are also instances of target nucleic acids.

[0087] The locations on the target nucleic acid to which the antisense compounds hybridize are defined as at least a 5-nucleotide long portion of a target region to which an active antisense compound is targeted.

[0088] While the specific sequences of certain exemplary target segments are set forth herein, one of skill in the art will recognize that these serve to illustrate and describe particular instances within the scope of the present disclosure. Additional target segments are readily identifiable by one having ordinary skill in the art in view of this disclosure.

[0089] Target segments 5-100 nucleotides in length comprising a stretch of at least five (5) consecutive nucleotides selected from within the illustrative preferred target segments are considered to be suitable for targeting as well.

[0090] Target segments can include DNA or RNA sequences that comprise at least the 5 consecutive nucleotides from the 5'-terminus of one of the illustrative preferred target segments (the remaining nucleotides being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5'-terminus of the target segment and continuing until the DNA or RNA contains about 5 to about 100 nucleotides). Similarly preferred target segments are represented by DNA or RNA sequences that comprise at least the 5 consecutive nucleotides from the 3'-terminus of one of the illustrative preferred target segments (the remaining nucleotides being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of the target segment and continuing until the DNA or RNA contains about 5 to about 100 nucleotides). One having skill in the art armed with the target segments illustrated herein will be able, without undue experimentation, to identify further preferred target segments.

[0091] Once one or more target regions, segments or sites have been identified, antisense compounds are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

[0092] In instances of the disclosure the oligonucleotides bind to an antisense strand of a particular target. The oligonucleotides are at least 5 nucleotides in length and can be synthesized so each oligonucleotide targets overlapping sequences such that oligonucleotides are synthesized to cover the entire length of the target polynucleotide. The targets also include coding as well as non coding regions.

[0093] In one instance, it is preferred to target specific nucleic acids by antisense oligonucleotides. Targeting an antisense compound to a particular nucleic acid, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a non coding polynucleotide such as for example, non coding RNA (ncRNA).

[0094] RNAs can be classified into (1) messenger RNAs (mRNAs), which are translated into proteins, and (2) non-protein-coding RNAs (ncRNAs). ncRNAs comprise microRNAs, antisense transcripts and other Transcriptional Units (TU) containing a high density of stop codons and lacking any extensive "Open Reading Frame". Many ncRNAs appear to start from initiation sites in 3' untranslated regions (3'UTRs) of protein-coding loci. ncRNAs are often rare and at least half of the ncRNAs that have been sequenced by the FANTOM consortium seem not to be polyadenylated. Most researchers have for obvious reasons focused on polyadenylated mRNAs that are processed and exported to the cytoplasm. Recently, it was shown that the set of non-polyadenylated nuclear RNAs may be very large, and that many such transcripts arise from so-called intergenic regions (Cheng, J. et al. (2005) Science 308 (5725), 1149-1154; Kapranov, P. et al. (2005). Genome Res 15 (7), 987-997). The mechanism by which ncRNAs may regulate gene expression is by base pairing with target transcripts. The RNAs that function by base pairing can be grouped into (1) cis encoded RNAs that are encoded at the same genetic location, but on the opposite strand to the RNAs they act upon and therefore display perfect complementarity to their target, and (2) trans-encoded RNAs that are encoded at a chromosomal location distinct from the RNAs they act upon and generally do not exhibit perfect base-pairing potential with their targets.

[0095] Without wishing to be bound by theory, perturbation of an antisense polynucleotide by the antisense oligonucleotides described herein can alter the expression of the corresponding sense messenger RNAs. However, this regulation can either be discordant (antisense knockdown results in messenger RNA elevation) or concordant (antisense knockdown results in concomitant messenger RNA reduction). In these cases, antisense oligonucleotides can be targeted to overlapping or non-overlapping parts of the antisense transcript resulting in its knockdown or sequestration. Coding as well as non-coding antisense can be targeted in an identical manner and that either category is capable of regulating the corresponding sense transcripts - either in a concordant or discordant manner. The strategies that are employed in identifying new oligonucleotides for use against a target can be based on the knockdown of antisense RNA transcripts

by antisense oligonucleotides or any other means of modulating the desired target.

[0096] *Strategy 1:* In the case of discordant regulation, knocking down the antisense transcript elevates the expression of the conventional (sense) gene. Should that latter gene encode for a known or putative drug target, then knockdown of its antisense counterpart could conceivably mimic the action of a receptor agonist or an enzyme stimulant.

[0097] *Strategy 2:* In the case of concordant regulation, one could concomitantly knock down both antisense and sense transcripts and thereby achieve synergistic reduction of the conventional (sense) gene expression. If, for example, an antisense oligonucleotide is used to achieve knockdown, then this strategy can be used to apply one antisense oligonucleotide targeted to the sense transcript and another antisense oligonucleotide to the corresponding antisense transcript, or a single energetically symmetric antisense oligonucleotide that simultaneously targets overlapping sense and antisense transcripts.

[0098] According to the present disclosure, antisense compounds include antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, siRNA compounds, single- or double-stranded RNA interference (RNAi) compounds such as siRNA compounds, and other oligomeric compounds which hybridize to at least a portion of the target nucleic acid and modulate its function. As such, they may be DNA, RNA, DNA-like, RNA-like, or mixtures thereof, or may be mimetics of one or more of these. These compounds may be single-stranded, doublestranded, circular or hairpin oligomeric compounds and may contain structural elements such as internal or terminal bulges, mismatches or loops. Antisense compounds are routinely prepared linearly but can be joined or otherwise prepared to be circular and/or branched. Antisense compounds can include constructs such as, for example, two strands hybridized to form a wholly or partially double-stranded compound or a single strand with sufficient self-complementarity to allow for hybridization and formation of a fully or partially double-stranded compound. The two strands can be linked internally leaving free 3' or 5' termini or can be linked to form a continuous hairpin structure or loop. The hairpin structure may contain an overhang on either the 5' or 3' terminus producing an extension of single stranded character. The double stranded compounds optionally can include overhangs on the ends. Further modifications can include conjugate groups attached to one of the termini, selected nucleotide positions, sugar positions or to one of the internucleoside linkages. Alternatively, the two strands can be linked via a non-nucleic acid moiety or linker group. When formed from only one strand, dsRNA can take the form of a self-complementary hairpin-type molecule that doubles back on itself to form a duplex. Thus, the dsRNAs can be fully or partially double stranded. Specific modulation of gene expression can be achieved by stable expression of dsRNA hairpins in transgenic cell lines, however, in some instances, the gene expression or function is up regulated. When formed from two strands, or a single strand that takes the form of a self-complementary hairpin-type molecule doubled back on itself to form a duplex, the two strands (or duplex-forming regions of a single strand) are complementary RNA strands that base pair in Watson-Crick fashion.

[0099] Once introduced to a system, the compounds of the disclosure may elicit the action of one or more enzymes or structural proteins to effect cleavage or other modification of the target nucleic acid or may work via occupancy-based mechanisms. In general, nucleic acids (including oligonucleotides) may be described as "DNA-like" (i.e., generally having one or more 2'-deoxy sugars and, generally, T rather than U bases) or "RNA-like" (i.e., generally having one or more 2'-hydroxyl or 2'-modified sugars and, generally U rather than T bases). Nucleic acid helices can adopt more than one type of structure, most commonly the A- and B-forms. It is believed that, in general, oligonucleotides which have B-form-like structure are "DNA-like" and those which have A-formlike structure are "RNA-like." In some (chimeric) instances, an antisense compound may contain both A- and B-form regions.

[0100] In another preferred instance, the desired oligonucleotides or antisense compounds, comprise at least one of: antisense RNA, antisense DNA, chimeric antisense oligonucleotides, antisense oligonucleotides comprising modified linkages, interference RNA (RNAi), short interfering RNA (siRNA); a micro, interfering RNA (miRNA); a small, temporal RNA (stRNA); or a short, hairpin RNA (shRNA); small RNA-induced gene activation (RNAa); small activating RNAs (saRNAs), or combinations thereof.

[0101] dsRNA can also activate gene expression, a mechanism that has been termed "small RNA-induced gene activation" or RNAa. dsRNAs targeting gene promoters induce potent transcriptional activation of associated genes. RNAa was demonstrated in human cells using synthetic dsRNAs, termed "small activating RNAs" (saRNAs). It is currently not known whether RNAa is conserved in other organisms.

[0102] Small double-stranded RNA (dsRNA), such as small interfering RNA (siRNA) and microRNA (miRNA), have been found to be the trigger of an evolutionary conserved mechanism known as RNA interference (RNAi). RNAi invariably leads to gene silencing via remodeling chromatin to thereby suppress transcription, degrading complementary mRNA, or blocking protein translation. However, in instances described in detail in the examples section which follows, oligonucleotides are shown to increase the expression and/or function of the Brain derived neurotrophic factor (BDNF) polynucleotides and encoded products thereof. dsRNAs may also act as small activating RNAs (saRNA). Without wishing to be bound by theory, by targeting sequences in gene promoters, saRNAs would induce target gene expression in a phenomenon referred to as dsRNA-induced transcriptional activation (RNAa).

[0103] In a further instance, the "preferred target segments" identified herein may be employed in a screen for additional compounds that modulate the expression of Brain derived neurotrophic factor (BDNF) polynucleotides. "Modulators"

are those compounds that decrease or increase the expression of a nucleic acid molecule encoding Brain derived neurotrophic factor (BDNF) and which comprise at least a 5-nucleotide portion that is complementary to a preferred target segment. The screening method comprises the steps of contacting a preferred target segment of a nucleic acid molecule encoding sense or natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF) with one or more candidate modulators, and selecting for one or more candidate modulators which decrease or increase the expression of a nucleic acid molecule encoding Brain derived neurotrophic factor (BDNF) polynucleotides, e.g. SEQ ID NOS: 3 to 8. Once it is shown that the candidate modulator or modulators are capable of modulating (e.g. either decreasing or increasing) the expression of a nucleic acid molecule encoding Brain derived neurotrophic factor (BDNF) polynucleotides, the modulator may then be employed in further investigative studies of the function of Brain derived neurotrophic factor (BDNF) polynucleotides, or for use as a research, diagnostic, or therapeutic agent in accordance with the present disclosure.

[0104] Targeting the natural antisense sequence preferably modulates the function of the target gene. For example, the BDNF gene (e.g. accession number NM_170735, Fig. 2). In a preferred instance, the target is an antisense polynucleotide of the BDNF gene. In a preferred instance, an antisense oligonucleotide targets sense and/or natural antisense sequences of Brain derived neurotrophic factor (BDNF) polynucleotides (e.g. accession number NM_170735, Fig.2), variants, alleles, isoforms, homologs, mutants, derivatives, fragments and complementary sequences thereto. Preferably the oligonucleotide is an antisense molecule and the targets include coding and noncoding regions of antisense and/or sense BDNF polynucleotides.

[0105] The preferred target segments of the present disclosure may be also be combined with their respective complementary antisense compounds of the present disclosure to form stabilized double-stranded (duplexed) oligonucleotides.

[0106] Such double stranded oligonucleotide moieties have been shown in the art to modulate target expression and regulate translation as well as RNA processing via an antisense mechanism. Moreover, the double-stranded moieties may be subject to chemical modifications (Fire et al., (1998) Nature, 391, 806-811; Timmons and Fire, (1998) Nature, 395, 854; Timmons et al., (2001) Gene, 263, 103-112; Tabara et al., (1998) Science, 282, 430-431; Montgomery et al., (1998) Proc. Natl. Acad. Sci. USA, 95, 15502-15507; Tuschl et al., (1999) Genes Dev., 13, 3191-3197; Elbashir et al., (2001) Nature, 411, 494-498; Elbashir et al., (2001) Genes Dev. 15, 188-200). For example, such double-stranded moieties have been shown to inhibit the target by the classical hybridization of antisense strand of the duplex to the target, thereby triggering enzymatic degradation of the target (Tijsterman et al., (2002) Science, 295, 694-697).

[0107] In a preferred instance, an antisense oligonucleotide targets Brain derived neurotrophic factor (BDNF) polynucleotides (e.g. accession number NM_170735), variants, alleles, isoforms, homologs, mutants, derivatives, fragments and complementary sequences thereto. Preferably the oligonucleotide is an antisense molecule.

[0108] In accordance with instances of the disclosure, the target nucleic acid molecule is not limited to Brain derived neurotrophic factor (BDNF) alone but extends to any of the isoforms, receptors, homologs and the like of Brain derived neurotrophic factor (BDNF) molecules.

[0109] In another preferred instance, an oligonucleotide targets a natural antisense sequence of BDNF polynucleotides, for example, polynucleotides set forth as SEQ ID NO: 2, and any variants, alleles, homologs, mutants, derivatives, fragments and complementary sequences thereto. Examples of antisense oligonucleotides are set forth as SEQ ID NOS: 3 to 8.

[0110] In one instance, the oligonucleotides are complementary to or bind to nucleic acid sequences of Brain derived neurotrophic factor (BDNF) antisense, including without limitation noncoding sense and/or antisense sequences associated with Brain derived neurotrophic factor (BDNF) polynucleotides and modulate expression and/or function of Brain derived neurotrophic factor (BDNF) molecules.

[0111] In another preferred instance, the oligonucleotides are complementary to or bind to nucleic acid sequences of BDNF natural antisense, set forth as SEQ ID NO: 2 and modulate expression and/or function of BDNF molecules.

[0112] In a preferred instance, oligonucleotides comprise sequences of at least 5 consecutive nucleotides of SEQ ID NOS: 3 to 8 and modulate expression and/or function of Brain derived neurotrophic factor (BDNF) molecules.

[0113] The polynucleotide targets comprise BDNF, including family members thereof, variants of BDNF; mutants of BDNF, including SNPs; noncoding sequences of BDNF; alleles of BDNF; species variants, fragments and the like. Preferably the oligonucleotide is an antisense molecule.

[0114] In another preferred instance, the oligonucleotide targeting Brain derived neurotrophic factor (BDNF) polynucleotides, comprise: antisense RNA, interference RNA (RNAi), short interfering RNA (siRNA); micro interfering RNA (miRNA); a small, temporal RNA (stRNA); or a short, hairpin RNA (shRNA); small RNA-induced gene activation (RNAa); or, small activating RNA (saRNA).

[0115] In another preferred instance, targeting of Brain derived neurotrophic factor (BDNF) polynucleotides, e.g. SEQ ID NO: 2, modulates the expression or function of these targets. In one instance, expression or function is up-regulated as compared to a control. In another preferred instance, expression or function is down-regulated as compared to a control.

[0116] In another preferred instance, antisense compounds comprise sequences set forth as SEQ ID NOS: 3 to 8.

These oligonucleotides can comprise one or more modified nucleotides, shorter or longer fragments, modified bonds and the like.

[0117] In another preferred instance, SEQ ID NOS: 3 to 8 comprise one or more LNA nucleotides.

[0118] Table 1 shows exemplary antisense oligonucleotides useful in the methods of the disclosure.

Table 1

Sequence ID	Oligo Name	Sequence
SEQ ID NO:3	CUR-0076	C*+T*+T*G*A*A*T*T*G*T*T*+G*+T*+A
SEQ ID NO:4	CUR-0075	A*+G*+T*T*G*C*A*A*G*A*G*T*+T*+G*+G
SEQ ID NO:5	CUR-0074	A*+T*+C*T*G*T*T*C*T*G*C*T*+G*+T*+C
SEQ ID NO:6	CUR-0071	C*+A*+T*A*T*T*C*T*T*G*G*A*+C*+G*+A
SEQ ID NO:7	CUR-0072	T*+G*+T*G*C*T*G*T*T*G*T*A*+A*+G*+A
SEQ ID NO:8	CUR-0073	T*+G*+A*C*A*G*A*G*G*A*G*T*+A*+T*+T

[0119] The modulation of a desired target nucleic acid can be carried out in several ways known in the art. For example, antisense oligonucleotides, siRNA etc. Enzymatic nucleic acid molecules (e.g., ribozymes) are nucleic acid molecules capable of catalyzing one or more of a variety of reactions, including the ability to repeatedly cleave other separate nucleic acid molecules in a nucleotide base sequence-specific manner. Such enzymatic nucleic acid molecules can be used, for example, to target virtually any RNA transcript (Zaug et al., 324, Nature 429 1986; Cech, 260 JAMA 3030, 1988; and Jefferies et al., 17 Nucleic Acids Research 1371, 1989).

[0120] Because of their sequence-specificity, trans-cleaving enzymatic nucleic acid molecules show promise as therapeutic agents for human disease (Usman & McSwiggen, (1995) Ann. Rep. Med. Chem. 30, 285-294; Christoffersen and Marr, (1995) J. Med. Chem. 38, 2023-2037). Enzymatic nucleic acid molecules can be designed to cleave specific RNA targets within the background of cellular RNA. Such a cleavage event renders the mRNA non-functional and abrogates protein expression from that RNA. In this manner, synthesis of a protein associated with a disease state can be selectively inhibited.

[0121] In general, enzymatic nucleic acids with RNA cleaving activity act by first binding to a target RNA. Such binding occurs through the target binding portion of an enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.

[0122] Several approaches such as in vitro selection (evolution) strategies (Orgel, (1979) Proc. R. Soc. London, B 205, 435) have been used to evolve new nucleic acid catalysts capable of catalyzing a variety of reactions, such as cleavage and ligation of phosphodiester linkages and amide linkages, (Joyce, (1989) Gene, 82, 83-87; Beaudry et al., (1992) Science 257, 635-641; Joyce, (1992) Scientific American 267, 90-97; Breaker et al., (1994) TIBTECH 12, 268; Bartel et al., (1993) Science 261:1411- 1418; Szostak, (1993) TIBS 17, 89-93; Kumar et al., (1995) FASEB J., 9, 1183; Breaker, (1996) Curr. Op. Biotech., 7, 442).

[0123] The development of ribozymes that are optimal for catalytic activity would contribute significantly to any strategy that employs RNA-cleaving ribozymes for the purpose of regulating gene expression. The hammerhead ribozyme, for example, functions with a catalytic rate (kcat) of about 1 min⁻¹ in the presence of saturating (10 mM) concentrations of Mg²⁺ cofactor. An artificial "RNA ligase" ribozyme has been shown to catalyze the corresponding self-modification reaction with a rate of about 100 min⁻¹. In addition, it is known that certain modified hammerhead ribozymes that have substrate binding arms made of DNA catalyze RNA cleavage with multiple turn-over rates that approach 100 min⁻¹. Finally, replacement of a specific residue within the catalytic core of the hammerhead with certain nucleotide analogues gives modified ribozymes that show as much as a 10-fold improvement in catalytic rate. These findings demonstrate that ribozymes can promote chemical transformations with catalytic rates that are significantly greater than those displayed in vitro by most natural self-cleaving ribozymes. It is then possible that the structures of certain self-cleaving ribozymes may be optimized to give maximal catalytic activity, or that entirely new RNA motifs can be made that display significantly faster rates for RNA phosphodiester cleavage.

[0124] Intermolecular cleavage of an RNA substrate by an RNA catalyst that fits the "hammerhead" model was first shown in 1987 (Uhlenbeck, O. C. (1987) Nature, 328: 596-600). The RNA catalyst was recovered and reacted with multiple RNA molecules, demonstrating that it was truly catalytic.

[0125] Catalytic RNAs designed based on the "hammerhead" motif have been used to cleave specific target sequences by making appropriate base changes in the catalytic RNA to maintain necessary base pairing with the target sequences (Haseloff and Gerlach, (1988) *Nature*, 334, 585; Walbot and Bruening, (1988) *Nature*, 334, 196; Uhlenbeck, O. C. (1987) *Nature*, 328: 596-600; Koizumi, M., et al. (1988) *FEBS Lett.*, 228: 228-230). This has allowed use of the catalytic RNA to cleave specific target sequences and indicates that catalytic RNAs designed according to the "hammerhead" model

[0126] RNA interference (RNAi) has become a powerful tool for modulating gene expression in mammals and mammalian cells. This approach requires the delivery of small interfering RNA (siRNA) either as RNA itself or as DNA, using an expression plasmid or virus and the coding sequence for small hairpin RNAs that are processed to siRNAs. This system enables efficient transport of the pre-siRNAs to the cytoplasm where they are active and permit the use of regulated and tissue specific promoters for gene expression.

[0127] In a preferred instance, an oligonucleotide or antisense compound comprises an oligomer or polymer of ribonucleic acid (RNA) and/or deoxyribonucleic acid (DNA), or a mimetic, chimera, analog or homolog thereof. This term includes oligonucleotides composed of naturally occurring nucleotides, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally occurring portions which function similarly. Such modified or substituted oligonucleotides are often desired over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for a target nucleic acid and increased stability in the presence of nucleases.

[0128] According to the present disclosure, the oligonucleotides or "antisense compounds" include antisense oligonucleotides (e.g. RNA, DNA, mimetic, chimera, analog or homolog thereof), ribozymes, external guide sequence (EGS) oligonucleotides, siRNA compounds, single- or double-stranded RNA interference (RNAi) compounds such as siRNA compounds, saRNA, aRNA, and other oligomeric compounds which hybridize to at least a portion of the target nucleic acid and modulate its function. As such, they may be DNA, RNA, DNA-like, RNA-like, or mixtures thereof, or may be mimetics of one or more of these. These compounds may be single-stranded, double-stranded, circular or hairpin oligomeric compounds and may contain structural elements such as internal or terminal bulges, mismatches or loops. Antisense compounds are routinely prepared linearly but can be joined or otherwise prepared to be circular and/or branched. Antisense compounds can include constructs such as, for example, two strands hybridized to form a wholly or partially double-stranded compound or a single strand with sufficient self-complementarity to allow for hybridization and formation of a fully or partially double-stranded compound. The two strands can be linked internally leaving free 3' or 5' termini or can be linked to form a continuous hairpin structure or loop. The hairpin structure may contain an overhang on either the 5' or 3' terminus producing an extension of single stranded character. The double stranded compounds optionally can include overhangs on the ends. Further modifications can include conjugate groups attached to one of the termini, selected nucleotide positions, sugar positions or to one of the internucleoside linkages. Alternatively, the two strands can be linked via a non-nucleic acid moiety or linker group. When formed from only one strand, dsRNA can take the form of a self-complementary hairpin-type molecule that doubles back on itself to form a duplex. Thus, the dsRNAs can be fully or partially double stranded. Specific modulation of gene expression can be achieved by stable expression of dsRNA hairpins in transgenic cell lines (Hammond et al., (1991) *Nat. Rev. Genet.*, 2, 110-119; Matzke et al., (2001) *Curr. Opin. Genet. Dev.*, 11, 221-227; Sharp, (2001) *Genes Dev.*, 15, 485-490). When formed from two strands, or a single strand that takes the form of a self-complementary hairpin-type molecule doubled back on itself to form a duplex, the two strands (or duplex-forming regions of a single strand) are complementary RNA strands that base pair in Watson-Crick fashion.

[0129] Once introduced to a system, the compounds of the disclosure may elicit the action of one or more enzymes or structural proteins to effect cleavage or other modification of the target nucleic acid or may work via occupancy-based mechanisms. In general, nucleic acids (including oligonucleotides) may be described as "DNA-like" (i.e., generally having one or more 2'-deoxy sugars and, generally, T rather than U bases) or "RNA-like" (i.e., generally having one or more 2'-hydroxyl or 2'-modified sugars and, generally U rather than T bases). Nucleic acid helices can adopt more than one type of structure, most commonly the A- and B-forms. It is believed that, in general, oligonucleotides which have B-form-like structure are "DNA-like" and those which have A-formlike structure are "RNA-like." In some (chimeric) instances, an antisense compound may contain both A- and B-form regions.

[0130] The antisense compounds in accordance with this disclosure can comprise an antisense portion from about 5 to about 80 nucleotides (i.e. from about 5 to about 80 linked nucleosides) in length. This refers to the length of the antisense strand or portion of the antisense compound. In other words, a single-stranded antisense compound of the disclosure comprises from 5 to about 80 nucleotides, and a double-stranded antisense compound of the disclosure (such as a dsRNA, for example) comprises a sense and an antisense strand or portion of 5 to about 80 nucleotides in length. One of ordinary skill in the art will appreciate that this comprehends antisense portions of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleotides in length, or any range therewithin.

[0131] In one instance, the antisense compounds of the disclosure have antisense portions of 10 to 50 nucleotides in length. One having ordinary skill in the art will appreciate that this embodies oligonucleotides having antisense portions of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length, or any range therewithin. In some instances, the oligonucleotides are 15 nucleotides in length.

[0132] In one instance, the antisense or oligonucleotide compounds of the disclosure have antisense portions of 12 or 13 to 30 nucleotides in length. One having ordinary skill in the art will appreciate that this embodies antisense compounds having antisense portions of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides in length, or any range therewithin.

[0133] In another preferred instance, the oligomeric compounds of the present disclosure also include variants in which a different base is present at one or more of the nucleotide positions in the compound. For example, if the first nucleotide is an adenosine, variants may be produced which contain thymidine, guanosine or cytidine at this position. This may be done at any of the positions of the antisense or dsRNA compounds. These compounds are then tested using the methods described herein to determine their ability to inhibit expression of a target nucleic acid.

[0134] In some instances, homology, sequence identity or complementarity, between the antisense compound and target is from about 40% to about 60%. In some instances, homology, sequence identity or complementarity, is from about 60% to about 70%. In some instances, homology, sequence identity or complementarity, is from about 70% to about 80%. In some instances, homology, sequence identity or complementarity, is from about 80% to about 90%. In some instances, homology, sequence identity or complementarity, is about 90%, about 92%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100%.

[0135] In another preferred instance, the antisense oligonucleotides, such as for example, nucleic acid molecules set forth in SEQ ID NOS: 2 to 8 comprise one or more substitutions or modifications. In one instance, the nucleotides are substituted with locked nucleic acids (LNA).

[0136] In another preferred instance, the oligonucleotides target one or more regions of the nucleic acid molecules sense and/or antisense of coding and/or non-coding sequences associated with BDNF and the sequences set forth as SEQ ID NOS: 1, 2. The oligonucleotides are also targeted to overlapping regions of SEQ ID NOS: 1, 2.

[0137] Certain preferred oligonucleotides of this disclosure are chimeric oligonucleotides. "Chimeric oligonucleotides" or "chimera," in the context of this disclosure, are oligonucleotides which contain two or more chemically distinct regions, each made up of at least one nucleotide. These oligonucleotides typically contain at least one region of modified nucleotides that confers one or more beneficial properties (such as, for example, increased nuclease resistance, increased uptake into cells, increased binding affinity for the target) and a region that is a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of antisense modulation of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art. In one preferred instance, a chimeric oligonucleotide comprises at least one region modified to increase target binding affinity, and, usually, a region that acts as a substrate for RNase H. Affinity of an oligonucleotide for its target (in this case, a nucleic acid encoding ras) is routinely determined by measuring the T_m of an oligonucleotide/target pair, which is the temperature at which the oligonucleotide and target dissociate; dissociation is detected spectrophotometrically. The higher the T_m, the greater is the affinity of the oligonucleotide for the target.

[0138] Chimeric antisense compounds of the disclosure may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotides mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures comprise, but are not limited to, US patent nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922.

[0139] In another preferred instance, the region of the oligonucleotide which is modified comprises at least one nucleotide modified at the 2' position of the sugar, most preferably a 2'-O-alkyl, 2'-O-alkyl-O-alkyl or 2'-fluoro-modified nucleotide. In other preferred instances, RNA modifications include 2'-fluoro, 2'-amino and 2' O-methyl modifications on the ribose of pyrimidines, abasic residues or an inverted base at the 3' end of the RNA. Such modifications are routinely incorporated into oligonucleotides and these oligonucleotides have been shown to have a higher T_m (i.e., higher target binding affinity) than; 2'-deoxyoligonucleotides against a given target. The effect of such increased affinity is to greatly enhance RNAi oligonucleotide inhibition of gene expression. RNase H is a cellular endonuclease that cleaves the RNA strand of RNA:DNA duplexes; activation of this enzyme therefore results in cleavage of the RNA target, and thus can greatly enhance the efficiency of RNAi inhibition. Cleavage of the RNA target can be routinely demonstrated by gel electrophoresis. In another preferred instance, the chimeric oligonucleotide is also modified to enhance nuclease resistance. Cells contain a variety of exo- and endo-nucleases which can degrade nucleic acids. A number of nucleotide and

nucleoside modifications have been shown to make the oligonucleotide into which they are incorporated more resistant to nuclease digestion than the native oligodeoxynucleotide. Nuclease resistance is routinely measured by incubating oligonucleotides with cellular extracts or isolated nuclease solutions and measuring the extent of intact oligonucleotide remaining over time, usually by gel electrophoresis. Oligonucleotides which have been modified to enhance their nuclease resistance survive intact for a longer time than unmodified oligonucleotides. A variety of oligonucleotide modifications have been demonstrated to enhance or confer nuclease resistance. Oligonucleotides which contain at least one phosphorothioate modification are presently more preferred. In some cases, oligonucleotide modifications which enhance target binding affinity are also, independently, able to enhance nuclease resistance. Some desirable modifications can be found in De Mesmaeker et al. (1995) *Acc. Chem. Res.*, 28:366-374.

[0140] Specific examples of some preferred oligonucleotides envisioned for this disclosure include those comprising modified backbones, for example, phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most preferred are oligonucleotides with phosphorothioate backbones and those with heteroatom backbones, particularly CH₂--NH--O--CH₂, CH₂--N(CH₃)--O--CH₂ [known as a methylene(methylimino) or MMI backbone], CH₂--O--N(CH₃)--CH₂, CH₂--N(CH₃)--N(CH₃)--CH₂ and O--N(CH₃)--CH₂--CH₂ backbones, wherein the native phosphodiester backbone is represented as O--P--O--CH₂. The amide backbones disclosed by De Mesmaeker et al. (1995) *Acc. Chem. Res.* 28:366-374 are also preferred. Also preferred are oligonucleotides having morpholino backbone structures (Summerton and Weller, U.S. Pat. No. 5,034,506). In other preferred instances, such as the peptide nucleic acid (PNA) backbone, the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleotides being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone (Nielsen et al. (1991) *Science* 254, 1497). Oligonucleotides may also comprise one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH, SH, SCH₃, F, OCN, OCH₃ OCH₃, OCH₃ O(CH₂)_n CH₃, O(CH₂)_n NH₂ or O(CH₂)_n CH₃ where n is from 1 to about 10; C1 to C10 lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF₃; OCF₃; O--, S--, or N-alkyl; O--, S--, or N-alkenyl; SOCH₃; SO₂ CH₃; ONO₂; NO₂; N₃; NH₂; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy [2'-O-CH₂ CH₂ OCH₃, also known as 2'-O-(2-methoxyethyl)] (Martin et al., (1995) *Helv. Chim. Acta*, 78, 486). Other preferred modifications include 2'-methoxy (2'-O--CH₃), 2'-propoxy (2'-OCH₂ CH₂CH₃) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyls in place of the pentofuranosyl group.

[0141] Oligonucleotides may also include, additionally or alternatively, nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleotides include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U). Modified nucleotides include nucleotides found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-Me pyrimidines, particularly 5-methylcytosine (also referred to as 5-methyl-2' deoxycytosine and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, as well as synthetic nucleotides, e.g., 2-aminoadenine, 2-(methylamino)adenine, 2-(imidazolylalkyl)adenine, 2-(aminoalkylamino)adenine or other heterosubstituted alkyladenines, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 8-azaguanine, 7-deazaguanine, N⁶ (6-aminohexyl)adenine and 2,6-diaminopurine. (Kornberg, A., *DNA Replication*, W. H. Freeman & Co., San Francisco, 1980, pp75-77; Gebeyehu, G., (1987) et al. *Nucl. Acids Res.* 15:4513). A "universal" base known in the art, e.g., inosine, may be included. 5-Me-C substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C. (Sanghvi, Y. S., in Crooke, S. T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions.

[0142] Another modification of the oligonucleotides of the disclosure involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety, a cholesteryl moiety (Letsinger et al., (1989) *Proc. Natl. Acad. Sci. USA* 86, 6553), cholic acid (Manoharan et al. (1994) *Bioorg. Med. Chem. Lett.* 4, 1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al. (1992) *Ann. N.Y. Acad. Sci.* 660, 306; Manoharan et al. (1993) *Bioorg. Med. Chem. Lett.* 3, 2765), a thiocholesterol (Oberhauser et al., (1992) *Nucl. Acids Res.* 20, 533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al. *EMBO J.* 1991, 10, 111; Kabanov et al. (1990) *FEBS Lett.* 259, 327; Svinarchuk et al. (1993) *Biochimie* 75, 49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero- 3-H-phosphonate (Manoharan et al. (1995) *Tetrahedron Lett.* 36, 3651; Shea et al. (1990) *Nucl. Acids Res.* 18, 3777), a polyamine or a polyethylene glycol chain (Manoharan et al. (1995) *Nucleosides & Nucleotides*, 14, 969), or adamantane acetic acid (Manoharan et al. (1995) *Tetrahedron Lett.* 36, 3651). Oligonucleotides comprising lipophilic moieties, and methods for preparing such oligonucleotides are known in the art, for example, U.S. Pat. Nos. 5,138,045, 5,218,105 and 5,459,255.

[0143] It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide. The present disclosure also includes oligonucleotides which are chimeric oligonucleotides as hereinbefore defined.

[0144] In another instance, the nucleic acid molecule of the present disclosure is conjugated with another moiety including but not limited to abasic nucleotides, polyether, polyamine, polyamides, peptides, carbohydrates, lipid, or polyhydrocarbon compounds. Those skilled in the art will recognize that these molecules can be linked to one or more of any nucleotides comprising the nucleic acid molecule at several positions on the sugar, base or phosphate group.

[0145] The oligonucleotides used in accordance with this disclosure may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the talents of one of ordinary skill in the art. It is also well known to use similar techniques to prepare other oligonucleotides such as the phosphorothioates and alkylated derivatives. It is also well known to use similar techniques and commercially available modified amidites and controlled-pore glass (CPG) products such as biotin, fluorescein, acridine or psoralen-modified amidites and/or CPG (available from Glen Research, Sterling VA) to synthesize fluorescently labeled, biotinylated or other modified oligonucleotides such as cholesterol-modified oligonucleotides.

[0146] In accordance with the disclosure, use of modifications such as the use of LNA monomers to enhance the potency, specificity and duration of action and broaden the routes of administration of oligonucleotides comprised of current chemistries such as MOE, ANA, FANA, PS etc (Uhlman, et al. (2000) Current Opinions in Drug Discovery & Development Vol. 3 No 2). This can be achieved by substituting some of the monomers in the current oligonucleotides by LNA monomers. The LNA modified oligonucleotide may have a size similar to the parent compound or may be larger or preferably smaller. It is preferred that such LNA-modified oligonucleotides contain less than about 70%, more preferably less than about 60%, most preferably less than about 50% LNA monomers and that their sizes are between about 5 and 25 nucleotides, more preferably between about 12 and 20 nucleotides.

[0147] Preferred modified oligonucleotide backbones comprise, but not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

[0148] Representative United States patents that teach the preparation of the above phosphorus containing linkages comprise, but are not limited to, US patent nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050.

[0149] Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These comprise those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

[0150] Representative United States patents that teach the preparation of the above oligonucleosides comprise, but are not limited to, US patent nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439.

[0151] In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds comprise, but are not limited to, US patent nos. 5,539,082; 5,714,331; and 5,719,262. Further teaching of PNA compounds can be found in Nielsen, et al. (1991) Science 254, 1497-1500.

[0152] In another preferred instance of the disclosure the oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular- CH₂-NH-O-CH₂-, -CH₂-N (CH₃)-O-CH₂-known as a

methylene (methylimino) or MMI backbone, -CH₂-O-N(CH₃)-CH₂-, -CH₂N(CH₃)-N(CH₃)-CH₂-and-O-N(CH₃)-CH₂-CH₂- wherein the native phosphodiester backbone is represented as -O=P-O-CH₂- of the above referenced US patent no. 5,489,677, and the amide backbones of the above referenced US patent no. 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced US patent no. 5,034,506.

[0153] Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C to CO alkyl or C2 to CO alkenyl and alkynyl. Particularly preferred are O(CH₂)_nOmCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON(CH₂)_nCH₃)₂ where n and m can be from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C to CO, (lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification comprises 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., (1995) *Helv. Chim. Acta*, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification comprises 2'-dimethylaminoethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as described in examples herein below, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂.

[0154] Other preferred modifications comprise 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-O-CH₂CH₂CH₂NH₂) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures comprise, but are not limited to, US patent nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920.

[0155] Oligonucleotides may also comprise nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleotides comprise the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleotides comprise other synthetic and natural nucleotides such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo-uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylquanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine.

[0156] Further, nucleotides comprise those disclosed in United States Patent No. 3,687,808, those disclosed in 'The Concise Encyclopedia of Polymer Science And Engineering', pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., 'Angewandte Chemie, International Edition', 1991, 30, page 613, and those disclosed by Sanghvi, Y.S., Chapter 15, 'Antisense Research and Applications', pages 289-302, Crooke, S.T. and Lebleu, B. ea., CRC Press, 1993. Certain of these nucleotides are particularly useful for increasing the binding affinity of the oligomeric compounds of the disclosure. These comprise 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, comprising 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds, 'Antisense Research and Applications', CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

[0157] Representative United States patents that teach the preparation of the above noted modified nucleotides as well as other modified nucleotides comprise, but are not limited to, US patent nos. 3,687,808, as well as 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,596,091; 5,614,617; 5,750,692, and 5,681,941.

[0158] Another modification of the oligonucleotides of the disclosure involves chemically linking to the oligonucleotide one or more moieties or conjugates, which enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide.

[0159] Such moieties comprise but are not limited to, lipid moieties such as a cholesterol moiety (Letsinger et al., (1989) *Proc. Natl. Acad. Sci. USA*, 86, 6553-6556), cholic acid (Manoharan et al., (1994) *Bioorg. Med. Chem. Lett.*, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., (1992) *Ann. N. Y. Acad. Sci.*, 660, 306-309; Manoharan et al., (1993) *Bioorg. Med. Chem. Lett.*, 3, 2765-2770), a thiocholesterol (Oberhauser et al., (1992) *Nucl. Acids Res.*, 20,

533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Kabanov et al., (1990) FEBS Lett., 259, 327-330; Svinarchuk et al., (1993) Biochimie 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., (1995) Tetrahedron Lett., 36, 3651-3654; Shea et al., (1990) Nucl. Acids Res., 18, 3777-3783), a polyamine or a polyethylene glycol chain (Mancharan et al., (1995) Nucleosides & Nucleotides, 14, 969-973), or adamantane acetic acid (Manoharan et al., (1995) Tetrahedron Lett., 36, 3651-3654), a palmityl moiety (Mishra et al., (1995) Biochim. Biophys. Acta, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-t oxycholesterol moiety (Crooke et al., (1996) J. Pharmacol. Exp. Ther., 277, 923-937).

[0160] Representative United States patents that teach the preparation of such oligonucleotides conjugates comprise, but are not limited to, US patent nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552, 538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486, 603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762, 779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082, 830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5, 245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391, 723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5, 565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599, 928 and 5,688,941.

[0161] *Drug discovery:* The compounds of the present disclosure can also be applied in the areas of drug discovery and target validation. The present disclosure comprehends the use of the compounds and preferred target segments identified herein in drug discovery efforts to elucidate relationships that exist between Brain derived neurotrophic factor (BDNF) polynucleotides and a disease state, phenotype, or condition. These methods include detecting or modulating Brain derived neurotrophic factor (BDNF) polynucleotides comprising contacting a sample, tissue, cell, or organism with the compounds of the present disclosure, measuring the nucleic acid or protein level of Brain derived neurotrophic factor (BDNF) polynucleotides and/or a related phenotypic or chemical endpoint at some time after treatment, and optionally comparing the measured value to a non-treated sample or sample treated with a further compound of the disclosure. These methods can also be performed in parallel or in combination with other experiments to determine the function of unknown genes for the process of target validation or to determine the validity of a particular gene product as a target for treatment or prevention of a particular disease, condition, or phenotype.

Assessing Up-regulation or Inhibition of Gene Expression:

[0162] Transfer of an exogenous nucleic acid into a host cell or organism can be assessed by directly detecting the presence of the nucleic acid in the cell or organism. Such detection can be achieved by several methods well known in the art. For example, the presence of the exogenous nucleic acid can be detected by Southern blot or by a polymerase chain reaction (PCR) technique using primers that specifically amplify nucleotide sequences associated with the nucleic acid. Expression of the exogenous nucleic acids can also be measured using conventional methods including gene expression analysis. For instance, mRNA produced from an exogenous nucleic acid can be detected and quantified using a Northern blot and reverse transcription PCR (RT-PCR).

[0163] Expression of RNA from the exogenous nucleic acid can also be detected by measuring an enzymatic activity or a reporter protein activity. For example, antisense modulatory activity can be measured indirectly as a decrease or increase in target nucleic acid expression as an indication that the exogenous nucleic acid is producing the effector RNA. Based on sequence conservation, primers can be designed and used to amplify coding regions of the target genes. Initially, the most highly expressed coding region from each gene can be used to build a model control gene, although any coding or non coding region can be used. Each control gene is assembled by inserting each coding region between a reporter coding region and its poly(A) signal. These plasmids would produce an mRNA with a reporter gene in the upstream portion of the gene and a potential RNAi target in the 3' non-coding region. The effectiveness of individual antisense oligonucleotides would be assayed by modulation of the reporter gene. Reporter genes useful in the methods of the present disclosure include acetohydroxyacid synthase (AHAS), alkaline phosphatase (AP), beta galactosidase (LacZ), beta glucuronidase (GUS), chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), cyan fluorescent protein (CFP), horseradish peroxidase (HRP), luciferase (Luc), nopaline synthase (NOS), octopine synthase (OCS), and derivatives thereof. Multiple selectable markers are available that confer resistance to ampicillin, bleomycin, chloramphenicol, gentamycin, hygromycin, kanamycin, lincomycin, methotrexate, phosphinothricin, puromycin, and tetracycline. Methods to determine modulation of a reporter gene are well known in the art, and include, but are not limited to, fluorometric methods (e.g. fluorescence spectroscopy, Fluorescence Activated Cell Sorting (FACS), fluorescence microscopy), antibiotic resistance determination.

[0164] BDNF protein and mRNA expression can be assayed using methods known to those of skill in the art and described elsewhere herein. For example, immunoassays such as the ELISA can be used to measure protein levels. BDNF ELISA kits are available commercially, e.g., from R&D Systems (Minneapolis, MN).

[0165] In instances, BDNF expression (e.g., mRNA or protein) in a sample (e.g., cells or tissues in vivo or in vitro) treated using an antisense oligonucleotide of the disclosure is evaluated by comparison with BDNF expression in a

control sample. For example, expression of the protein or nucleic acid can be compared using methods known to those of skill in the art with that in a mock-treated or untreated sample. Alternatively, comparison with a sample treated with a control antisense oligonucleotide (e.g., one having an altered or different sequence) can be made depending on the information desired. In another instance, a difference in the expression of the BDNF protein or nucleic acid in a treated

vs an untreated sample can be compared with the difference in expression of a different nucleic acid (including any standard deemed appropriate by the researcher, e.g., a housekeeping gene) in a treated sample vs an untreated sample. **[0166]** Observed differences can be expressed as desired, e.g., in the form of a ratio or fraction, for use in a comparison with control. In instances, the level of BDNF mRNA or protein, in a sample treated with an antisense oligonucleotide of the present disclosure, is increased or decreased by about 1.25-fold to about 10-fold or more relative to an untreated sample or a sample treated with a control nucleic acid. In instances, the level of BDNF mRNA or protein is increased or decreased by at least about 1.25-fold, at least about 1.3-fold, at least about 1.4-fold, at least about 1.5-fold, at least about 1.6-fold, at least about 1.7-fold, at least about 1.8-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 4.5-fold, at least about 5-fold, at least about 5.5-fold, at least about 6-fold, at least about 6.5-fold, at least about 7-fold, at least about 7.5-fold, at least about 8-fold, at least about 8.5-fold, at least about 9-fold, at least about 9.5-fold, or at least about 10-fold or more.

Kits, Research Reagents, Diagnostics, and Therapeutics

[0167] The compounds of the present disclosure can be utilized for diagnostics, therapeutics, and prophylaxis, and as research reagents and components of kits. Furthermore, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes or to distinguish between functions of various members of a biological pathway.

[0168] For use in kits and diagnostics and in various biological systems, the compounds of the present disclosure, either alone or in combination with other compounds or therapeutics, are useful as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

[0169] As used herein the term "biological system" or "system" is defined as any organism, cell, cell culture or tissue that expresses, or is made competent to express products of the Brain derived neurotrophic factor (BDNF) genes. These include, but are not limited to, humans, transgenic animals, cells, cell cultures, tissues, xenografts, transplants and combinations thereof.

[0170] As one non limiting example, expression patterns within cells or tissues treated with one or more antisense compounds are compared to control cells or tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other compounds that affect expression patterns.

[0171] Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and Vilo, (2000) FEBS Lett., 480, 17-24; Celis, et al., (2000) FEBS Lett., 480, 2-16), SAGE (serial analysis of gene expression) (Madden, et al., (2000) Drug Discov. Today, 5, 415- 425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, (1999) Methods Enzymol., 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, et al., (2000) Proc. Natl. Acad. Sci. U.S.A., 97, 1976-81), protein arrays and proteomics (Celis, et al., (2000) FEBS Lett., 480, 2-16; Jungblut, et al., Electrophoresis, 1999, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, et al., FEBS Lett., 2000, 480, 2-16; Larsson, et al., J. Biotechnol., 2000, 80, 143-57), subtractive RNA fingerprinting (SuRF) (Fuchs, et al., (2000) Anal. Biochem. 286, 91-98; Larson, et al., (2000) Cytometry 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and Belmont, (2000) Curr. Opin. Microbiol. 3, 316-21), comparative genomic hybridization (Carulli, et al., (1998) J. Cell Biochem. Suppl., 31, 286-96), FISH (fluorescent in situ hybridization) techniques (Going and Gusterson, (1999) Eur. J. Cancer, 35, 1895-904) and mass spectrometry methods (To, Comb. (2000) Chem. High Throughput Screen, 3, 235-41).

[0172] The compounds of the disclosure are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding Brain derived neurotrophic factor (BDNF). For example, oligonucleotides that hybridize with such efficiency and under such conditions as disclosed herein as to be effective Brain derived neurotrophic factor (BDNF) modulators are effective primers or probes under conditions favoring gene amplification or detection, respectively. These primers and probes are useful in methods requiring the specific detection of nucleic acid molecules encoding Brain derived neurotrophic factor (BDNF) and in the amplification of said nucleic acid molecules for detection or for use in further studies of Brain derived neurotrophic factor (BDNF). Hybridization of the antisense oligonucleotides, particularly the primers and probes, of the disclosure with a nucleic acid encoding Brain derived neurotrophic factor (BDNF) can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabeling of the oligonucleotide, or any other suitable detection means. Kits using such detection means for detecting

the level of Brain derived neurotrophic factor (BDNF) in a sample may also be prepared.

[0173] The specificity and sensitivity of antisense are also harnessed by those of skill in the art for therapeutic uses. Antisense compounds have been employed as therapeutic moieties in the treatment of disease states in animals, including humans. Antisense oligonucleotide drugs have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that antisense compounds can be useful therapeutic modalities that can be configured to be useful in treatment regimes for the treatment of cells, tissues and animals, especially humans.

[0174] For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of Brain derived neurotrophic factor (BDNF) polynucleotides is treated by administering antisense compounds in accordance with this disclosure. For example, in one non-limiting instance, the methods comprise the step of administering to the animal in need of treatment, a therapeutically effective amount of Brain derived neurotrophic factor (BDNF) modulator. The Brain derived neurotrophic factor (BDNF) modulators of the present disclosure effectively modulate the activity of the Brain derived neurotrophic factor (BDNF) or modulate the expression of the Brain derived neurotrophic factor (BDNF) protein. In one instance, the activity or expression of Brain derived neurotrophic factor (BDNF) in an animal is inhibited by about 10% as compared to a control. Preferably, the activity or expression of Brain derived neurotrophic factor (BDNF) in an animal is inhibited by about 30%. More preferably, the activity or expression of Brain derived neurotrophic factor (BDNF) in an animal is inhibited by 50% or more. Thus, the oligomeric compounds modulate expression of Brain derived neurotrophic factor (BDNF) mRNA by at least 10%, by at least 50%, by at least 25%, by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 75%, by at least 80%, by at least 85%, by at least 90%, by at least 95%, by at least 98%, by at least 99%, or by 100% as compared to a control.

[0175] In one instance, the activity or expression of Brain derived neurotrophic factor (BDNF) and/or in an animal is increased by about 10% as compared to a control. Preferably, the activity or expression of Brain derived neurotrophic factor (BDNF) in an animal is increased by about 30%. More preferably, the activity or expression of Brain derived neurotrophic factor (BDNF) in an animal is increased by 50% or more. Thus, the oligomeric compounds modulate expression of Brain derived neurotrophic factor (BDNF) mRNA by at least 10%, by at least 50%, by at least 25%, by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 75%, by at least 80%, by at least 85%, by at least 90%, by at least 95%, by at least 98%, by at least 99%, or by 100% as compared to a control.

[0176] For example, the reduction of the expression of Brain derived neurotrophic factor (BDNF) may be measured in serum, blood, adipose tissue, liver or any other body fluid, tissue or organ of the animal. Preferably, the cells contained within said fluids, tissues or organs being analyzed contain a nucleic acid molecule encoding Brain derived neurotrophic factor (BDNF) peptides and/or the Brain derived neurotrophic factor (BDNF) protein itself.

[0177] The compounds of the disclosure can be utilized in pharmaceutical compositions by adding an effective amount of a compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the compounds and methods of the disclosure may also be useful prophylactically.

Conjugates

[0178] Another modification of the oligonucleotides of the disclosure involves chemically linking to the oligonucleotide one or more moieties or conjugates that enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. These moieties or conjugates can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the disclosure include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this disclosure, include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence-specific hybridization with the target nucleic acid. Groups that enhance the pharmacokinetic properties, in the context of this disclosure, include groups that improve uptake, distribution, metabolism or excretion of the compounds of the present disclosure. Representative conjugate groups are disclosed in International Patent Application No. PCT/US92/09196, filed Oct. 23, 1992, and U.S. Pat. No. 6,287,860. Conjugate moieties include, but are not limited to, lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-5- tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-Hphosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety. Oligonucleotides of the disclosure may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepam, indomethacin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.

[0179] Representative United States patents that teach the preparation of such oligonucleotides conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941.

Formulations

[0180] The compounds of the disclosure may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption-assisting formulations include, but are not limited to, U.S. Pat. Nos. 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,165; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756.

[0181] Although, the antisense oligonucleotides do not need to be administered in the context of a vector in order to modulate a target expression and/or function, instances of the disclosure relates to expression vector constructs for the expression of antisense oligonucleotides, comprising promoters, hybrid promoter gene sequences and possess a strong constitutive promoter activity, or a promoter activity which can be induced in the desired case.

[0182] In an instance, disclosure practice involves administering at least one of the foregoing antisense oligonucleotides with a suitable nucleic acid delivery system. In one instance, that system includes a non-viral vector operably linked to the polynucleotide. Examples of such nonviral vectors include the oligonucleotide alone (e.g. any one or more of SEQ ID NOS: 3 to 8) or in combination with a suitable protein, polysaccharide or lipid formulation.

[0183] Additionally suitable nucleic acid delivery systems include viral vector, typically sequence from at least one of an adenovirus, adenovirus-associated virus (AAV), helper-dependent adenovirus, retrovirus, or hemagglutinin virus of Japan-liposome (HVJ) complex. Preferably, the viral vector comprises a strong eukaryotic promoter operably linked to the polynucleotide e.g., a cytomegalovirus (CMV) promoter.

[0184] Additionally preferred vectors include viral vectors, fusion proteins and chemical conjugates. Retroviral vectors include Moloney murine leukemia viruses and HIV-based viruses. One preferred HIV-based viral vector comprises at least two vectors wherein the gag and pol genes are from an HIV genome and the env gene is from another virus. DNA viral vectors are preferred. These vectors include pox vectors such as orthopox or avipox vectors, herpesvirus vectors such as a herpes simplex I virus (HSV) vector [Geller, A.I. et al., (1995) J. Neurochem, 64: 487; Lim, F., et al., in DNA Cloning: Mammalian Systems, D. Glover, Ed. (Oxford Univ. Press, Oxford England) (1995); Geller, A.I. et al., (1993) Proc Natl. Acad. Sci.: U.S.A.:90 7603; Geller, A.I., et al., (1990) Proc Natl. Acad. Sci USA: 87:1149], Adenovirus Vectors (LeGal LaSalle et al., Science, 259:988 (1993); Davidson, et al., (1993) Nat. Genet. 3: 219; Yang, et al., (1995) J. Virol. 69: 2004) and Adeno-associated Virus Vectors (Kapliitt, M.G., et al., (1994) Nat. Genet. 8:148).

[0185] The antisense compounds of the disclosure encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof.

[0186] The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the disclosure: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto. For oligonucleotides, preferred examples of pharmaceutically acceptable salts and their uses are further described in U.S. Pat. No. 6,287,860.

[0187] The present disclosure also includes pharmaceutical compositions and formulations that include the antisense compounds of the disclosure. The pharmaceutical compositions of the present disclosure may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.

[0188] For treating tissues in the central nervous system, administration can be made by, e.g., injection or infusion into the cerebrospinal fluid. Administration of antisense RNA into cerebrospinal fluid is described, e.g., in U.S. Pat. App. Pub. No. 2007/0117772, "Methods for slowing familial ALS disease progression,".

[0189] When it is intended that the antisense oligonucleotide of the present disclosure be administered to cells in the central nervous system, administration can be with one or more agents capable of promoting penetration of the subject antisense oligonucleotide across the blood-brain barrier. Injection can be made, e.g., in the entorhinal cortex or hippocampus. Delivery of neurotrophic factors by administration of an adenovirus vector to motor neurons in muscle tissue is described in, e.g., U.S. Pat. No. 6,632,427, "Adenoviral-vector-mediated gene transfer into medullary motor neurons,".

Delivery of vectors directly to the brain, e.g., the striatum, the thalamus, the hippocampus, or the substantia nigra, is known in the art and described, e.g., in U.S. Pat. No. 6,756,523, "Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain,". Administration can be rapid as by injection or made over a period of time as by slow infusion or administration of slow release formulations.

The subject antisense oligonucleotides can also be linked or conjugated with agents that provide desirable pharmaceutical or pharmacodynamic properties. For example, the antisense oligonucleotide can be coupled to any substance, known in the art to promote penetration or transport across the blood-brain barrier, such as an antibody to the transferrin receptor, and administered by intravenous injection. The antisense compound can be linked with a viral vector, for example, that makes the antisense compound more effective and/or increases the transport of the antisense compound across the blood-brain barrier. Osmotic blood brain barrier disruption can also be accomplished by, e.g., infusion of sugars including, but not limited to, meso erythritol, xylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, myoinositol, L(-) fructose, D(-) mannitol, D(+) glucose, D(+) arabinose, D(-) arabinose, cellobiose, D(+) maltose, D(+) raffinose, L(+) rhamnose, D(+) melibiose, D(-) ribose, adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, and L(-) lyxose, or amino acids including, but not limited to, glutamine, lysine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, tyrosine, valine, and taurine. Methods and materials for enhancing blood brain barrier penetration are described, e.g., in U. S. Patent No. 4,866,042, "Method for the delivery of genetic material across the blood brain barrier," 6,294,520, "Material for passage through the blood-brain barrier," and 6,936,589, "Parenteral delivery systems,".

[0190] The subject antisense compounds may be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. For example, cationic lipids may be included in the formulation to facilitate oligonucleotide uptake. One such composition shown to facilitate uptake is LIPOFECTIN (available from GIBCO-BRL, Bethesda, MD).

[0191] Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

[0192] The pharmaceutical formulations of the present disclosure, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

[0193] The compositions of the present disclosure may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present disclosure may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

[0194] Pharmaceutical compositions of the present disclosure include, but are not limited to, solutions, emulsions, foams and liposome-containing formulations. The pharmaceutical compositions and formulations of the present disclosure may comprise one or more penetration enhancers, carriers, excipients or other active or inactive ingredients.

[0195] Emulsions are typically heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. Emulsions may contain additional components in addition to the dispersed phases, and the active drug that may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Microemulsions are included as an instance of the present disclosure. Emulsions and their uses are well known in the art and are further described in U.S. Pat. No. 6,287,860.

[0196] Formulations of the present disclosure include liposomal formulations. As used in the present disclosure, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers. Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior that contains the composition to be delivered. Cationic liposomes are positively charged liposomes that are believed to interact with negatively charged DNA molecules to form a stable complex. Liposomes that are pH-sensitive or negatively-charged are believed to entrap DNA rather than complex with it. Both cationic and noncationic liposomes have been used to deliver DNA to cells.

[0197] Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids. When incorporated into liposomes, these specialized lipids result in liposomes with enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome comprises one or more glycolipids or is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. Liposomes and their uses are further described in U.S. Pat. No. 6,287,860.

[0198] The pharmaceutical formulations and compositions of the present disclosure may also include surfactants. The use of surfactants in drug products, formulations and in emulsions is well known in the art. Surfactants and their uses are further described in U.S. Pat. No. 6,287,860.

[0199] In one instance, the present disclosure employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs. Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating nonsurfactants. Penetration enhancers and their uses are further described in U.S. Pat. No. 6,287,860.

[0200] One of skill in the art will recognize that formulations are routinely designed according to their intended use, i.e. route of administration.

[0201] Preferred formulations for topical administration include those in which the oligonucleotides of the disclosure are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoyl-phosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoyl-phosphatidyl ethanolamine DOTMA).

[0202] For topical or other administration, oligonucleotides of the disclosure may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters, pharmaceutically acceptable salts thereof, and their uses are further described in U.S. Pat. No. 6,287,860.

[0203] Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitabets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Preferred oral formulations are those in which oligonucleotides of the disclosure are administered in conjunction with one or more penetration enhancers surfactants and chelators. Preferred surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Preferred bile acids/salts and fatty acids and their uses are further described in U.S. Pat. No. 6,287,860. Also preferred are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly preferred combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the disclosure may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents and their uses are further described in U.S. Pat. No. 6,287,860.

[0204] Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions that may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

[0205] Certain instances of the disclosure provide pharmaceutical compositions containing one or more oligomeric compounds and one or more other chemotherapeutic agents that function by a non-antisense mechanism. Examples of such chemotherapeutic agents include but are not limited to cancer chemotherapeutic drugs such as daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bischloroethyl- nitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5- azacytidine, hydroxyurea, deoxycytosine, 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). When used with the compounds of the disclosure, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the disclosure. Combinations of antisense compounds and other non-antisense drugs are also within the scope of this disclosure. Two or more combined compounds may be used together or sequentially.

[0206] In another related instance, compositions of the disclosure may contain one or more antisense compounds,

particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. For example, the first target may be a particular antisense sequence of Brain derived neurotrophic factor (BDNF), and the second target may be a region from another nucleotide sequence. Alternatively, compositions of the disclosure may contain two or more antisense compounds targeted to different regions of the same Brain derived neurotrophic factor (BDNF) nucleic acid target. Numerous examples of antisense compounds are illustrated herein and others may be selected from among suitable compounds known in the art. Two or more combined compounds may be used together or sequentially.

Dosing:

[0207] The formulation of therapeutic compositions and their subsequent administration (dosing) is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC50s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 μ g to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 μ g to 100 g per kg of body weight, once or more daily, to once every 20 years. In instances, a patient is treated with a dosage of drug that is at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100 mg/kg body weight. Certain injected dosages of antisense oligonucleotides are described, e.g., in U.S. Pat. No. 7,563,884, "Antisense modulation of PTP1B expression,".

[0208] While various instances of the present disclosure have been described above, it should be understood that they have been presented by way of example only, and not limitation. Numerous changes to the disclosed instances can be made in accordance with the disclosure herein without departing from the spirit or scope of the disclosure. Thus, the breadth and scope of the present disclosure should not be limited by any of the above described instances.

[0209] By their citation of various references in this document, Applicants do not admit any particular reference is "prior art" to their invention. Instances of inventive compositions and methods are illustrated in the following examples.

EXAMPLES

[0210] The following non-limiting Examples serve to illustrate selected instances of the disclosure. It will be appreciated that variations in proportions and alternatives in elements of the components shown will be apparent to those skilled in the art and are within the scope of instances of the present disclosure.

Example 1: Design of antisense oligonucleotides specific for a nucleic acid molecule antisense to a Brain derived neurotrophic factor (BDNF) polynucleotide and/or a sense strand of Brain derived neurotrophic factor (BDNF) polynucleotide

[0211] As indicated above the term "oligonucleotide specific for" or "oligonucleotide targets" refers to an oligonucleotide having a sequence (i) capable of forming a stable complex with a portion of the targeted gene, or (ii) capable of forming a stable duplex with a portion of an mRNA transcript of the targeted gene.

[0212] Selection of appropriate oligonucleotides is facilitated by using computer programs that automatically align nucleic acid sequences and indicate regions of identity or homology. Such programs are used to compare nucleic acid sequences obtained, for example, by searching databases such as GenBank or by sequencing PCR products. Comparison of nucleic acid sequences from a range of species allows the selection of nucleic acid sequences that display an appropriate degree of identity between species. In the case of genes that have not been sequenced, Southern blots are performed to allow a determination of the degree of identity between genes in target species and other species. By performing Southern blots at varying degrees of stringency, as is well known in the art, it is possible to obtain an approximate measure of identity. These procedures allow the selection of oligonucleotides that exhibit a high degree of complementarity to target nucleic acid sequences in a subject to be controlled and a lower degree of complementarity to corresponding nucleic acid sequences in other species. One skilled in the art will realize that there is considerable

latitude in selecting appropriate regions of genes for use in the present disclosure.

[0213] An antisense compound is "specifically hybridizable" when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a modulation of function and/or activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and under conditions in which assays are performed in the case of in vitro assays

[0214] The hybridization properties of the oligonucleotides described herein can be determined by one or more in vitro assays as known in the art. For example, the properties of the oligonucleotides described herein can be obtained by determination of binding strength between the target natural antisense and a potential drug molecules using melting curve assay.

[0215] The binding strength between the target natural antisense and a potential drug molecule (Molecule) can be estimated using any of the established methods of measuring the strength of intermolecular interactions, for example, a melting curve assay.

[0216] Melting curve assay determines the temperature at which a rapid transition from double-stranded to single-stranded conformation occurs for the natural antisense/Molecule complex. This temperature is widely accepted as a reliable measure of the interaction strength between the two molecules.

[0217] A melting curve assay can be performed using a cDNA copy of the actual natural antisense RNA molecule or a synthetic DNA or RNA nucleotide corresponding to the binding site of the Molecule. Multiple kits containing all necessary reagents to perform this assay are available (e.g. Applied Biosystems Inc. MeltDoctor kit). These kits include a suitable buffer solution containing one of the double strand DNA (dsDNA) binding dyes (such as ABI HRM dyes, SYBR Green, SYTO, etc.). The properties of the dsDNA dyes are such that they emit almost no fluorescence in free form, but are highly fluorescent when bound to dsDNA.

[0218] To perform the assay the cDNA or a corresponding oligonucleotide are mixed with Molecule in concentrations defined by the particular manufacturer's protocols. The mixture is heated to 95 °C to dissociate all pre-formed dsDNA complexes, then slowly cooled to room temperature or other lower temperature defined by the kit manufacturer to allow the DNA molecules to anneal. The newly formed complexes are then slowly heated to 95 °C with simultaneous continuous collection of data on the amount of fluorescence that is produced by the reaction. The fluorescence intensity is inversely proportional to the amounts of dsDNA present in the reaction. The data can be collected using a real time PCR instrument compatible with the kit (e.g. ABI's StepOne Plus Real Time PCR System or LightTyper instrument, Roche Diagnostics, Lewes, UK).

[0219] Melting peaks are constructed by plotting the negative derivative of fluorescence with respect to temperature ($-d(\text{Fluorescence})/dT$) on the y-axis) against temperature (x-axis) using appropriate software (for example LightTyper (Roche) or SDS Dissociation Curve, ABI). The data is analyzed to identify the temperature of the rapid transition from dsDNA complex to single strand molecules. This temperature is called T_m and is directly proportional to the strength of interaction between the two molecules. Typically, T_m will exceed 40 °C.

Example 2: Modulation of BDNF polynucleotides

Treatment of HepG2 cells with antisense oligonucleotides:

[0220] HepG2 cells from ATCC (cat# HB-8065) were grown in growth media (MEM/EBSS (Hyclone cat #SH30024, or Mediatech cat # MT-10-010-CV) +10% FBS (Mediatech cat# MT35- 011-CV)+ penicillin/streptomycin (Mediatech cat# MT30-002-CI)) at 37°C and 5% CO₂. One day before the experiment the cells were replated at the density of $1.5 \times 10^5/\text{ml}$ into 6 well plates and incubated at 37°C and 5% CO₂. On the day of the experiment the media in the 6 well plates was changed to fresh growth media. All antisense oligonucleotides were diluted to the concentration of 20 µM. Two µl of this solution was incubated with 400 µl of Opti-MEM media (Gibco cat#31985-070) and 4 µl of Lipofectamine 2000 (Invitrogen cat# 11668019) at room temperature for 20 min and applied to each well of the 6 well plates with HepG2 cells. A Similar mixture including 2 µl of water instead of the oligonucleotide solution was used for the mock-transfected controls. After 3-18 h of incubation at 37°C and 5% CO₂ the media was changed to fresh growth media. 48 h after addition of antisense oligonucleotides the media was removed and RNA was extracted from the cells using SV Total RNA Isolation System from Promega (cat# Z3105) or RNeasy Total RNA Isolation kit from Qiagen (cat# 74181) following the manufacturers' instructions. 600 ng of RNA was added to the reverse transcription reaction performed using Verso cDNA kit from Thermo Scientific (cat#AB1453B) or High Capacity cDNA Reverse Transcription Kit (cat# 4368813) as described in the manufacturer's protocol. The cDNA from this reverse transcription reaction was used to monitor gene expression by real time PCR using ABI Taqman Gene Expression Mix (cat#4369510) and primers/probes designed by ABI (Applied Biosystems Taqman Gene Expression Assay by Applied Biosystems Inc., Foster City CA). The following PCR cycle was used: 50°C for 2 min, 95°C for 10 min, 40 cycles of (95°C for 15 seconds, 60°C for 1 min) using StepOne Plus Real Time PCR Machine (Applied Biosystems).

[0221] Fold change in gene expression after treatment with antisense oligonucleotides was calculated based on the difference in 18S-normalized dCt values between treated and mock-transfected samples.

[0222] Detection oligos for BDNF antisense:

5 ABI assay ID Hs00417345_m1
Context sequence GCACACCTGGAGATACTCTATTATA (SEQ ID No.: 9)

[0223] Detection oligos for BDNF:

10 ABI assay ID Hs00542425_s1
CCTGCAGAATGGCCTGGAATTACAA (SEQ ID No.: 10)

Results:

15 **[0224]** Real time PCR results show that the levels of the BDNF mRNA in HepG2 cells are significantly increased 48 h after treatment with two of the LNA gapmers with fully phosphothioated backbone designed to BDNF antisense (CUR-71, P=0.04, CUR-73, P=0.07, CUR-76, P=0.03) (Fig. 1A). In the same samples the levels of BDNF antisense were significantly decreased after treatment with all oligos except CUR-72, which is possibly due to different oligos affecting different splice variants of BDNF and/or BDNF antisense (Fig. 1B).

20 *Treatment of CHP212 cells with antisense oligonucleotides:*

[0225] CHP212 cells from ATCC (cat# CRL-2273) were grown in growth media (MEM/F12 (ATCC cat # 30-2003 and Mediatech cat# 10-080-CV) +10% FBS (Mediatech cat# MT35-011-CV)+ penicillin/streptomycin (Mediatech cat# MT30-002-Cl)) at 37°C and 5% CO₂. One day before the experiment the cells were replated at the density of 1.5×10^5 /ml into 6 well plates and incubated at 37°C and 5% CO₂. On the day of the experiment the media in the 6 well plates was changed to fresh growth media. All antisense oligonucleotides were diluted to the concentration of 20 µM. Two µl of this solution was incubated with 400 µl of Opti-MEM media (Gibco cat#31985-070) and 4 µl of Lipofectamine 2000 (Invitrogen cat# 11668019) at room temperature for 20 min and applied to each well of the 6 well plates with CHP212 cells. Similar mixture including 2 µl of water instead of the oligonucleotide solution was used for the mock-transfected controls. After 3-18 h of incubation at 37°C and 5% CO₂ the media was changed to fresh growth media. 48 h after addition of antisense oligonucleotides the media was removed and RNA was extracted from the cells using SV Total RNA Isolation System from Promega (cat # Z3105) or RNeasy Total RNA Isolation kit from Qiagen (cat# 74181) following the manufacturers' instructions. 600 ng of RNA was added to the reverse transcription reaction performed using Verso cDNA kit from Thermo Scientific (cat#AB1453B) or High Capacity cDNA Reverse Transcription Kit (cat# 4368813) as described in the manufacturer's protocol. The cDNA from this reverse transcription reaction was used to monitor gene expression by real time PCR using ABI Taqman Gene Expression Mix (cat#4369510) and primers/probes designed by ABI (Applied Biosystems Taqman Gene Expression Assay: Hs00542425_s1 by Applied Biosystems Inc., Foster City CA). The following PCR cycle was used: 50°C for 2 min, 95°C for 10 min, 40 cycles of (95°C for 15 seconds, 60°C for 1 min) using StepOne Plus Real Time PCR Machine (Applied Biosystems).

[0226] Fold change in gene expression after treatment with antisense oligonucleotides was calculated based on the difference in 18S-normalized dCt values between treated and mock-transfected samples.

Results:

45 **[0227]** Real time PCR results show that the levels of the BDNF mRNA in CHP212 cells are significantly increased 48 h after treatment with three of the oligos designed to BDNF antisense (Fig. 1C).

50 *Example 3: Antisense Modulation of BDNF polynucleotide and protein product and effect on memory and learning in amyloid-transgenic mice*

[0228] Antisense oligonucleotides specific for BDNF-AS (e.g., oligonucleotides identified by SEQ ID NOS 3-8) are administered to J20 mice, which express the human amyloid precursor protein (APP) transgene bearing both the Swedish and Indiana APP mutations. As described by, e.g., Nagahara, et al., 2009, "Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease," Nature Medicine 15(3): 331-337, incorporated herein by reference, these mice show cortical plaques and progressive cell loss in the entorhinal cortex beginning at age 2-3 months, and cognitive decline by 6-7 months. Pre-treatment blood samples are collected several days before dosing by collecting 4-7 drops from the tail vein. Each antisense oligonucleotide is dissolved in PBS and administered

into a mouse by injection into the entorhinal cortex or the hippocampus at about 10 mg/kg. Control mice (age-matched WT littermates) are administered the same volume of PBS alone. One month later, spatial memory is tested in the Morris water maze in treated and control mice, and their performance compared. Restorative effects are also tested by measuring hippocampal-dependent and hippocampal-independent learning. After testing, the mice are sacrificed and brain tissues (entorhinal cortex and hippocampal dentate gyrus) are collected for analysis of expression of BDNF protein and mRNA. Human BDNF protein concentration and secretion levels are determined using an enzyme linked immunosorbent assay (ELISA) kit (available commercially, e.g., Quantikine human BDNF, R&D Systems, Minneapolis, MN), according to the manufacturer's instructions. mRNA is assayed using RT-PCR, as described elsewhere herein.

Example 4: Antisense modulation of BDNF polynucleotide and protein product and effect on memory and learning in SAM-P8 mice.

[0229] The P8 strain of senescence accelerated mice (SAM), as described, e.g., in U.S. Pat. No. 6,310,048, "Antisense modulation of amyloid beta protein expression," incorporated herein by reference, show an age-related increase in impaired learning (acquisition) and memory (retention) as well as an age-related increase in the accumulation of amyloid precursor protein and A β P. SAM-P8 mice have a median life span of 17.2 months, as opposed to a normal life span of 24 months for standard R1 mice.

[0230] SAM-P8 mice are divided into seven groups of 10 mice each. At 11 months of age (4 weeks prior to training) one group is given 0.2 microliters of calf serum by intracerebral ventricular injection (ICV), while the other six groups are given one or two 0.2 microliter injections (each of 2 microliters and having 60 ng of oligonucleotide) ICV of antisense oligonucleotides of the present disclosure. Administration is performed by drilling a hole through the skull over the third ventricle (-0.5 relative to bregma; 0.5 mm right of central suture). The scalp is closed and the mice are returned to their cages. Two weeks after this first injection, one of the groups of treated mice and the group that had received serum are injected with the saline vehicle that is used as the carrier for the antisense oligonucleotides. At this same time (two weeks before training), each one of the oligonucleotides is administered in saline ICV to all of the mice in one group. Each administration contains 0.2 microliter (60 ng of oligonucleotide per injection).

[0231] Two weeks after the last injection, when the mice are 12 months of age, they are trained on footshock avoidance in a T-maze. The training and testing procedures are the same as described by Flood et al., Physiology & Behavior, 58:819-822 (1995); and Flood et al., Neurobiology of Aging, 14:159-166 (1993), and U.S. Pat. No. 6,310,048, all incorporated by reference herein. All mice are trained until they make their first avoidance response. Retention test scores when tested 1 hr after training and one week later are compared. One week after original training, retention for both 4 and 12 month-old mice is tested by continuing the training until each mouse makes 5 avoidances in 6 consecutive training trials. Results are expressed as means and with a standard error of the means. The trials to first avoidance, or to a criterion of 5 avoidances in 6 consecutive trials are analyzed in separate one way ANOVAs. Statistical differences between the means of the 12 month-old mice that received antisense oligonucleotides are compared to the means of the 12 month-old mice that received the saline solution vehicle using Dunnett's T-test.

[0232] Samples are recovered from the amygdala, hippocampal, and septum regions of the brains of each of four mice, two treated with the saline vehicle and the other two treated with the antisense oligonucleotides. The samples are tested for BDNF protein expression by ELISA or immuno-blotting against an antibody that specifically hybridizes to BDNF.

Example 5: Antisense modulation of BDNF polynucleotide and protein product and effect on disease progression in patients with Amyotrophic Lateral Sclerosis

[0233] A pharmaceutical composition comprising an antisense oligonucleotide of the present disclosure (e.g., an oligonucleotide identified by any of SEQ ID NOS: 3-8) is administered to the cerebrospinal fluid of an individual suffering from familial ALS. A Medtronic SyncroMed II pump is used to deliver the composition to the cerebrospinal fluid. The pump is surgically implanted according to the manufacturer instructions. The pump reservoir is loaded with the pharmaceutical composition in phosphate-buffered saline. The pharmaceutical composition is administered at an amount that yields an infusion of 8 mg to 12 mg/day of the antisense oligonucleotide into the cerebrospinal fluid. Antisense oligonucleotide is infused, for at least 28 days. The drug is pumped at a programmed dose into a catheter that is surgically intrathecally implanted.

[0234] Disease progression is measured by methods routine in the art and described herein, for example, using indicators including ALSFRS-R, and measurements of FEV₁, FVC, and muscle strength. These methods are used by a physician to assess disease state at initiation of treatment, and to provide a baseline for disease state. Subsequent assessments are performed at intervals, as determined by the physician, during the delivery period. Expression of BDNF protein and mRNA in cerebrospinal fluid is assayed. Human BDNF protein concentration and secretion levels are determined using an enzyme linked immunosorbent assay (ELISA) kit (e.g., Quantikine human BDNF, R&D Systems, Minneapolis, MN), according to the manufacturer's instructions. mRNA is assayed using RT-PCR, as described elsewhere

herein.

[0235] Although the disclosure has been illustrated and described with respect to one or more implementations, equivalent alterations and modifications will occur to others skilled in the art upon the reading and understanding of this specification and the annexed drawings. In addition, while a particular feature of the disclosure may have been disclosed with respect to only one of several implementations, such feature may be combined with one or more other features of the other implementations as may be desired and advantageous for any given or particular application.

[0236] The Abstract of the disclosure will allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the following claims.

Claims

1. An antisense oligonucleotide which targets a Brain derived neurotrophic factor (BDNF) natural antisense transcript for use as a therapeutic compound, wherein the BDNF natural antisense transcript is a BDNFOS transcript, and wherein the antisense oligonucleotide increases the expression of a Brain derived neurotrophic factor (BDNF).
2. An antisense oligonucleotide which targets a Brain derived neurotrophic factor (BDNF) natural antisense transcript, wherein the BDNF natural antisense transcript is a BDNFOS transcript, for use in the prevention or treatment of a Brain derived neurotrophic factor (BDNF) associated disease or disorder, wherein said antisense oligonucleotide increases the expression of a Brain derived neurotrophic factor (BDNF), wherein the disease or disorder is selected from the group consisting of neuro-otological disease or disorder, hearing loss, Rett syndrome, Alzheimer's disease, schizophrenia, Huntington's disease, spinal cord injury, depression, cognitive impairment, a bipolar disorder, WAGR syndrome and obesity.
3. Use of an antisense oligonucleotide which targets a Brain derived neurotrophic factor (BDNF) natural antisense transcript, wherein the BDNF natural antisense transcript is a BDNFOS transcript, for the manufacture of a medicament for the prevention or treatment of a Brain derived neurotrophic factor (BDNF) associated disease or disorder, wherein said antisense oligonucleotide increases the expression of a Brain derived neurotrophic factor (BDNF), wherein the disease or disorder is selected from the group consisting of neuro-otological disease or disorder, hearing loss, Rett syndrome, Alzheimer's disease, schizophrenia, Huntington's disease, spinal cord injury, depression, cognitive impairment, a bipolar disorder, WAGR syndrome and obesity.
4. An *in vitro* method of increasing the expression of a Brain derived neurotrophic factor (BDNF) in patient cells or tissues comprising: contacting said cells or tissues with an antisense oligonucleotide which targets a Brain derived neurotrophic factor (BDNF) natural antisense transcript, wherein the BDNF natural antisense transcript is a BDNFOS transcript; thereby increasing the expression of a Brain derived neurotrophic factor (BDNF).
5. Use according to Claim 3, or an antisense oligonucleotide for use according to Claim 1 or Claim 2, or a method according to Claim 4, wherein the natural antisense transcript has the nucleic acid sequence as set forth in SEQ ID NO: 2.
6. Use according to Claim 3 or Claim 5, or an antisense oligonucleotide for use according to any one of Claims 1, 2, or 5, or a method according to Claim 4 or Claim 5, wherein the antisense oligonucleotide is single stranded, or wherein the antisense oligonucleotide is a siRNA compound.
7. Use according to any one of Claims 3, 5 or 6, or an antisense oligonucleotide for use according to any one of Claims 1, 2, 5 or 6, or a method according to any one of Claims 4 to 6, wherein the antisense oligonucleotide comprises one of SEQ ID NOs: 3, 5, 6, 7, or 8.
8. Use according to any one of Claims 3, 5 to 7, or an antisense oligonucleotide for use according to any one of Claims 1, 2, 5 to 7, or a method according to any one of Claims 4 to 7, wherein the expression of a Brain derived neurotrophic factor (BDNF) is increased by at least 10%.
9. Use according to any one of Claims 3, 5 to 8, or an antisense oligonucleotide for use according to any one of Claims 1, 2, 5 to 8, or a method according to any one of Claims 4 to 8, wherein the antisense oligonucleotide further comprises one or more modifications comprising:

- a. at least one modified internucleoside linkage selected from: a phosphorothioate, alkylphosphonate, phos-

phorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetam-
date, carboxymethyl ester, and combinations thereof;

b. at least one modified nucleotide selected from: a peptide nucleic acid (PNA), a locked nucleic acid (LNA),
an arabino-nucleic acid (FANA), an analogue, a derivative, and combinations thereof; or

c. at least one modified sugar moiety selected from: a 2'-O-methoxyethyl modified sugar moiety, a 2'-Fluoro
modified sugar moiety, a 2'-methoxy modified sugar moiety, a 2'-O-alkyl modified sugar moiety, a bicyclic sugar
moiety, and combinations thereof.

10. An antisense oligonucleotide which targets a Brain derived neurotrophic factor (BDNF) natural antisense transcript,
wherein the BDNF natural antisense transcript is a BDNFOS transcript, wherein the oligonucleotide increases the
expression of a Brain derived neurotrophic factor (BDNF), wherein the antisense oligonucleotide is a siRNA com-
pound.

11. An antisense oligonucleotide which targets a Brain derived neurotrophic factor (BDNF) natural antisense transcript,
wherein the BDNF natural antisense transcript is a BDNFOS transcript, wherein the oligonucleotide increases the
expression of a Brain derived neurotrophic factor (BDNF), wherein the antisense oligonucleotide comprises one of
SEQ ID NOs: 3, 5, 6, 7, or 8.

12. The antisense oligonucleotide according to Claim 10 or Claim 11, wherein the BDNFOS transcript has the nucleic
acid sequence as set forth in SEQ ID NO: 2.

13. The antisense oligonucleotide according to Claim 11 or Claim 12, wherein the antisense oligonucleotide is single
stranded or wherein the antisense oligonucleotide is a siRNA compound.

14. The antisense oligonucleotide according to any one of Claims 10 to 13, wherein the expression of a Brain derived
neurotrophic factor (BDNF) is increased by at least 10%.

15. The antisense oligonucleotide according to any one of Claims 10 to 14, wherein the antisense oligonucleotide further
comprises one or more modifications comprising:

a. at least one modified internucleoside linkage selected from: a phosphorothioate, alkylphosphonate, phos-
phorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetami-
date, carboxymethyl ester, and combinations thereof;

b. at least one modified nucleotide selected from: a peptide nucleic acid (PNA), a locked nucleic acid (LNA),
an arabino-nucleic acid (FANA), an analogue, a derivative, and combinations thereof; or

c. at least one modified sugar moiety selected from: a 2'-O-methoxyethyl modified sugar moiety, a 2'-Fluoro
modified sugar moiety, a 2'-methoxy modified sugar moiety, a 2'-O-alkyl modified sugar moiety, a bicyclic sugar
moiety, and combinations thereof.

16. An antisense oligonucleotide according to any one of Claims 10, 12-15, wherein the antisense oligonucleotide is
between 10 to 30 nucleotides in length.

17. An antisense oligonucleotide according to any one of Claims 10, 12-16, wherein the antisense oligonucleotide has
at least 90% sequence complementarity to a BDNFOS transcript.

18. A pharmaceutical composition comprising at least one antisense oligonucleotide according to any one of Claims 10
to 17 and a pharmaceutically acceptable excipient.

Patentansprüche

1. Antisense-Oligonukleotid, das auf ein natürliches BDNF-(Brain Derived Neurotrophic Factor)-Antisense-Transkript
zur Verwendung als therapeutische Verbindung gerichtet ist, wobei das natürliche BDNF-Antisense-Transkript ein
BDNFOS-Transkript ist und wobei das Antisense-Oligonukleotid die Expression eines BDNF (Brain Derived Neu-
rotrophic Factor) erhöht.

2. Antisense-Oligonukleotid, das auf ein natürliches BDNF-(Brain Derived Neurotrophic Factor)-Antisense-Transkript
gerichtet ist, wobei das natürliche BDNF-Antisense-Transkript ein BDNFOS-Transkript zur Verwendung bei der

Verhütung oder Behandlung einer mit einer BDNF-(Brain Derived Neurotrophic Factor)-assoziierten Krankheit oder Störung ist, wobei das genannte Antisense-Oligonukleotid die Expression eines BDNF (Brain Derived Neurotrophic Factor) erhöht, wobei die Krankheit oder Störung ausgewählt ist aus der Gruppe bestehend aus neuro-otologischer Krankheit oder Störung, Hörverlust, Rett-Syndrom, Alzheimer-Krankheit, Schizophrenie, Huntington-Krankheit, Rückenmarksverletzung, Depression, kognitiver Beeinträchtigung, bipolarer Störung, WAGR-Syndrom und Fettleibigkeit.

3. Verwendung eines Antisense-Oligonukleotids, das auf ein natürliches BDNF-(Brain Derived Neurotrophic Factor)-Antisense-Transkript gerichtet ist, wobei das natürliche BDNF-Antisense-Transkript ein BDNFOS-Transkript ist, für die Herstellung eines Medikaments zur Verhütung oder Behandlung einer mit einer BDNF-(Brain Derived Neurotrophic Factor)-assoziierten Krankheit oder Störung, wobei das genannte Antisense-Oligonukleotid die Expression eines BDNF (Brain Derived Neurotrophic Factor) erhöht, wobei die Krankheit oder Störung ausgewählt ist aus der Gruppe bestehend aus neuro-otologischer Krankheit oder Störung, Hörverlust, Rett-Syndrom, Alzheimer-Krankheit, Schizophrenie, Huntington-Krankheit, Rückenmarksverletzung, Depression, kognitiver Beeinträchtigung, bipolarer Störung, WAGR-Syndrom und Fettleibigkeit.

4. *In-vitro*-Verfahren zum Erhöhen der Expression eines BDNF (Brain Derived Neurotrophic Factor) in Patientenzellen oder -geweben, das Folgendes beinhaltet: Inkontaktbringen der genannten Zellen oder Gewebe mit einem Antisense-Oligonukleotid, das auf ein natürliches BDNF-(Brain Derived Neurotrophic Factor)-Antisense-Transkript gerichtet ist, wobei das natürliche BDNF-Antisense-Transkript ein BDNFOS-Transkript ist; um dadurch die Expression eines BDNF (Brain Derived Neurotrophic Factor) zu erhöhen.

5. Verwendung nach Anspruch 3 oder Antisense-Oligonukleotid zur Verwendung nach Anspruch 1 oder Anspruch 2, oder Verfahren nach Anspruch 4, wobei das natürliche Antisense-Transkript die Nukleinsäuresequenz gemäß SEQ ID Nr. 2 hat.

6. Verwendung nach Anspruch 3 oder Anspruch 5 oder Antisense-Oligonukleotid zur Verwendung nach Anspruch 1, 2 oder 5 oder Verfahren nach Anspruch 4 oder Anspruch 5, wobei das Antisense-Oligonukleotid einzelsträngig ist oder wobei das Antisense-Oligonukleotid eine siRNA-Verbindung ist.

7. Verwendung nach einem der Ansprüche 3, 5 oder 6 oder Antisense-Oligonukleotid zur Verwendung nach Anspruch 1, 2, 5 oder 6 oder Verfahren nach einem der Ansprüche 4 bis 6, wobei das Antisense-Oligonukleotid SEQ ID Nr. 3, 5, 6, 7 oder 8 umfasst.

8. Verwendung nach einem der Ansprüche 3, 5 bis 7 oder Antisense-Oligonukleotid zur Verwendung nach einem der Ansprüche 1, 2, 5 bis 7 oder Verfahren nach einem der Ansprüche 4 bis 7, wobei die Expression eines BDNF (Brain Derived Neurotrophic Factor) um wenigstens 10 % erhöht wird.

9. Verwendung nach einem der Ansprüche 3, 5 bis 8 oder Antisense-Oligonukleotid zur Verwendung nach einem der Ansprüche 1, 2, 5 bis 8 oder Verfahren nach einem der Ansprüche 4 bis 8, wobei das Antisense-Oligonukleotid ferner eine oder mehrere Modifikationen umfasst, die Folgendes beinhalten:

a. wenigstens eine modifizierte Internukleosidverknüpfung, ausgewählt aus: einem Phosphorothioat, Alkylphosphonat, Phosphorodithioat, Alkylphosphonothioat, Phosphoramidat, Carbamat, Carbonat, Phosphattriester, Acetamidat, Carboxymethylester und Kombinationen davon;

b. wenigstens ein modifiziertes Nukleotid, ausgewählt aus: einer Peptidnukleinsäure (PNA), einer gesperrten Nukleinsäure (LNA), einer Arabinonukleinsäure (FANA), einem Analog, einem Derivat und Kombinationen davon; oder

c. wenigstens einen modifizierten Zuckeranteil, ausgewählt aus: einem 2'-O-Methoxyethyl-modifizierten Zuckeranteil, einem 2'-Fluor-modifizierten Zuckeranteil, einem 2'-Methoxy-modifizierten Zuckeranteil, einem 2'-O-Alkyl-modifizierten Zuckeranteil, einem bicyclischen Zuckeranteil und Kombinationen davon.

10. Antisense-Oligonukleotid, das auf ein natürliches BDNF-(Brain Derived Neurotrophic Factor)-Antisense-Transkript gerichtet ist, wobei das natürliche BDNF-Antisense-Transkript ein BDNFOS-Transkript ist, wobei das Oligonukleotid die Expression eines BDNF (Brain Derived Neurotrophic Factor) erhöht, wobei das Antisense-Oligonukleotid eine siRNA-Verbindung ist.

11. Antisense-Oligonukleotid, das ein natürliches BDNF-(Brain Derived Neurotrophic Factor)-Antisense-Transkript tar-

getiert, wobei das natürliche BDNF-Antisense-Transkript ein BDNFOS-Transkript ist, wobei das Oligonukleotid die Expression eines BDNF (Brain Derived Neurotrophic Factor) erhöht, wobei das Antisense-Oligonukleotid eine SEQ ID Nr. 3, 5, 6, 7 oder 8 umfasst.

- 5 12. Antisense-Oligonukleotid nach Anspruch 10 oder Anspruch 11, wobei das BDNFOS-Transkript die Nukleinsäuresequenz gemäß SEQ ID Nr. 2 hat.
13. Antisense-Oligonukleotid nach Anspruch 11 oder Anspruch 12, wobei das Antisense-Oligonukleotid einzelsträngig ist oder wobei das Antisense-Oligonukleotid eine siRNA-Verbindung ist.
- 10 14. Antisense-Oligonukleotid nach einem der Ansprüche 10 bis 13, wobei die Expression eines BDNF-(Brain Derived Neurotrophic Factor) um wenigstens 10 % erhöht ist.
- 15 15. Antisense-Oligonukleotid nach einem der Ansprüche 10 bis 14, wobei das Antisense-Oligonukleotid ferner eine oder mehrere Modifikationen umfasst, die Folgendes beinhalten:
 - a. wenigstens eine modifizierte Internukleosidverknüpfung, ausgewählt aus: einem Phosphorothioat, Alkylphosphonat, Phosphorodithioat, Alkylphosphonothioat, Phosphoramidat, Carbamat, Carbonat, Phosphattriester, Acetamidat, Carboxymethylester und Kombinationen davon;
 - 20 b. wenigstens ein modifiziertes Nukleotid, ausgewählt aus: einer Peptidnukleinsäure (PNA), einer gesperrten Nukleinsäure (LNA), einer Arabinonukleinsäure (FANA), einem Analog, einem Derivat und Kombinationen davon; oder
 - c. wenigstens einen modifizierten Zuckeranteil, ausgewählt aus: einem 2'-O-Methoxyethyl-modifizierten Zuckeranteil, einem 2'-Fluor-modifizierten Zuckeranteil, einem 2'-Methoxy-modifizierten Zuckeranteil, einem 2'-O-Alkyl-modifizierten Zuckeranteil, einem bicyclischen Zuckeranteil und Kombinationen davon.
16. Antisense-Oligonukleotid nach einem der Ansprüche 10, 12-15, wobei das Antisense-Oligonukleotid eine Länge zwischen 10 und 30 Nukleotiden hat.
- 30 17. Antisense-Oligonukleotid nach einem der Ansprüche 10, 12-16, wobei das Antisense-Oligonukleotid wenigstens 90 % Sequenzkomplementarität zu einem BDNFOS-Transkript hat.
18. Pharmazeutische Zusammensetzung, die wenigstens ein Antisense-Oligonukleotid nach einem der Ansprüche 10 bis 17 und einen pharmazeutisch akzeptablen Exzipienten umfasst.
- 35

Revendications

- 40 1. Oligonucléotide antisens qui cible un transcrit antisens naturel du facteur neurotrophique dérivé du cerveau (brain derived neurotrophic factor (BDNF)) destiné à une utilisation comme composé thérapeutique, le transcrit antisens naturel du BDNF étant un transcrit de BDNFOS, et l'oligonucléotide antisens augmentant l'expression d'un facteur neurotrophique dérivé du cerveau (BDNF).
- 45 2. Oligonucléotide antisens qui cible un transcrit antisens naturel du facteur neurotrophique dérivé du cerveau (BDNF), le transcrit antisens naturel du BDNF étant un transcrit de BDNFOS, destiné à une utilisation dans la prévention ou le traitement d'une maladie ou d'un trouble associé(e) au facteur neurotrophique dérivé du cerveau (BDNF), ledit oligonucléotide antisens augmentant l'expression d'un facteur neurotrophique dérivé du cerveau (BDNF), la maladie ou le trouble étant sélectionné(e) dans le groupe constitué d'une maladie ou d'un trouble neuro-otologique, d'une perte auditive, du syndrome de Rett, de la maladie d'Alzheimer, de la schizophrénie, de la maladie de Huntington, d'une lésion de la moelle épinière, d'une dépression, d'un trouble cognitif, d'un trouble bipolaire, du syndrome de WAGR et de l'obésité.
- 50
- 55 3. Utilisation d'un oligonucléotide antisens qui cible un transcrit antisens naturel du facteur neurotrophique dérivé du cerveau (BDNF), le transcrit antisens naturel du BDNF étant un transcrit de BDNFOS, pour la fabrication d'un médicament destiné à la prévention ou au traitement d'une maladie ou d'un trouble associé(e) au facteur neurotrophique dérivé du cerveau (BDNF), ledit oligonucléotide antisens augmentant l'expression d'un facteur neurotrophique dérivé du cerveau (BDNF), la maladie ou le trouble étant sélectionné(e) dans le groupe constitué d'une maladie ou d'un trouble neuro-otologique, d'une perte auditive, du syndrome de Rett, de la maladie d'Alzheimer, de la

schizophrénie, de la maladie de Huntington, d'une lésion de la moelle épinière, d'une dépression, d'un trouble cognitif, d'un trouble bipolaire, du syndrome de WAGR et de l'obésité.

- 5 4. Procédé *in vitro* d'augmentation de l'expression d'un facteur neurotrophique dérivé du cerveau (BDNF) dans des cellules ou des tissus de patients, comprenant : la mise en contact desdites cellules ou desdits tissus avec un oligonucléotide antisens qui cible un transcrit antisens naturel du facteur neurotrophique dérivé du cerveau (BDNF), le transcrit antisens naturel du BDNF étant un transcrit de BDNFOS ; en augmentant ainsi l'expression d'un facteur neurotrophique dérivé du cerveau (BDNF).
- 10 5. Utilisation selon la revendication 3, ou oligonucléotide antisens destiné à une utilisation selon la revendication 1 ou la revendication 2, ou procédé selon la revendication 4, le transcrit antisens naturel ayant la séquence d'acide nucléique telle qu'énoncée dans la SÉQ. ID n° 2.
- 15 6. Utilisation selon la revendication 3 ou la revendication 5, ou oligonucléotide antisens destiné à une utilisation selon l'une quelconque des revendications 1, 2 ou 5, ou procédé selon la revendication 4 ou la revendication 5, l'oligonucléotide antisens étant simple brin, ou l'oligonucléotide antisens étant un composé ARNsi.
- 20 7. Utilisation selon l'une quelconque des revendications 3, 5 ou 6, ou oligonucléotide antisens destiné à une utilisation selon l'une quelconque des revendications 1, 2, 5 ou 6, ou procédé selon l'une quelconque des revendications 4 à 6, l'oligonucléotide antisens comprenant une des SÉQ. ID n°s 3, 5, 6, 7 ou 8.
- 25 8. Utilisation selon l'une quelconque des revendications 3, 5 à 7, ou oligonucléotide antisens destiné à une utilisation selon l'une quelconque des revendications 1, 2, 5 à 7, ou procédé selon l'une quelconque des revendications 4 à 7, l'expression d'un facteur neurotrophique dérivé du cerveau (BDNF) étant augmentée d'au moins 10 %.
- 30 9. Utilisation selon l'une quelconque des revendications 3, 5 à 8, ou oligonucléotide antisens destiné à une utilisation selon l'une quelconque des revendications 1, 2, 5 à 8, ou procédé selon l'une quelconque des revendications 4 à 8, l'oligonucléotide antisens comprenant en outre une ou plusieurs modifications comprenant :
 - a. au moins une liaison internucléosides modifiée sélectionnée parmi : un phosphorothioate, un alkylphosphonate, un phosphorodithioate, un alkylphosphonothioate, un phosphoramidate, un carbamate, un carbonate, un triester de phosphate, un acétamidate, un ester carboxyméthyle, et des combinaisons de ceux-ci ;
 - b. au moins un nucléotide modifié sélectionné parmi : un acide nucléique peptidique (PNA), un acide nucléique bloqué (LNA), un acide arabino-nucléique (FANA), un analogue, un dérivé, et des combinaisons de ceux-ci ; ou
 - 35 c. au moins une fraction sucre modifiée sélectionnée parmi : une fraction sucre modifiée par un groupe 2'-O-méthoxyéthyle, une fraction sucre modifiée par un groupe 2'-fluoro, une fraction sucre modifiée par un groupe 2'-méthoxy, une fraction sucre modifiée par un groupe 2'-O-alkyle, une fraction sucre bicyclique, et des combinaisons de celles-ci.
- 40 10. Oligonucléotide antisens qui cible un transcrit antisens naturel du facteur neurotrophique dérivé du cerveau (BDNF), le transcrit antisens naturel du BDNF étant un transcrit de BDNFOS, l'oligonucléotide augmentant l'expression d'un facteur neurotrophique dérivé du cerveau (BDNF), l'oligonucléotide antisens étant un composé ARNsi.
- 45 11. Oligonucléotide antisens qui cible un transcrit antisens naturel du facteur neurotrophique dérivé du cerveau (BDNF), le transcrit antisens naturel du BDNF étant un transcrit de BDNFOS, l'oligonucléotide augmentant l'expression d'un facteur neurotrophique dérivé du cerveau (BDNF), l'oligonucléotide antisens comprenant une des SÉQ. ID n°s 3, 5, 6, 7 ou 8.
- 50 12. Oligonucléotide antisens selon la revendication 10 ou la revendication 11, le transcrit de BDNFOS ayant la séquence d'acide nucléique telle qu'énoncée dans la SÉQ. ID n° 2.
- 55 13. Oligonucléotide antisens selon la revendication 11 ou la revendication 12, l'oligonucléotide antisens étant simple brin ou l'oligonucléotide antisens étant un composé ARNsi.
14. Oligonucléotide antisens selon l'une quelconque des revendications 10 à 13, l'expression d'un facteur neurotrophique dérivé du cerveau (BDNF) étant augmentée d'au moins 10 %.
15. Oligonucléotide antisens selon l'une quelconque des revendications 10 à 14, l'oligonucléotide antisens comprenant

en outre une ou plusieurs modifications comprenant :

- a. au moins une liaison internucléosides modifiée sélectionnée parmi : un phosphorothioate, un alkylphosphonate, un phosphorodithioate, un alkylphosphonothioate, un phosphoramidate, un carbamate, un carbonate, un triester de phosphate, un acétamidate, un ester carboxyméthyle, et des combinaisons de ceux-ci ;
- b. au moins un nucléotide modifié sélectionné parmi : un acide nucléique peptidique (PNA), un acide nucléique bloqué (LNA), un acide arabino-nucléique (FANA), un analogue, un dérivé, et des combinaisons de ceux-ci ; ou
- c. au moins une fraction sucre modifiée sélectionnée parmi : une fraction sucre modifiée par un groupe 2'-O-méthoxyéthyle, une fraction sucre modifiée par un groupe 2'-fluoro, une fraction sucre modifiée par un groupe 2'-méthoxy, une fraction sucre modifiée par un groupe 2'-O-alkyle, une fraction sucre bicyclique, et des combinaisons de celles-ci.


16. Oligonucléotide antisens selon l'une quelconque des revendications 10, 12 à 15, l'oligonucléotide antisens ayant une longueur entre 10 et 30 nucléotides.

17. Oligonucléotide antisens selon l'une quelconque des revendications 10, 12 à 16, l'oligonucléotide antisens ayant une complémentarité de séquence d'au moins 90 % avec un transcrit de BDNFOS.

18. Composition pharmaceutique comprenant au moins un oligonucléotide antisens selon l'une quelconque des revendications 10 à 17 et un excipient acceptable au plan pharmaceutique.

FIGURE 1

A



B




FIGURE 1 (cont.)

C




FIGURE 2

(SEQ ID NO: 1)

>gi|219842286|ref|NM_170735| Homo sapiens brain-derived neurotrophic factor (BDNF), transcript variant 1, mRNA.

CACACACACACACACACAGAGAGAACATCTCTAGTAAAAAGAAAAGTTGAGCTTCTTAGCTAGATGTGTGATT
 AGCCAGAAAAAGCCAAGGAGTGAAGGGTTTTAGAGAACTGGAGGAGATAAAGTGGAGTCTGCATATGGGAGGCATTT
 GAAATGGACTTAAATGTCTTTTTAATGCTGACTTTTTTCAGTTTTCTCCTTACCAGACACATTGTTTTTCATGACATTA
 GCCCCAGGCATAGACACATCATTTAAATGAACATGTCAAAAAATGATTTCTGTTTAGAAATAAGCAAAACATTTTCA
 GTTGTGACCACCCAGGTGTAGAATAAAGAACAGTGAATTTGGGAGCCCTGAGTTCTAACATAAACTTTCTTCATGAC
 ATAAGGCAAGTCTTCTATGGCCTTTGGTTTCTTACCTGTAAAAACAGGATGGCTCAATGAAATTATCTTTCTTCTTT
 GCTATAATAGAGTATCTCTGTGGGAAGAGGAAAAAAGTCAATTTAAAGGCTCCTTATAGTTCCCAACTGCTGT
 TTTATTGTGCTATTTCATGCCTAGACATCAGATAGTAGAAAGGCCCATCAGACCCCTCAGGCCACTGCTGTTCTGT
 CACACATTCCTGCAAAGGACCATGTTGCTAACTTGAAAAAATTACTATTAATTACACTTGCAGTTGTTGCTTAGTA
 ACATTTATGATTTTGTGTTTCTCGTGACAGCATGAGCAGAGATCATTAAAAATTAACTTACAAAGCTGCTAAAGTG
 GGAAGAAGGAGAACTTGAAGCCACAATTTTTGCAGTTGCTTAGAAGCCATCTAATCTCAGGTTATATGCTAGATCTT
 GGGGGCAAACACTGTCATGTCTCTGTTTATATTAAACCACATACAGCACACTACTGACACTGATTTGTGTCTGGTGC
 AGCTGGAGTTTATCACCAGACATAAAAAACCTTGACCTGCAGAAATGGCCTGGAATTACAATCAGATGGGCCACA
 TGGCATCCCGGTGAAAGAAAGCCCTAACAGTTTTCTGTCTGTTTCTGCTTTCTCCCTACAGTTCCACCAGGTGAG
 AAGAGTGATGACCATCCTTTTCTTACTATGTTATTTCATCTTTGGTTGTCATGAAGGCTGCCCCCATGAAAGAAG
 CAAACATCCGAGGACAAGGTGGCTTGGCCTACCCAGGTGTGCGGACCCATGGGACTCTGGAGAGCGTGAATGGGCCC
 AAGGCAGGTTCAAGAGGCTTGACATCATTGGCTGACACTTTCGAACACGTGATAGAAGAGCTGTTGGATGAGGACCA
 GAAAGTTCGGCCCAATGAAGAAAACAATAAGGACGCAGACTTGTACACGTCCAGGGTGATGCTCAGTAGTCAAGTGC
 CTTTGGAGCCTCCTCTTCTCTTTCTGCTGGAGGAATACAAAAATTACCTAGATGCTGCAAACATGTCCATGAGGGTC
 CGGCGCCACTCTGACCTTGCCCGCGGAGGGGAGCTGAGCGTGTGTGACAGTATTAGTGAGTGGGTAACGGCGGCAGA
 CAAAAAGACTGCAGTGGACATGTGCGGCGGGGACGGTCACAGTCTTGAAGAGTCCCTGTATCAAAAGGCCAACTGA
 AGCAATACTTCTACGAGACCAAGTGAATCCCATGGTTTACACAAAAGAAGGCTGCAGGGGCATAGACAAAAGGCAT
 TGGAACCTCCAGTGCCGAACCTACCCAGTGTGACGTGCGGGCCCTTACCATGGATAGCAAAAAGAGAATTGGCTGGCG
 ATTCTAAGGATAGACACTTCTTGTGTATGTACATTGACCATTAAGAGGGAAGATAGTGGATTTATGTTGTATAGA
 TTAGATTATATTGAGACAAAATTATCTATTTGTATATATACATAACAGGGTAAATTATTCAGTTAAGAAAAAATA
 ATTTTATGAAGTGCATGTATAAATGAAGTTTATACAGTACAGTGGTTCTACAATCTATTTATTGGACATGTCCATGA
 CCAGAAGGGAAACAGTCATTTGCGCACAACTTAAAGTCTGCATTACATTCTTGATAATGTTGTGGTTTGTGTC
 GTTGCCAAGAACTGAAAACATAAAAAAGTTAAAAAATAATAAATTGCATGCTGCTTAATTGTGAATTGATAATAA
 ACTGTCTCTTTCAGAAAACAGAAAAAACACACACACACACAAAAAATTGAACCAAAACATTCCGTTTACATT
 TTAGACAGTAAGTATCTTCGTTCTGTTAGTACTATCTGTTTTACTGCTTTTAACTTCTGATAGCGTTGGGAATTA
 AAACAATGTCAAGGTGCTGTTGTCTATTGCTTTACTGGCTTAGGGGATGGGGGATGGGGGTATATTTTTGTTTGT
 TGTGTTTTTTTTCTGTTTGTGTTTGTGTTTTTGTGTTTGTGTTTGTGTTTGTGTTTGTGTTTGTGTTTGTGTTT
 TATATTCTGGCTGATAAAAGATACATTGTATGTTGTGAAGATGTTTGCAATATCGATCAGATGACTAGAAAGTGAA
 TAAAAATTAAAGGCAACTGAACAAAAAATGCTCACACTCCACATCCCGTGATGCACCTCCAGGCCCGCTCATTCT
 TTGGGCGTTGGTCAGAGTAAGCTGCTTTGACGGAAGGACCTATGTTGCTCAGAACACATTCTTTCCCCCCTCCC
 CCTCTGGTCTCCTCTTGTGTTTGTGTTTAAAGGAAGAAAAATCAGTTGCGCGTTCTGAAATATTTTACCCTGCTGTGA
 ACAAGTGAACACATTGTGTACATCATGACACTCGTATAAGCATGGAGAACAGTGATTTTTTTTTTAGAACAGAAAAAC
 AACAAAAAATAACCCCAAAATGAAGATTATTTTTTATGAGGAGTGAACATTTGGGTAAATCATGGCTAAAGCTTAAAA
 AAAACTCATGGTGAGGCTTAACAATGTCTTGTAAGCAAAAGGTAGAGCCCTGTATCAACCCAGAAACACCTAGATCA
 GAACAGGAATCCACATTGCCAGTGACATGAGACTGAACAGCCAAATGGAGGCTATGTGGAGTTGGCATTGCATTTAC
 CGGCAGTGCGGGAGGAATTTCTGAGTGGCCATCCCAAGTCTAGGTGGAGGTGGGGCATGGTATTTGAGACATTCCA
 AAACGAAGGCCTCTGAAGGACCCCTCAGAGGTGGCTCTGGAATGACATGTGTCAAGCTGCTTGGACCTCGTCTTTA
 AGTGCCTACATTATCTAACTGTGCTCAAGAGGTTCTCGACTGGAGGACCACACTCAAGCCGACTTATGCCCACCATC
 CCACCTCTGGATAATTTTGCATAAAATTGGATTAGCTGGAGCAGGTTGGGAGCCAAATGTGGCATTGTGATCATG
 AGATTGATGCAATGAGATAGAAGATGTTTGTCTACCTGAACACTTATTGCTTTGAACTAGACTTGAGGAAACCAGGG
 TTTATCTTTTGAGAACTTTTGGTAAGGGAAAAGGGAACAGGAAAAGAAACCCCAACTCAGGCCGAATGATCAAGGG
 GACCCATAGGAAATCTTGTCCAGAGACAAGACTTCGGGAAGGTGTCTGGACATTCAGAACACCAAGACTTGAAGGTG
 CCTTGCTCAATGGAAGAGGCCAGGACAGAGCTGACAAAAATTTGCTCCCCAGTGAAGGCCACAGCAACCTTCTGCCC
 ATCCTGTCTGTTTCATGGAGAGGGTCCCTGCCTCACCTCTGCCATTTTGGGTTAGGAGAAGTCAAGTTGGGAGCCTGA
 AATAGTGGTCTTGGAAAAATGGATCCCCAGTGAAAACCTAGAGCTCTAAGCCCATTCAGCCCATTTTCACACCTGAAA
 ATGTTAGTGATCACCCTTGGACCAGCATCCTTAAGTATCAGAAAGCCCCAAGCAATTGCTGCATCTTAGTAGGGTG
 AGGGATAAGCAAAAGAGGATGTTTACCATAACCCAGGAATGAAGATACCATCAGCAAGAATTTCAATTTGTTCAGT

CTTTCATTTAGAGCTAGTCTTTTACAGTACCATCTGAATACCTCTTTGAAAGAAGGAAGACTTTACGTAGTGTAGAT
 TTGTTTTGTGTTGTTTTGAAAATATTATCTTTGTAATTATTTTTTAATATGTAAGGAATGCTTGGAAATATCTGCTATAT
 GTCAACTTTATGCAGCTTCCTTTTGTAGGGACAAATTTAAACAAACAACCCCCCATCACAACTTAAAGGATTGCAA
 GGGCCAGATCTGTTAAGTGGTTTCATAGGAGACACATCCAGCAATTGTGTGGTCAGTGGCTCTTTTACCCAATAAGA
 TACATCACAGTACATGCTTGATGGTTTATGTTGACCTAAGATTTATTTTGTAAAAATCTCTCTGTTGTGTTTCGT
 TCTTGTCTGTTTTGTTTTGTTTTTAAAGTCTTGCTGTGGTCTCTTTGTGGCAGAAGTGTTCATGCATGGCAGCA
 GGCCTGTTGCTTTTTTATGGCGATTCCCATTTGAAAATGTAAGTAAATGTCTGTGGCCTTGTCTCTCTATGGTAAAG
 ATATTATTCACCATGTAAACAAAAACAATATTTATTGTATTTTAGTATATTATATAATTATGTTATTGAAAAAA
 ATTGGCATTAAACTTAACCGCATCAGAACCTATTGTAATAACAAGTCTATTTAAGTGTACTAATTAACATATAAT
 ATATGTTTTAAATATAGAATTTTTAATGTTTTTAAATATATTTTCAAAGTACATAAAA

(SEQ ID NO: 11)

>hg18_knownGene_uc009yjj.1 range=chr11:27633018-27679176 5'pad=0 3'pad=0
 strand=- repeatMasking=none
 GTAAACCAATAGCCCCATGCTCTGTGCGATTTCATTGTGTGCTCGCGTTCGCAAGCTCCGTAGTGCAGGAAGGTGC
 GGGAAAGgtgtgtctgtgccccgggaacgcacgcctctcccagagaacttggtgctgggatggggaggaagggga
 gagttgaaagctaggggagcgagacctcggggcgctgcgattctcactcgctccctcccgccccagcgccccacagccg
 gggttctcgagaggcgcgggacgcgggttccccgggctgaggctggggctggaacaccctcgaaagccgcggg
 cgtctgtccaaggcgccccaggaggcgagactcgagggcgatgtcgcgggccctaggggagggaggtgagga
 cagggccccggggagcggggagttccgggcgccccctcggttccccgcgcgaggaaagacgcggcggttccctttaag
 cggccgcctcgaaacgggtatcggtagcgcgggcgagcggggagcgggggcgggggggggggggggggcgcg
 cgtttgaccaatcgaaactcaaccgaagactaaataatgtctgacccggcgcaaggcgagcctggagctccggg
 tccccgacgctgcccgcgcgcgcgcggcgacccgcgcctcgctgtccccgcgcaccccgtagcgctcgggctc
 ccgggcccggacagaggagccagcccggtgcgcctccacctcctgctcggggggctttaatgagacacccacgct
 gctgtggggccggcggggagcagcaccgcgagcggggacgggctgctggcgctggagccagaatcggaaccacgatgt
 gactccgcgcgcggggacccgtagggttgtgtggaccccgaggtaggcaagcgctgggaatggggcttggtgcagg
 agctgccgctccgcgggagagagttgactgggggatccccacccccaaagtgtgggacgagggcagctctccttctt
 tccctccctccggtagaaggagacgatttgaggttactcttggggagtttctcccccatcccaacccagaaggtc
 agccggcaccaccagggaaggggacccggggaagtacgaagtagaggaggggaaggcctggaggagaccagagc
 tgcgtgatgggagcaagacggcgacccggggatccctcgagccctccccagcccaggagtagtcgagagagact
 tagggggccagagctgcgagggctcctgactgaggggaggggtgctggggctaggctaggaatccttcagggggtgg
 gtggtccccgcgcgacttgcgggggagtgagggaagcttgcgcctcagccgcacccctcccccgagctgc
 acacggctacctgctccccaggaattgagactgaagtggacttacaagtccgaagccaatgtagcttgaaaaacttg
 ggaggcggaattcctaccgctgggaactgaaagggctgcgcacactctcgggcaggccgaacccacatctctacca
 tcctgcgccccctctctgaagcgccctccagggaagttaagagttttgacttccggggagtggttgggatgtacgtg
 ggggattcttgactcgggttagtctctggggatgcagagccgggaagaggaatgggtgagtgagttactcctggaaa
 gaaatagctgaggattgggggctctgtgcctgacgggcaagaagaaggggagattacagactaggggcatccctaag
 gaagaagcctcggggctgcgaggggtgaactggaggtgacgtgttgggtgttgggggtagagcggggatgaggac
 cgggggtggaggggagcgaggaggaggggggacccagagaacgaagctagggaaggtagaggggtgccctctgccc
 ccatgctgccaagagcagctactggggcggggaggtgggggtggggaagtgttaaggaaggttttgcgggatccc
 ttagagagctggttaggaggacttgtgaatggtgctgctgactccagctcggtggggcgctgcgactcgctcgctggt
 ggattttgactcctcgttcttgtttggttctatgcaagtttccctcgcgctgggggagctttgataagcctcgatt
 ggcggtgtgttagggcttcttggtatcttattttagggctcctctagttatcctgcaacttactccttaatgtcagtagc
 aaccaaagaacattttccgacaagcacgcaggaatgttcttgccagaagcaagaaggcatatttctgagtggtt
 attaatcctcctagtaaatcttttaagcaaaagtaatatgtaattgggaacgttgattttcctaactgcatataaaagg
 cgacatgatattaaatgagacccctccctactgactcaatatcctgcaaaatctctctctccctttattattatgg
 aaaaaatctatttttatatgagtttgttgtaaggtcaaaagccattttggtcttacaatttgatatgtctttacattt
 taacttattgaggcataattacagatttaatttgtatgaacgtgtgtgccttcaatgcttatctcatgcaacataat
 ttttaggttgagatttctgatgttatggcatgtagcgtttcaaggcattacacataataggtaacatagcatgttg
 aaattacaccacaaagttttgacctgggaacagcaccttttaaaacaatcactaaactctgttctctgttttctg
 attttgcaaatgcttgccttaagacttt
 caggagaggtaaaaaaaaggaaagagacacttgttgaaatgtaaccataacctttactgggaatttaaaacatgttgg
 tcaccattactggaattccaggggccataaagtcgttgtcttttttttcttacttctattttgtaaaatgtgataaa
 tgttggtaaatatagaccagtagtaagtattatgacactaaaagcattatgtatgtggaactattttaagttattac
 agaacattttctatttataaatgatataagcagaaagaaatgatttccagataaacaaggcttacgtacatgttttg
 aagcattagaacattgcagacactcttagacatcacattttttaagcaaaataacagtaatttttccatacctttt
 ggagcctttcatagccattcagagctgagtttagtagctggaagtttccctttatttttaaggtgatatttttaaaacca
 ttaacatgtatagtaggtcaacattggtgcatccagaaaatgaagcatttaggaaatctgttccagtgcttttca

[illegible]

gcaatggttgaggggacttggaaatgcatgacttagggacaagaaaacttaggctggaatggcaagtgggtttttgaat
 gttgggttgagaagaattctaaaactgtgaaggattagtaaaaaataacattcagattgctaattgcctactgtggctg
 ggagattagagtgtcaacatgtgtgatgtatttttgacatccttattttgaggatgggcttcaaaagatttgacgaac
 tgtcataagtgttaattttgtgttgccttcagacagcaggttctagaaccaatgatgtaaatttagatactctacatggta
 gttagaaaactttccattaatttaatttagcaaatattgaaatgctcactgcatacagagcactttattagaggaata
 tataataaagaaaaaagaggtctgggtgtgggtcctcatgctgtaatcccagcactctgggaggtgaggtgggagg
 atcacttgagcccaggagatcattacgagctctggacaacatagcaagaccccatctttacaaaagacaaaaaaatt
 atccaagcctggtgacagggcactttagtcccagctacttgggaggtgagggcagtaggatcgtttgagcccaggag
 gttggggctgcagtgcagcgtgattgtcccactgctcttcagcctgggtgacagagtgcagaccccggttgagggaag
 gaaggaaggaaggaaggaaggttaggaaggtgaaatgaaaccccttttagaaatgacactaaaatgggaggttgag
 taaggtattttctgaagtgcctttgtactgttttttctaaatgcattggccataagtctgctccttattttatagtc
 cataaacaatcctaagtagaacagttatattttctgcctttgaatcatctacttgaagtgtttagcatcatgaatt
 gagtatcagaaatccctccattttctttgcaaagcgtgtattttacttttcttattttgtatacagattctcaaaa
 ttggctatttttctttgggttagacagaacagaatgtctggaaaaaaagtcttatcaaatcaggtgcccacaaat
 tgcttaagaaattaacttttgaggttatatttttttaggttcagtagctaaactaagaaaacttctcacccgttcac
 ctctacttttggaaccacaaaactcttcagatattacagttttccaaagagtcttctcttttaataataaactaaaa
 ggaattgactcctcccccactccctcaggcctcagcatggaatagagttacttttttcttaataattttactata
 acttattttgtctctctgtagaacagctggagattaagcaacatggccatgcataaaaatgcaaggttagaccataag
 atgagcagccactccaagtatgaatgagtaacttattctttgtgatctctcactactgcttttaggtattaatagtgt
 cagtcagcaagcaaacagtttaataattacatctccttttaggatcatatagtttatagttgtatgtgttcttg
 cgtgtatgttttctctgtttcacaattctttttcttaagtgaagaatgttatatgtagcaaatgggtctttcatta
 attcatttgttaattcacccgtgcatttaattgagtgcccagtgagtgctcaggcactgggctacttggatttcttttcc
 ctgtattgatccatatacttccaggtgctccttgatatggctctccattgactctctcatataaggttttcattacc
 tattcacatactccctcccaagagactgggtccaaaagtataaatcttgagcaagttctctgagttatttcagaact
 tcttgcccccaactgtatttttaattattgactggtagcattttggaataacttaacctctcttttttaagattga
 agttctttatcctctctgattttcaggtgtcagtttgtgtacaaattgagacaataaaaatgtttgttagacatttt
 cttaagcattttgtatgtgagaatcttcatgaagaactcttttaacaatgactctatagcagaagccacagta
 gagggagaactactgaatcaaagatggtgtttgagtcctatgattttatgatggatttttttttttttacatacaag
 gatatgcatgggtcttttagtattcaggaatctgttcttccacttgacagtattttataaattgtgtgtttcccccctaa
 aaaaacttaaaattgtgagaatgcttccatttactagaagttgggttaattgattatgccaataaggaaaataagacag
 aaaaatcagtttagtgtaataactattttgcctttaaattttagtaaattagtaacagtatctcttgggggttactaga
 aaccactttttaatccaataggtctcttctcattgtgaagtcaggaggtgattttgcttaaatgtgtagtataggaat
 ctatatgtgtgttcaaggatcatgtaaatagctgatataatcggagcacagtttggcatcalttaactcagaaata
 tttaaactcttgctatacaacatggaagcaaaccttgtgcatagtttgtgtgtgtgtgtgtgtgaatctcaaaaaa
 agaaaaaatcacaggatcaggaagtcggaataggtcccacttttcttctagtaccaaacctacagccatgttcccta
 gccttctcttttactcccaagcaagacagacagggcaaatgaccatcctgctgcccatttctgtgtatattcacttgc
 attgagagttgtattcacctgcttgttgagagtattcacaaatgggtacctgataaagtagactctttaaacatg
 tgaattttttgtcattgtataatgttttagaaaataatcatgtatataaatggttgaatattaatacaggattgccttctc
 aagtatttttattaatcattaaaatgtgtgtcattatacaattttatttttaagtgttttctaaaataaccagatta
 ttttctgattttcacatccctgacaatgacttttctaaacttggtagccagggaacagaaaacctaacactgcagtg
 tctcactcataagtgggagctgaacagagagaacacatggactcagggaggggaaccacacacactggggcctggag
 cagggggcaggggaaggagagagtgctcaggacaaacagacaaatagctaagtcagtcgagccttaataacctagg
 tgatgggttgataggtgcagcaaacaccatgacacataattacctatgtaacaaacctgcacattctgcacatgta
 tcccggaacttaaaagtaaaaaataataataaaaataaaaataaacttagtagcatctattgttccagagcctgt
 aattgctcttcaggcagctctcacataaaaaacctaggagaaccttccactgtcactgttccatgaggtgttaggaaaac
 ttgctctactgcagtgccccagtaggcattggtagctgagacaaaattcagctgggtttgtgttactacgatttcccta
 cgtgatttccacttgcattgtagacaagattgcacacttcaataataatcttgcacaaatgtgtgtgtattccatacat
 ttttaaaatgcattcacatatctcattccatttgatcctacaaataaactctataaaaaagattggcagacattattt
 ctataaacagaggaggaaactggagcttagagaagctaaatagcaatccaaaatgcacagctgtagaaccagagca
 aggatgatagcccagtgacttcacctaacctagtccttaccaccactccagctgtctataacccaaacctgcagtg
 attcaagtaagaaaccatattcttgccttgatgcatttaattgtgagacctggagcaggaacaggtgatattgtcacc
 ctggcctactgtccacctttgtctccagcagagactggtaaccttctgtgtgccaaaggaataaagtggtaatgggaa
 gattaaaaatgttttttccaaggagttttttaatttaatttttttaaaaaagaaaaaactcttagagggaaaaatga
 atatatgacttttgatgtattgttcccttagtaacttagttataattttacttaaacctgagactcttgctaagtga
 tgattagaaatattaggtggctggccagatggcaaataggaacagctgcagtcctgcagctcccagagagatcaatgc
 agaaggtgggtgatttctgcatttccaactgaggtaccgggctcatctcattgggactgggttagacagtggtgcag
 cccatggaggggtgagccaaagcaggttgagcattggcctcactcaggaagcgcaaggggtcaggggaactccctccc
 ctgccaaggggaagcctgagggactgtgcatgagggacagtgctatctggccagatactacacatttccctacag
 tctttgcagccggcagaccaggagattcccttgggtgctacaccaccagggccctgggtttcaagtacaaaactgg
 gtggccatttgggcagacaccaggttagctgcaggagtttttctcatacccccagtgccacctgaaattccagtgag

acagaaccattcactccccggaaaggggctgaaggccaggcagccaagtgatctagctcagcagatcccccccca
 tggagcacggcaaggttaagatctgctgggttgaaattctcactgccagcacagctgcctgaagtcacactgggatgc
 tccagcttggtcgggggaggggcatccgccattactaggcttgagtaggctgttttctctcacaatgtaaacaaa
 gccactgggaagtttgaaactgggtggagcctaccacagctcagcaaaagccctgtagccagattgcctctctagatt
 ctccctctctgggcaggcatctgggaagaaaggcagcagccccagtcaggggcttatagataaaaactcccatctc
 atgggacagagcacctgggagaggggtggtgtgtggcccagcttcagcagacttaaatgttctttgctgttggt
 gtgaagagagcagtggtatctccagcacagcacttgagctctgctaaggacagactgccttcttaagcaggtccct
 gaccctcgtgattcctgagtgaggagacacctcccagcaggggtcgacagacacttcatacaggagagctctggctgg
 catctggtgggtgccccctctgggacaaaccttccagaggaaggaacaggcagcagtccttctgtctgcagcttct
 gctggtgataccaggcaaacagggtctggagtggaacctccacaaattccagcagacctgcagcagaggggctga
 ctgttagaaggaaaacttaacaaacaggaatagcatcaacatcaacaaaaggatgtccacagcaaaaccccgtaaa
 aggtcgccaacatcaaagatcaaacatagataaatccacaaggatgaggaaaatccagcacaacaaaggctgaaaatt
 ccaaaaaccagaatgcctcttctctcctcaaggagcacaaactcttggccagcaagggaacaaaactggatggagaat
 gaggtttgatgaattgacagaagtatgcttcagaaagtgggtaaaaacagactcctccaagctaaaggagcatgctct
 aaccatgcaagaagctaagaaccttgaaaaagggttgagggaattgctaactagaataactagtttagagaaga
 acataaatgacctaatggagctgaaaaacacagcagcagaaactctgtgaagcatacacaagcttcaataactgaatc
 gaagagcagaggaagatatcagagattgaagatcaatttaataagaaataagcatgaagacagattagagaaaa
 aaagaatgaaaaggaaaggaacaaagcctccaagaatgtgggactatgtgaaaagaccaaactatttcttgggt
 gtacctgaaagtggcggggacaatggaaccaagttggaaaacactccttaggatattatccaggagaacttccccaa
 actagcaagacaagccaacattcaaatcaggaaatacagagaaacaccacaaagataccctcaagaagagcaaac
 caagacatgtaattgtcagattcaccaaggttgaaatgcaggaaaaaaaggttaagggcagcgagagagaaaggctcg
 gttacccaaaaagggaagcccatcagactaacagtggtatctctcagcagaaacctacaagcctacaagccagaaga
 gagtgggggccaatattcaacattcttaagaaaaagaattttcaaccagaatttcatatccagccaactaagcttc
 agaagtgaagtagaataaaaatcctttacagacgagcaaatgctgagagattttgtcaccaccaggcatgccttaca
 agagctcctgaaggagtagtaataaggaaggaaaaaccggtaccagccactgcagaaacataccaaattgtaaa
 gaccattgaaactatgaagaaactgcatcaactaatgggcaaaataaccagctaacatcataatgacaggatcaaat
 tcacacataacaatattaccttaaatataaatgggctaatagccccaaattaaaagaccacagactggcaaatggga
 taaagagtcaagacccatcagtggtgtgttctgagaccatctcacatgcaagacacacataggctgaaaata
 aagggtgagggaagatctaccaagcaaatggaaagcaaaaaaaagcaggggttgcaatcctagtctctgataaaa
 cagactttaaaccaacaaagatcaaaagagacaaagaaggccattacataatgataaagggatcaattcaacaagaa
 gagctaactatcctaaacatatatgcaccaatacaggagcaccagattcataaagcaagttcttagagaccacaca
 aagagaccaagactccacacataatagtgtgagactttaacaccccaatgtcaatattaggtcaacgagacagaa
 aattaacaagcatattcaggatttgaactcagctctggaccagtggaactaatagacatctacagaactctccacc
 ccatatcaacagaatatacattcttctcagcaccacatcacacttattctaaaattgaccacataattggaaagtaa
 acactcctcagcaaatgcaaaagaatgaaatcataacaaacagctctctcagaccaaagtgcattaaattagaact
 caggattaagaaactaactcaaaaccatacaactacagtggaactgaacaacctgctcctgaatgactactgagta
 aataacaaaaaaggagcagaataaaatacattatttgagaccaatgagaataaagatacaacataccagaatctctg
 ggacacagctaaacacagtggttaggggaaattcatagcaataaatgccacaggagaaagcaggaagactaaaat
 caacactctaacatcacaattaaaggaactagagaagcaagagcaaacacattcaaaagctagcagaagacaagaaa
 taactaagatcagagcagaactgaaggagattagagacacaaaaaaccttcaaaaaaatcagtgatccagaagct
 ggtttttgaaaagattaacaaaatagatagaatgctagccagattgataaagaagaaaagagagaagaatcaata
 gacgcaataaaagatgataaaggagatataccactgatccacaaaaatacaatctaccatcagagaacactataa
 acactctatgcaataaaactagaaaatctagaagaatgaataaattcctggacacatacaccctcctaagactaa
 aggaagaagtcaaatcctgaatagaccaataataagttctgaaatcgaggcagtaattaacgacctaccaacccaaa
 aaaagcccaggaccagacggattcacagctgaattctaccagaagtacaaagaagagctggtaccattccttctgaa
 actattccaatcaatagaaaaggagggaatcctccttaactcattttatgagtcgggcacatcctctgatacaaaaac
 ctggcagagacacagcaaaaaataaaattgtaggccaatatccctgatgaacattgatgcaaaaatcttcaataaa
 aaactggtaaaactgaatccagcagcacatcaaaaagcttatctacatgataatttggttctatccctgggatgcaa
 ggctggttcaacatagcaaatcaataaagataatccatcacataaagagaaccaatgacaaaaaccacatgattat
 ttcaatagatgcagaaaaggcctttcataaaattcaacagcccttcatgctaaaaactctcaataaactaggattg
 atggaacatatctcaaaaataaagagctatttatgagaaacccacagccaatatcatactgaatgggcaaaagctg
 gaagcattcatttgaaaaccgggcacaaaacaaggatgcctctgtcaccactcctattcaacatagatttgacggtt
 ctaggccagggaatcaggcaatagaaagaataaagcatattcaaataggaagagaggaagtcaaatgtctctgtt
 tgcagatgacatgattgtatatttagaaaaccccatcatctcagcccaaatctccttaagctgataagcaacttca
 gcaagctcaggatataaaatcaatgtgcaaaaatcacagcattcctatacaccaataatgacaaacagccaaagt
 catgagtgaactcccattcacaattgctacaaagagaataaaatgcctaggaatacaacttacaagggtatgtgaagg
 acctctttaagagaactacaaaccactgctcaatgaataaagagaggacacaaacaaatggaagaacatttccattc
 tcatgttaggaagaatcaatatcgtgaaaatggccatctgcccagaagtaatttatagatccaatgctatccccat
 caagctaccattgactttcttcatagaattagaaaaactactttaatttcatatggaacaaaaaacagcccgta
 tagccaagacaatcctaagcaaatgaacaagctggaggcatcatgctacctgacttcaaactataactacaaggcta

cagtaacccaaaacatcatggtactggtacataaacagatagatagaccaatggaacagaaacagaggcctcagaata
 acgccacacatctacaaccatctgatctttgacaaaacatgacaaaaacgaatgcagaaaggattccctatttaa
 taaatggtgtcgggaaaaactggctagccatttgcagaaaaactgaaactggacccttctctacacgttatatacaaaaa
 ttaactcaagatggattaaagacttaaacataaaaacataaaaaacccctagaagaaaacctaggcaataacc
 attcaggacatagggcatggcaagacttcatgactaaaaataccaaaagcaatggcaacaaaagccaaaattgacaaa
 tgggatctaatataactaaagagcttctgcacagcaaaaagaaactaacatcagagtgaacagggaaccgacagaatg
 ggtgaaatTTTTTgcaacgtatccatctgacaaaaggctaataccagaatctacaaggaaacctaaacaagtttaca
 agaaaaaaaacaccccatcaaaaagtggcggaagggtatgaacagatgcttctcaaaagaagaatttatgctgcc
 aacaaacatacgaagaaaagctcatcatcactggtcatttagagaaatgcaaatcaaaaccacagtgagataccatct
 tatgccagtttagaatggcgatcattaaaaagtcaggaaacaacagatgcaggagaggatgtagagaaataggaacac
 ttttacactgttgggtggagtgtaaattagttcaaccattgtggaagacagtggtgatttctcaaggatctagaa
 ccagaaatatcttttgaccagccatcccattactgggtatatactcaaaggattataaatcatgctactataaaga
 cacatgcacatgtatgtttattgtggcactattcacaatagcaaagacttggaaccaatccgaatgcccatcaatga
 tagactggataaagaaaatgtgacacacatacaccatggaatactatgcagccataaaaaaggatgagttcatgtcc
 tttgcaggacatggatgaagctggaacacatcattcttggcaaggtaacacaggaacagaaaaccaaaccacat
 gttctcactcataagtgggagttgaacagtgagaacacatggacactgggaggagaacatcacacactggggcctgt
 cagggtgtaggagctaggggaggatagcattagggaataacctaattgtagatgacaagttgatgagtcagagca
 accaccatggcatctgtatacctaggttaacaaacctgcacgttctgcacatgtacccagaacttaaaagtattatt
 attattattataataataataaaaaagaaatacaataaaaatagaatgcagcatacagcagtgatttctcaaacacat
 tcagcatcagaattacccttgaatctttaaaaatatatacatatgagatcttagtctccaagatttgtagtttgg
 tattgggtccctgggcctatgttgggtttgaaacttctacagatgggttggatgtatgggacagtttaagaatcgc
 tgaactaaaatcaataaaactgaatatcctgtgatttagagagacttatcgtttatttctactatccaagtacttgca
 ttagagcgtggctagaagggtatttgcagccttgaataatcagaaattcagacattttgagatgagagaactgctg
 aagattttattctgacttgaaataaattttctaattagaaacttccaggtgagagcaaaaggcctggaaacaatatcc
 tgagccagaggaggatcgagtttgaactccaggcctaacacttactaggtctatgacctgggtcagtaatttaaatt
 ctctgtatctcaacctctcaacagggtatttggtagggattaaatgtgttagtctgtgaagtgccttagagcagtg
 ttggcatagtaaatgcttaataatgaatttcagccactgtttttatttttagtacttccagctccccaaaaagatact
 ttttttagacttgtattaaagacaataaaaaagtttaatacagcatgcttcatacctaataatgcttctactttatagcaa
 agtttacaagactaaaactgttttgttgaattctctgagctcatgtgtttattaatgattttttctgctgtttat
 tcatctgaattctactattcttcaagacctagctggaactctggttcttagaaagacttctcccaataataaac
 ctgcccctatctgagttcttaggtggtctgtacctcaatttggtaatttaattgtatatgcacttatataacaaaac
 attattgtgtgtctttgtgtatcagattcttaggtggaagttgtagatatgatgtttttgtctagaaaaatgttct
 agaatgtcctactcaggacagctctgttgactttaaagacacatttcttaacagacacttcatgaggcagccccagc
 ctgtacctgtgttcttgacctgatgatcaagtttgatttaagcctcaccacttactagctctgtgattttgggcaa
 gttacttgaattctctgtgtgtagatagaacaatgttgagggaataccctttcccccatccttgtgtttccacaagg
 gaacttgccttctaataagtaacactttcaggggaatattctaggcccttctcttatccccattacttgttcttct
 gtgaaaagaggagaggttaactctgagtggaatgaaatccttaactcttcttgactcttggaactcttgagacataa
 agcaatggagacacttgactgaaattgaggtgacctgtattttgattcttattttggcaacttatttctattctgt
 tcccaattcaaaatcccaaggggagaggaagataattgattaccagaagtatgtaatgggtggtaggaagttgaata
 aatggtaactttttaaaagttgcatgagatatagtccttatccagagaagctaagtttgccttttcttctctcat
 gtatttttagtattatttctacaattagattgtaaaccttttaaaagcaagaatatttctacattttcttactcctga
 tagcacacagtagactgctgggcacatacatagtaggtggtctgttaggtacttgcataatgattcaacatgttttt
 cctcatggaaaaagaaagatttcagtatgttcttatcagcttaggaaggcactctgaataggaaatcagttctaggc
 aggtatccataaatgggttatgatttccaacttacttgcgccagaggctcgctaattgttgaactcttcatgggtact
 ttgtcttgcctcatgagctatacatgctaaagggttagcagatcatataatcttttgatctacaaaatatgatcttt
 attgaacaaaaacttggccaaaggcctttctcctttgccaccttctcctcttttctattctcttttttgggaatg
 ccctttgtgcatgttagttacagcatgtaccacattgcactgtattgttgggtttttgggtctaacccacccttaaca
 ctgcagtcocccaaagggcagaaattcagttctcattcattttgatgtcctcagtgccctgtgctcagagaatatctatta
 tttgaaaaaataagtgcaaaagtaatttttagggagactacatcacactcatctaaactgcaagtttgacaagttgaga
 tccaaaagaaaggtctcctaataaacctgccacagaaatttgggtgacctttgtagctctggagaaagcagagc
 aaaaaatgaaacctaaaaattatttgggttttttaaaaaatgttttctcatggagtaaaaggtctacagctgagttct
 tttcatatgagggaatgacagaaacacagctggttctgactttcagcttcaactgagcgaccagagctctgctggtg
 aaacagggaacttgtattgtgcccctgacgtgcaccttgaagggtgcagctcattgtccctttgttcacataaatagt
 tttttaagaattgtttttgatcttgtgagcctctaactaaatgattaaccatgcaaagttggccattttggggttaata
 ctgaagcacttctcttgagggtcatttgacaggtgggaatgtgcccacctccttgggtctctggttttcatgtcatac
 ttgcaaatcagtgacagtttaacttggggcaatcacttagcaagttctattgagttaccaagtttaattattcccact
 ttgcatgaagcaaccttgaaaatgattttcctaagcaagtaacatccaaactcagtaaccttcttaataacctttgc
 tgaatgaataaatgactaattcataaaaaatgtaacatatctttaattcttacttacgggcagtttaagcctctgtg
 gtaagaggaggcctcggttgagataacataggatagtaagcctcctagagaaatttctatatggaacatgggtctg
 ctatgaagctagaagtgagaggacattatatttgaccattatatttggcttcagagcttctcaacatggggccaaa

gtcaagggtcccttgtttcattaagaggaggtccaggagtgcatgacacccatcagactactgagacccagctggaaac
taggcaccttgcacaggggcttgcctaatacaaaatagttcttatttttctgagttccaagtaactagtttccctaa
cccagtgctctgtagtagtgccaagtgaggtagctaccttcaatgaacttccctcatgaggttatttctagcctattgga
atgtttcggttttaggagggtaggaagggaagtcttgaatttttggttagtttaattgttgtagacagctttgac
catccgttttaattgggagatctgttttccagatgactatacatgtggaaaggagaagtttttgagtgttttttttaa
ccccttttaagaatggtttttcatttagtctctacatttgggggtaaaaggctctctagggagacttttcaaaagt
atgtgaagtttgcacatctgatttccagaggtgagttggaggcctatctgtgtatgacagacacatgtctccaacaacta
tatgttcacaaggactaagagccatccttttgggtccatcattcaacattgatctcacattcgtgttcgtatcagta
tctttacagtgcgctcccagttacatctccctaatttcccttagtaggcttcacagaatttgcagtgtagtgaatgg
cagatgaccacatgtggagtcatttaaccacatcttccactgcaagtcagcccgctcttgatgtctgtttatgtttta
gattccatcttttggaaagatttccctctctgcaactatctcagtatctcagatgcttttgagactgggtcccttttcc
cctcctatgtttggccatggccacccccctcaggggtgtgtgtgtgtttcacagctgctgtttgtaggggtgacctta
caatgtacaaagctctttcccatatgttgacaatccctgggtgtgtgtgtgtgagttaggcaggggtgtgtatacgtgt
cctcatcatattacagtggttaaggcaacaggggtttttgaatttgatcacccatgaatttgtctaatgtgttggtaaa
aaatggtcatgtatcagccgtttcacagggtcagcttaatagaaagtgggagttaggcaggaccagaattcaggact
tcagcccccgggtcccaggactattctctatacccaattgtcccacttgaatcagtttctctagggaaatatctc
caaaactgagctggaccacaggaacttcttaattgtagtcttaccaggaaaaacaagcaaggaactgggtgtaaa
tctctgtttttggtgattggtggagatttggagattgtctgtgtcaaaagttaaagccactagattaaatgttttgt
taataaattgggtatttttaatttaattttgacagtttaattacattattcaaaaatcaaaaataaaattttaaag
aagtttacctgaaaagtcttggcccacttataccctgtcacctcagtatccccaatacataccatctataaggt
gatcatttgtatttagtttctgtgtaatccttgatagtggttttatatagatacaggtaaatatgagtatgtactat
tatttccccccacccccacccctgttttttttttgagacggagtcctcgtctgtcgtcccgaggtggagtgagtgga
cgatctcggtcaccgcaagctccaccattttcccccttttttaaaacaaaaggtagtagccatatatacactattt
tacaccttgggttttactactaataatataccagagagctttccatcattttgtacatatgcacctataatctgtca
attattcccagaagtgaattgctgggtcagcaggaaaaatcatgtataattttgataggatttgccatattgtcct
gcacagggcttgaattgtttgtactcccaccttttagtgtagagaagacctgttttctccatagcctcatcaaacaga
gtgtgtgagattagatgagaaataggaggtgagcagtcctttaccccatccgtagtttgcagtgaggaaactgcaca
gttgcaagagctggtgcaggtatcagattagttccagtggaacgctgcctcaccatggccatgggcttgccgcccagc
tctagtgcacacacggaatggaccacgttggcacttgcagaatttccctgtagcagaaagtgaacatgcattcat
tattcatctaaactagcgaatgaaagtgtgtaaatgacacacagtggttttttagaaccacaaaagaaatggacaattt
caacacactgtgtataaggctttcaatgctcttttctcagctattaacattattttcaggactgagttcaagagatg
tatcccaaatcacagggtatgtcttgtaagcttggaaacttctactcaagggtatgttttttgaggaaatgatttta
cacttactcaacatttgaattaaataatttagtactttataagataaatttaaactgtccaagtacaataataacat
tgaactatgatgcattatttctagactttttccctaaagtgtccaagtgttttccctgcattaggcacaataggggatc
atataaaaatgcccagatttaccggcctagataacatctccaccatttgagcagcatatattccagggtcatccccaca
taactccttaccatttctcattagaaaggttgattcttagtcttatttttctctgaggacagcaaaaaaaaaaatccc
cttcagttccactgcatagaaaagtgtgtaaatgacacacagtggttttttagaaccacaaaagaaatggacaattt
tttatagaattttgacagggccactgtataggggaaagtcaactcctcttccctttatagaagagttgcacctggac
agttgcattgatgactgtatccagctacacaagaggtcattcctgggcataagaatggactgccaaaatctagctg
aaacaccattgacaaaatagacattttctttgttaataatcctgtgaaggctttcataacagacatttccagtttt
gttctcagggtccttgcagctgctcctctaaaagtgtgctctcttccaagagctgacaatggccagaagcaaggtgt
tctgtcttttggccatcatcatctaaacttgcacacacatttgggatgtcagcctaggtataggttttgtatccac
tcagtatggcttgtgggtctggttgcctttgttattcatgctgagggcctctgggcacagtttgggtgtgagagaac
ccattccatgacctccttcccttgggtgttttgactcgatggctcttgggtggcacagtcgtgagtgctgtatgct
ctatccatgcccagacctctgttctgtgtctctgtgtgtgaagtcgttttctgaactattccttgataataaatt
tgagatgatcttgttctacctttcttttcaagtcacatcttagcccttagccacattcccgaaagacatgacaaat
ggatgggtcacaagtcacgtagcataggggtgcagaccagaggctttgaagggttctgttgggtgtctaaaaagaa
agattttgtgtcaccacgattttttttaaaggcatgttgacacttaggccttaattgaaagcgttcttactcaagta
gagttgacagaggagattttggtagtgcgggtgtgtgtgtgaagagcatgtgttctgttttcaatgccaatgaga
tcttctcacgggaaatgttctgacatctcaacaaatgaccttcatgcatagttttgacaaaataccctattaaagt
atgcatatatggttggtaaccttggtaataattcaatactggaacagagtagcaacaaagaaacattaggggttat
atthaacctctgtggaattagtggtgtaaaacaaactgcttatcagaaatgctcatatggggctttgttttaataaata
agaaactggcatatagggctgtcaggatatttctgccaagttagacctccctcacattataagacaccacatctatgt
ctgaccccatatggaaagaggcatagcaagccagcactggttcatattccctctccaccacataatgggtatgtgat
cttagggaaatccaccgaaactctctgggcctcagtttccctcagctataaatgggtggataatcaaatattttacctca
ccattaaataaattgttagctatttttttatcaagtttaatacaaaagagaacattttacttttttccagctatc
cagagcatcttccaaaatcctatcccaacaaatcagtgattgtattttattatagcaactgtaaaaatggagtc
ctgtcctatgcttagatgaaatatgttgggtattttaggttgcagtgcttctataggaatcagtggttagtgaaaacg
gggtggagataaacagatgttttccagtcctgttgggttccagtgaccgcaaatgaaatgtttccatataggtgcatt
ctaattggcttaaatgatgcagatattttctggccagccataggtatcttttgcacatcaagatgttaatttttccct

taatttttatagtagttcttgaggtacagccagtttcttgaatagggtccacatggctcattatgacagggcctgga
aactgccttactcgtgctgttgaaatgaaccgtagacacttcagaagagctgggagctggggtagagcagtggttagg
agaacatattcaattatatttctcctgcattaaagctacaagtaatgagcactttcctgtgctttacagTTAAGTAA
TTAAAAAGAAATTATAGAGTGGGATGCAAAAAATAACCCGAAGGACAACCTGGATGTGTGGAGCCACCAGCTTTTCTCCAT
GAGTGACACAAGGTTAACTCTTGTTACTACTCAGAATGCTGAGTTTCTACAGAAAAGGGTTGCGAGGTCCACCATGTTT
TGGCGCTTACCCACACGCTTCTGTATGGCATGACTGTGCATCCCAAGAAAGGGCTGTGCTGTGTACCTCCACGCTTT
CAGTGGAAATTTAACAAACTGATCCCTGAAAAATGGTTTCATAAAGgtgagtaacagagagctaatagccttctcttgc
taattttatctttcccccagatttcttgataatagtttgaaaaggagtggtattctttgggtctctagaggcaactt
acctttccagtttcttccatcacctgttttcatctctcttgttttttaatttaatgctgtatgtatttcagagga
taggatctaatactagtgcgggtcccttcatcaggtgagaattattcatctcattttcatttttagcccttctgaatta
tgacattgaagcccggcagtttgggtcctaagatgggtttaattatgtacagatactctttctataatggaaattgc
cagataactaattaaaccacaagaatacactgtctatttgaaaatttcaggagcacgctctgtggaaaaactgggaagg
gcatgctgtcaccacaagctctgggtctattaaaagttgtgttatgcagcactggtgtctagtgggtgttggctct
caactgccagaattcccatagcatttcatgggcagaaagtcagggtgtccagcaactactctgaaagtgacctgtgat
taaagtcgtcaattctgaagaaagagactgaaataagacaaatgggtcttaactttttctcttctctctcttgt
aaaaatgtgtgattgttctggcatgttcccaatccccacataatgccaacatcttttcttaaagggggattcccttt
atccttggatctgagaattattgcatgttctcccttttagggacaatgaatgcagttgcatcaccttgccttttttt
tttttttgtacacagcatgcttattcttggatgcagggacttgaaagacaaagccccactgcgtttcacacaatc
tcttatttagtaggtgtgcttgtgtgtaatttgaaaggagcgggtcccttactgtgtttacactgactcttttaaatg
tggggtgaaggtagaatcaaccataacttaagatgccactgggaaaaatagggtctgtgtcatctcagccccccc
atttgcaaatgacttaacagcagcactattagggttcctagtgtgagtcatttgcatttggactggtgaactgggtg
acttcttgggtgtttgaaacaaacaacctttgcagtccttctgtaaaaagcctgaacagtggaaccagtctccagttct
acttgcaaagctgcccccatcaaatccctcataatgttcaacttaaaaaatgttacacttttctctggaaatctaac
cttttttcttttttaaaagccatttttaagtacttcagtccttgaatcaaatgatcccaaatattggacaccaacct
gaatttgggttacctctcgggaactttatcgaagaagagagattttgggttggagaggggggttttgatgtttgatact
taattattactaatttaataatttcttggttgttaa
tttcatggtatttggtaggagagagctgtgatactgttgggttcaggacaagcttagaataaagaaatctgccttgagt
gagtgaagtgggttccctctgttgcattttcaccattaaaggacgaaaggaactcacaggaccagagacatctggctg
aaagcaatactagtgtgactggacatctactacctgccatagtttgggtcatatcgtttccagtatgattctgattgag
tgagtgatattaggtctatgttcagggtacagggaggctaattatgcttatattgccttgtagcattttggtaagaat
taatgattgtgtagatgtccagatttaggtcagcaaatattctaaaagttctcattgaactaatcatgtttataagta
gcctgtactttctatcataataacaatagtggaagagctagttgacataaaaggagccagattttacttaagtaaaa
aacacaaaagcaagaatattttcccatagaaattacaaaagcaagatattttcccatataaagtctcccataaaaac
aagttgaaccaaagaggaaagatgacaggtaaacgctatgacacgctaagaaagtatcataatacttaagttaacttc
aaccttttatttctcttatacctaagcagcctcttttctctttatcatttagtctgtgcttctcaactttgataagta
aaaaagttattgcaataataatcttattgaaatgcaggatctgattgagtggggtggggtaggtggaatgaggggtg
gggaagttgagattctgcatttcttagaagtttctactttatgttaaaatggctaataccatctcaacattgagaagt
aaggtttcacttaatttcagcctgtgtaagtttatacccatatgacatttcttaaactctaactcaggccccagg
aatttctccttagtttaaaatatttttaggaataaaattgaaattgcattaatacacaatttataaatttaacacaaa
aaattatttgaagtttgagacttttaggttgcatgaaatcaatttcatacttgaaaattttctataaattcaaaagtc
tgtgtattttaaatacaattttaaataacctgtgttacagtgacatttgttttctgtctctctctccaccatttccag
gtcatcatccctgtacagaaaaattttcccatatgatttcaccataaattcattaaatatgatgcttacttgataa
ttctccaggttcttttttttttaattatactttaagttctaggggtacatgtgcacaacctgcaggtttgttacat
atgtatacatgtgccattgtgggtgtgctgcacccattaaactcgtcatttacattaggtatatctcctaagtctatcc
ctccccctaccctactcctacaggtcccagtggtgagtttccccacctgtgtccaagttctcattgttct
agttccaccctatagtgagaaatcaggtgttttgggtttctgtccttgcgatagtttgcctcagaatgtatgctcctg
ctcactgatggacatttgggttggctccaagtttggctattgttaaatagtgccgcaataacatacgtgtgcatgtg
tctttatagtagcatgatttataatcctctgggtatataccagtaatgggtaggctgggtcgaatgggtatttctag
ttctagatcctagaggaatcgccacactgtctccacaatgtttgaactagtttacagtcctcatcaacagtgtaaaa
gtgttcttatttctctacatcctttccagcacctgttgtttccggactttaatgatcgccattctaactgggtgtgag
atggtatctcattgtggttttggatttgcatttctctgatggccagtgatgatgagcattttttcattgtgtcttttg
ctacataaatgtctctttttagaagtgctgttcatctccaccactttttagatggggtcattgtatttttct
ttgtaaatttggtttaagttcttttagattctggatattagccctttgtcagatgggttagattgtaaaaatttctcc
cattccgtaggtttcctattcactctgatggtagtttcttttgtgtgcagaagctctttagtttaattagatccca
tttgtcaatttttgcttttgggtgcatgttttgggtgttttagtcatgaagtccttgtccatgcctatgtcctgaa
tggatttgcctaggttttcttctaggggttttatgggttttaggtctaactgtgaagtccttaattcatcttgaatta
atttttgtataagggtgtaagaagggtatccagtttcagctttctacatatggctagccagttttccagcaccattt
atataatagaaatccttttccccatttcttggtttttgcaggtttgtcaaagatcagatgggtgtagatgtgtggta
ttgtttctgagggctgtgttctgttccatttggctctatatctctgttttggtagcaggtaccatgtgttttgggttact
gtagcccttgaatatagtttgaagtacaggtgagcgtgtatgcctccagctttgttcttttgggttaggattgtcttgg

gtagcgggctcttttttgggttccatatgaacctttaagtagtttttttccaattctgtggagaaagtcattggttagc
ttgatggggatggcattgaatctataaattaccttgggttagtatggccattttcatgatattgattcttccataccca
tgagaatggaatgttcttccatttgtttgcgtcctcttttatttcccttgagcagtggtttgtagtctccttgaaga
ggtcttccacatcccttgtaagttggattcctaagtatttttattctctttgaaacaatttgtgaatgggagttcactc
atgatttggctctctgtttgtctgttatttggtgtataggaatgcttgtgatttttgcacattgattttgtatcctga
gactttgctgaagttgcttatcagcttaaggagatttttgggctgagatgatggggttttctaaatatacaatcatgt
catctgcaaacagagacaatttgacttccctctcttcttatttgaatatcctttatttcttctattgctctgattgcc
ctggctagaacgtccaatactatttgtaataggagtggtgacagaggaacctctgttttggccagttttcaaagg
gaatgcttccagcttttggccattcgatgatgacattgggctgtgggtttgtcgtgaatagctcttatttttgagat
atgtcccatcaatacctagtttatttagagtttttagcacaaaggctgttgaattttgtcaaaggccttttctgcat
ctattgagataatcatggtttttgtcctttgattctgtttatatgatggattatatttattgattttgcatatgttga
ccagccttgcacccagggatgaagccaacttgatcatggtggataagctttttgatgttctgctggattcgggtttg
ccagtattttactgaggatttttccatcgatcttcatcagggatattggcctgaaattctctttttttgttgtgtct
ctgtcaggctgtggtatcaggatgatctggcctcataaaatgagttagggaggattccctcttttctatttgatta
gaatagttttcagaatgtgtaccagctcctcttataacctctgtgagaattcagctgtgaatccatctggtcctgagtg
attttttgggttgtaggctattaattatgctccaatttcagagcctgttattggtctattaagagattccaactc
tctctgggttagtcttgggagggtgtgtgtgtccaggaattataaaattcttttaggttttctagtttatttgcac
agaagtgtttatagtggttctctgatggtagtgttgtatttctgtgggattggtggtgatatcccccttatcacctttt
attgcatctatttgattcttttctcttttcttctttatttagtcttgcctagtcatatcaattttgttgatctttt
aaaaaaccagctcctgggttcattgatttttgaaggagttttctgtctctatctccttcagttctactctgatct
tagttatttcttgtcttctgctagcttttgaatgtgtttgctcttctctctctaaattgtgatgttaggggtgcaat
tttagacttttctgcttttctcttggggcattttagtgcataaaatttccctctacacactgctttaaatgtgtccc
agagattctggatgttgtgtctttgttctcattgggttccaagaacactctttatttctgccttcactctgtttaagt
accagtagtcactcaggagcaggttgtcagtttccatgtagttgagtggttctgagtgagtttcttaactcctgag
ttctagtttgaagcactgtagctctgagaggcagtttgttataatttctgttcttttaccatttgcctgaggagtgctt
tacttccaactatgtagtcatttttggaaatagtgatgtggtgcccagagaagaatgtatattctgttgatttggga
gtggagagttctgtagatgtctattaggtccgcttgggtgcagagctgagttcaatttctggatatctttgttaattt
ctgtcttgttgatctgtctaataattgaccgtggggtgataaagtctccattattattgtgtgggagttctaagctc
ctttgtaggctctcaaggacttgccttgtgaatctggtgctctctgtatttagtgcatatatttttaggatagttagc
tcttcttgtgaattgataccctttatcatattgtaatggccttcttctgtctctttgatctttgttgggtttaaagtc
tgttttatcagagactaggattgcaactcctgcttttttctgttccatttcccttggtagatcttccctcatccct
ttattttgagcctatgtgctctctgcacatgagatgggtctgctgaatacagcacactgatgggtcttgactcttt
atccaatttggcagtcocatgtcttttaactggagcatttagccatttaccatttaagggttaatatgtttatgtgtga
atttgatcctgtcattatgatgttagctgggtattttgtcgttagttgatgcagtttcttccctagcctcaatgatc
tttacaatttggcatgttttgcagtggtggtactggttgcctttccatgttttagtgcttccctcaggagctct
tgtaaggcaggcctgggtggtgacaaaatctctcagcatttgccttgcctgttaaaggattttatttctccttcaactat
gaagcttagtttggctggatgaattctgggttgaaaattctttcttttaagaattgtgaatatgtggccccact
ctctctgggtgtagagttctgcgcgaagagctgtgttagctgatggacttcccttgggtggaacctgcccctt
ctctctcgctgcacttaatgttttttcccttcaatttcaactttgggtgaatctgacaattatgtgtctttgagttactc
ttcttgaggagtatctttgcggcattctctgtatttctctgaatttgaatgctggcctgctcactagattggggaag
ttctcctggataatatcctgcagagcgttttccaacttgggtccattctccccatcactttcaggtacaccaatcag
atgtagatttggcttttccacatagtcccatatttcttggaggctttgttcatttcttttactctttttctctaa
acttctcttcttcttcaatttcaattttagcttcttcaatccctttcttccacttgattgaatcagctactgaagct
tgtcatgtgtcacatagttctcgtgccattgttttccagtcocatcaggtcatttaagggtcttctctatgtctgtttt
tctagttagccattcgtctaattgttttccaagggttttagcttctttgtctaaagggttccaacatcctcctttag
ctcggaggagtttgttattactgatcatctgaagccttcttctcacttgtgaaagtcatttctctgtccagcttt
gttccattgctggcgaggagctgcattcctttggaggagaagacgtgctctgattttttagaattttcagcttctctg
ctctgggttttctccccatcttattgggttttatctacctttgtctctttgatgtggtgacgtacagatgggggttttgg
gtggatgttcttctcttggtttagtttcttcttaacagtccaggacctcagctgcaggtctgttggagtttgcctgg
aggtccactccagacctgttgcctgggtatcaccagcagagctgcagacagcaaatattgcagaacgggcaaat
gttgcctcctgattgttctcttgaagcttctgtctcagagggcacttggccgtatgaggtgtcagctcggccctac
tgggagggtgcctccagttaggctactcaggggtcaggaaccacttgaagaggcagactgtccattctcagatata
atatccatgctgggaggaccctactcttttcaaagctgtcagacagggacatttaagctgcagaagtttctgct
gtcttttgttcagctgtgcccctgcccctagagggtggagtctacagaggcaggcaggcctccttgagctgcgggtgggc
tccaccatttgcagcttctggctgctttgtttacctactcaagctctcagcaatgggtggacaccctccccagcc
tcgctgctgctttgcagttcgatctcagactgctgtgctagcagtgagccaggctccgtgggcatgggacccctccga
gccaggcctgggacataatctcctggtgtgcccgtttgctaagaccattggaaaagcacagttatagggtggggagtg
tctgatttttccaggtaacctgcattggtcttcccttggctagggaagggaattcccccaacccttgtgcttctgtg
ggtgaggtgatgccccaccctgctttggctcatgctcgtgggttgcaccactgctgacacgcccaagcctgagatg
aacccggtaacctcagttggaaatgcagaaatcacccgtcttctgcactcactcacgctgggggctgtagactggagc

gttcatatttggccatcttggaaacctccctttccaagttctttattacagagtgggtcactgaaacttcatggaaca
 aattggaaattatcttcttaataatgtcactgtctaccatgtatgggaatttggtaaatattatattggtttcaata
 acatagtagatagaacattgtcaaatctaaacttcagtgaaattgttaacagatccacactgaaattctaaagaaaaca
 gaattcttaattgaagaggttaaaacttttacagggaaattgtcaactggcatttgggtcctgttaaacaacaaactgtttt
 taaaaaagtaaaactttaaaagtattttcagatgacctcatttgcataccaagtggcttgagtatgcttgatgctaa
 gacttcttgttacagactggagatgtgtgctactggggcagtggtgctctgtgacaaggaggcagaggatgagggc
 aaggttcgatgtgactgtgaattctgggtggctctggctatcgggagccttcattgattacagcaaaacagttgctt
 tcctagggcaatagtgtctctgtccaccaggtggagttcagtgggcatgatcaatcgctcactgtagcctcaacttc
 ttagactcaagtaatctcccacctcagcctcccaagtagctgaaactacaggtgtgcaccaccacacctaattttt
 ttaatttttaagttttttagagacatggctcactgtgttgccagggtgatctcgaattctcctgggctctagtgtat
 cctcccgctcggcctcccaaaggttggtattacaaatgtgagccactgcacctggcccttttgcaaccttcttgac
 aatgcattcctttattccctaactggaagtaacttctttctctttataaaattgtatctgtacctttctgggtcat
 ttctacctttatattctagttaactgtatgtcctacctccctcctaggaggaggtaagtaagactggaaagtagact
 tcatgtgtgatgaatgaatgaacaaaaggaagtctaacatattggatatagtcactggatgcaaatataaaattttt
 aaatattgatttgcagatttcatataaggtcaactcttaatagtttgcataatattgtaggaaccaaataat
 aacttcttcagcattaccattatctttataggactgtctaaaatgagcagccatatctttaaactgtgtttctctg
 attacagctcacaggttaaaacccaaagggctgggaacaaacaaagactttttttttctgtatgcctgaattat
 ctgtactgttgcctgttttccacacttggccataagaaacttagttctaacatgctacaatttttgcagttctttct
 cttagaaaaagaccacattgtctgaaatttcatccatttaagtaatacagccttaaagttgaaggatcttggctcatg
 attaatctagacctacaaagtagtatcttaattggcactccttttagaaagttaggttcaggacacacatagctgca
 gtgtccacattttgtagctccttctgtgtcacagccactctctctctgtgtgctgatattctaaaactggcaacac
 atcctgatggtaaaagcttgggttcaggagacaggtgacctactagctttatggcatttgacaggttacctaacctct
 ctgacgcataattgcctcatctatataatggggataataatacccatcctgtctccttgtaaaaaatcaaattagatg
 acgcctgtgaatgttctatagctctcttagacaaaatgtgaagttatgactacagcaagagtaaaagagcatgttggttat
 ggacattctttcagtgaaatgtotaagacttgtgagtcacacttaaagctaaacttgatatctacttcatgtattt
 ctttttagttctatgtactatattgaatttctgacagtggtgctatgaaagccttcttagcattttatagatgtgg
 ttgaattaatggctgtgaagccttaaagcagaattagacagcatcaatgaatttattaagtataaataatataat
 ctgcttagcaatattacacagcctctttatcttatgtgtgataaagagtcacccaaggttgaaaatgaagaattgt
 cctggaagctcttacttaactttttatttttcttaatacagtatataaaattactcattgaaagcttagcagaata
 agaaacaagaagttaaaaggtgaaaactacaaattttgtctattattattgttattacttcccaagctctcttattga
 tctgttagaaatagagctacacaggaaattgtaggacagtttagtatgtggtagtggttatctgtcttttaattatca
 agtaaggttttattccattagaggaaactcaagaagttggctcatggctgataattgctatctgtcaaatctcttagag
 cagggatccgcaacaccaggccatggattgttaccagtccttggcctgttaggaaccaggctgcacagtaggaagt
 gagcgcggtgagcaaacattgccatctgagctctgtctccttcagatcagcagcagcattagattctcatagaa
 gcatgagccctgttgtgaactgcacatgcaagggatctaggttgtgtgctccttatgagaatccaattccttatgat
 aatttaactgatgatctaaggtggaaccatttcatcccaaaacccatccacctgctactcccagaccgtggaaaaat
 tgtcttcccaaaaactggttctgtctgcccacaaaggttgggaccactgccttagagtttataatttgggggttagcac
 agcctattattacctgagaatttcaatgggttcaactgatcttcccaaatgaaaaggcttcttacgaaaaattatcc
 aaactgtcttttctcttagtttaataaaccttatcagtaagtttttactgagtactgctattacatttttctctgtta
 agcattatgggggtcagacatgatccattccctcaaagaacttacctttcagctgaagactgactagaatgagcaa
 atacggttaacaatttaacaagttagtaggccaagctcggccaacatggtgaaaccctgtctctactaaaaatacaaaa
 attagccgggcatggtggtggggcctgtaatcccagctacctcctgtctgagcaggagaattgcttgaaccaggga
 ggtggagattgcagtgagccgagattgcaccattgcactccagcctgggcgacagagcaagactctgtcttgggaaa
 aaaaacaaaacaaaacagtgagaagggaatcaagtactacgttaagatgtaattgtggaatttttagggaagggaaggcag
 tgtatgctggagtaattagagaaagggcatgcatgatttgatgcttgaactggatcatgaaggataagcaagattt
 tggcagcaagttagaggggagagaggagtttgcagaggaatggaacaagttaggagggcagtaattgtgtacggcactc
 caaggactctgtcctgatcggagcagaagttagatgaagcatttagtagtttgagaaagtttagctaagaaggggtgaggg
 cagatgttggagagagttgagtatcagagagaagacatttagatttgagcagatagaacaaaaatgccattgccagtt
 tttgtgaagagaatagattaggggtggttaccagggaagtggtcatcagagttgaatggagcagaaagagtgctg
 atacagcatcgggacgttgtggtcacaataagaggtggtgagggctgagccaagatggtggcagtggtggtgataaa
 aagggatggccaggacaaatatttttaaggaaaaatataacagacatcttactgactggattggaaggctatgcag
 gaaatatattgtcaacttgattccaggatttctatcctatgcctgggttgcccaaaatatcagggaaccattgtta
 gaaaaggtaggagataccactgttccaacaaaagatttaggttgggtgtgcacccacttaacttcaaggccttac
 aagttagtagacagtttagttagaattgcagaagtgcactcagagagcagggttgcaatgtggggttggaactttgt
 caccattgtgttaattcctaattctatgcagatgctcagcttgaggaataccatgtttgggcttcagaatgaaagc
 caagtaatatattactcagatgccaaattttccctctgaaatatgtgtcatggaactgagagaaacataataaagca
 ttaattattttctcataaagttattaataaaaagataagatcagtgaaaggcagagtaaacatagaagccaagta
 gaaaatggttatctataaagactcattactgtaggtggtgaaacaaaacaaattttccaacagcttaagatggtcctcag
 ttttttggaccatttttaagtagtttagtgggcacttagtaaatatgtattaaactatagttcatttaattctttt
 ttttttttttgagatggagtttactctgtgtcaccaggctgcatttttgccttcttagtgatatataaaatgtcg

agtttcacaatgatggtatcttagatttgattaaatatggtattaaaaaatagctgatcacagaaagtctctaccag
 tgtgatgtagatggctaaagtattccacatttgcaaaccttttattgacctaaataagagggtgcccttgggttgttt
 ttatttggactgggaatttaggagaaagctttttcattcagtggtgtaagtacaattctaccagaaatagaaaccccc
 atggacgatctatttctttagtggtacaggactcagaacattcacaagatttagttggttagcggaaatagacatctg
 tattttattcaaaccaattttcccttcctaattctgagaacattgtgcaatctaagcagtttctaagcatgtttgctat
 tcgtgcaaagttagagtaaatctaaaagaaatttttttgggtgttttagGGATGGTAATAAAGTCTCTTAGTGGTTGA
 AAATGTTATTTCTTACAAAAGTGGAGAACATTGCTTTTCAATACCAGAGTTTTTCAGCCATTTCTGCATTCTGACCT
 ATTGACTGGAGgttaggttgcctttgaattcagtaaaacttcatgggcagaaacacagtttcccttttctacttatttg
 gatatcatgatggccattgcatgtatgtgtcttttgaagtcctgcctcagaactgagaagttaggaataaaatta
 gggtcagggtctgggatgtactctttgtgctgagaaacacaatgcttcaggtaagtgtattctgaagtcttccacc
 acctgacggtaaccttgggttgggtccataggtatgttttcttttgccttgcattccatttgaattgggttccctaga
 gcatgctttagatgttagagccaaatttagagtagagcaacctctggcaaacaggaagagattaattttgtggtat
 gcttttaagggaacttcccaggaacttcaaaagcagaaaaaagacactagctgctatttccaaatgtgtaaaaca
 ccactcagcttttttaaaagtaggataaaactcagagcgcgcgacacgcgcgcgcgcacacacacacacacacaga
 gagaacatctctagtaaaaagaaagttgagctttcttagctagatgtgtgtatttagccagaaaaagccaaggagt
 aagggttttagagaactggaggagataaaagtgagctgcatattgggaggcatttgaaatggacttaaatgtctttt
 taatgtgacttttttcttctccttaccagacacattgttttcatgacattagccccaggcagacacacatctt
 taaaatgaacatgtcaaaaaatgatttctgttttagaaataagcaaaacattttcagttgtgaccacccagggtgtaga
 ataaagaacagtggaattgggagccctgagttctaataaacttttcttcatgacataaggcaagcttctctatggcc
 tttggttcttctacctgtaaaacaggatggctcaatgaaattatctttcttcttgcataatagagtagtctctgtg
 ggaagaggaaaaaaaagtcaatttaaggctccttatagttccccaactgctgttttattgtgctattcatgccta
 gacatcacatagctagaaaggcccatcagaccctcaggccactgctgttctctgtcacacattctctgcaaaggacca
 tgttgctaaacttgaaaaaattactattaattacattcagctgttgcttagtaacatttatgattttgtgtttct
 cgtgacagcatgagcagagatcattaaaaattaaacttcaaaagctgctaaagtgggaagaaggacatttgaagcc
 acaatttttgcacttgccttagaagccatctaattctcaggttttatatgctagatcttgggggaacactgcatgtctc
 tgggttatattaaccacatacagcacactactgacactgatttgtgtctggtgcagctggagtttatcaccaagac
 ataaaaaaccttgacctgcagaatggcctggaattacaatcagatgggcccacatggcatcccggtgaaagaaagc
 cctaaccagttttctgtcttgtttctgctttctccctacagTCCACCAGGTGAGAAGAGTGATGACCATCCTTTTC
 CTTACTATGGTTATTTCTACTTTGGTTGCATGAAGGCTGCCCCCATGAAAGAAGCAAACATCCGAGGACAAGGTGG
 CTTGGCCTACCCAGGTGTGCGGACCCATGGGACTCTGGAGAGCGTGAATGGGCCCAAGGCAGGTTCAAGAGGCTTGA
 CATCATTTGGCTGACACTTTTCAACACGTGATAGAAGAGCTGTTGGATGAGGACCAGAAAGTTCGGCCCAATGAAGAA
 AACAATAAGGACGCAGACTTGTACACGTCCAGGGTGATGCTCAGTAGTCAAGTGCCTTTGGAGCCTCCTCTCTCTT
 TCTGCTGGAGGAATACAAAATTACCTAGATGCTGCAACATGTCCATGAGGGTCCGGCGCCACTCTGACCCTGCC
 GCCGAGGGGAGCTGAGCGTGTGTGACAGTATTAGTGAGTGGGTAACGGCAGCAGACAAAAAGACTGCAGTGGACATG
 TCGGGCGGGACGGTCACAGTCCCTGAAAAGGTCCCTGTATCAAAAGGCCAACTGAAGCAATACTTCTACGAGACCAA
 GTGCAATCCCATGGGTTACACAAAAGAAGGCTGCAGGGGCATAGACAAAAGGCATTGGAACCTCCAGTGGCGAATA
 CCCAGTCGTACGTGCGGGCCCTTACCATGGATAGCAAAAAGAGAAATTGGCTGGCGATTTCATAAGGATGACACTTCT
 TGTGTATGTACATTGACCATTAAAAGGGGAAGATAGTGGATTATGTTGTATAGATTAGATTATATTGAGACAAAAA
 TTATCTATTTGTATATATACATAACAGGGTAAATTATTCAGTTAAGAAAAAAATAATTTTATGAAGTGCATGTATAA
 ATGAAGTTTATACAGTACAGTGGTTCTACAATCTATTTATTGGACATGTCCATGACCAGAAGGGAACAGTCATTTG
 CGCACAACTTAAAAAGTCTGCATTACATTCCTTGATAATGTTGTGGTTTGTGTCCTTGCCAAGAACTGAAAACATA
 AAAAGTTAAAAAAATAATAAATTGCATGCTGCTTTAATTGTGAATTGATAATAAACTGTCCTCTTTCAGAAAACAG
 AAAAAAACACACACACACACACAAAAAATTGAACCAAAAACATTCCGTTTACATTTTAGACAGTAAAGTATCTTCGT
 TCTTGTAGTACTATATCTGTTTTACTGCTTTTAACTTCTGATAGCGTTGGAATTAACAAATGTCAAGGTGCTGTT
 GTCATTGCTTTACTGGCTTAGGGGATGGGGATGGGGGTATATTTTGTGTTGTTTGTGTTTTTTTTTCGTTTGT
 TGTGTTGTTTTTTAGTTCCACAGGGAGTAGAGATGGGGAAAGAAATTCCTACAATATATATTCTGGCTGATAAAGA
 TACATTTGTATGTTGTGAAGATGTTTGCAATATCGATCAGATGACTAGAAAGTGAATAAAAAATTAAGGCAACTGAAC
 AAAAAATGCTCACACTCCACATCCCGTGATGCACCTCCAGGCCCGCTCATTCTTTGGGCGTTGGTCAGAGTAAG
 TGTCTTTTGACGGAAGGACCTATGTTTGTCTCAGAACACATTCTTTCCCCCTCCCCCTCTGGTCTCCTCTTTGTTT
 TGTTTTAAGGAAGAAAAATCAGTTGCGCTTCTGAAATATTTTACCAGTGTGAACAACTGATCAATTTGTGTCA
 CATCATGACACTCGTATAAGCATGGAGAACAGTGATTTTTTTTTTAGAACAGAAAAACAACAAAAAATAACCCAAAAAT
 GAAGATTATTTTTTATGAGGAGTGAACATTGGGTAAATCATGGCTAAGCTTAAAAAAACTCATGGTGAGGCTTAA
 CAATGCTTGTGAAGCAAAAGGTAGAGCCCTGTATCAACCCAGAAACACCTAGATCAGAACAGGAATCCACATTGCCA
 GTGACATGAGACTGAACAGCCAAATGGAGGCTATGTGGAGTTGGCATTGCATTTACCGGCAGTGGGGAGGAATTC
 TGAGTGGCCATCCCAAGGTCTAGGTGGAGGTGGGGCATGGTATTTGAGACATTCCAAAACGAAGGCCCTCTGAAGGAC
 CCTTCAGAGGTGGCTCTGGAATGACATGTGTCAAGCTGCTTGGACCTCGTGCTTTAAGTGCCTACATTATCTAATCTG
 TGCTCAAGAGGTTCTCGACTGGAGGACCACACTCAAGCCGACTTATGCCACCATCCACCTCTGGATAAATTTTGCA
 TAAAATTGGATTAGCCTGGAGCAGGTTGGGAGCCAAATGTGGCATTGTGATCATGAGATTGATGCAATGAGATAGA
 AGATGTTTGTCTACCTGAACACTTATTGCTTTGAAACTAGACTTGAGGAAACCAGGGTTTATCTTTTGAGAACTTTTG
 GTAAGGAAAAAGGGAACAGGAAAAGAAACCCCAACTCAGGCCGAATGATCAAGGGGACCCATAGGAAATCTTGTCC

AGAGACAAGACTTCGGGAAGGTGTCTGGACATTCAGAACACCAAGACTTGAAGGTGCCTTGCTCAATGGAAGAGGCC
 AGGACAGAGCTGACAAAAATTTTGTCTCCCAGTGAAGGCCACAGCAACCTTCTGCCCATCCTGTCTTCATGGAGAG
 GGTCCCTGCCTCACCTCTGCCATTTTGGGTAGGAGAAGTCAAGTTGGGAGCCTGAAATAGTGGTCTCTGGAAAAAT
 GGATCCCCAGTGAAGACTAGAGCTCTAAGCCCATTACAGCCCATTTCACACCTGAAAATGTTAGTGATCACCCTTGG
 ACCAGCATCCTTAAGTATCAGAAAGCCCCAAGCAATTGCTGCATCTTAGTAGGGTGAGGGATAAGCAAAAGAGGATG
 TTCACCATAACCCAGGAATGAAGATAACCATCAGCAAAGAATTTCAATTTGTTTCAGTCTTTTCATTTAGAGCTAGTCTT
 TCACAGTACCATCTGAATACCTCTTTGAAAGAAGGAAGACTTTACGTAGTGTAGATTTGTTTTGTGTGTTTGA
 TATTATCTTTGTAATTATTTTAAATATGTAAGGAATGCTTGGGAATATCTGCTGTATGTCAACTTTATGCAGCTTCCT
 TTTGAGGGACAAATTTAAACAAACAACCCCCATCACAACCTTAAAGGATTGCAAGGGCCAGATCTGTTAAGTGGT
 TTCATAGGAGACACATCCAGCAATTGTGTGTCAGTGGCTCTTTTACCCAATAAGATAACATCACAGTCACATGCTTG
 ATGGTTTATGTTGACCTAAGATTATTTTGTAAATCTCTCTGTTGTGTTCGTTCTTGTTCGTTTGTGTTTGT
 TTTTAAAGTCTTGCTGTGGTCTCTTTGTGGCAGAAGTGTTCATGCATGGCAGCAGGCCTGTTGCTTTTTTATGGC
 GATTCCCATTTGAAAATGTAAGTAAATGTCTGTGGCCTTGTCTCTCTATGGTAAAGATATTATTACCATGTAAAC
 AAAAAACAATATTTATTGTATTTTAGTATATTTATATAATTATGTTATTGAAAAAATTGGCATTAAAACTTAACCG
 CATCAGAAGCCTATTGTAAATACAAGTCTATTTAAGTGTACTAATTAACATATAATATATGTTTTAAATATAGAAT
 TTTTAAATGTTTTTAAATATATTTTCAAAGTACATA

FIGURE 3

Natural antisense sequence (NR_002832.1): SEQ ID NO: 2

>gi|84872122|ref|NR_002832.1| Homo sapiens BDNF opposite strand (non-protein coding) (BDNFOS), non-coding RNA

CNGCNNAAGATTTCTTCACAGGGTCCTTTAAACTGTCTNNNTTNTAAGAGGTCTTCCACTACAGGTAAAGGGAAAT
 TCCCTCTACCCTAGGGCCCTCAGGANCCCTTCTCTCTCACACGTTTCTTCGACTGCTNNNGATTTAAGCATTACAG
 CTGGCCACGCAACGCAAGAAGCAATAAGAACACAAAAACCTACCCTGTTCTNTCCTCTATCCGTGGCCTTTGCCACC
 ACCTCCACAACCTAGTTTCAGATTCTCTCTCTTTTCTCAAGGGAACGTCTAAAGCTCTCAAGTCCGTTTTGGCAGGGC
 GATTTTGTAAAGTCTGAANCATTTTCAGTGTGTCTCTCGATCTCAGGCAGCTCAAAAGAAAAGATCTGCTGGCTGCGTG
 AAGGTGCATTAGAAACCTGCTGCTACCTTGACGCTGGGCTGAGCATATGCTCCGGAACCTTGCTTCTCTCCAACAT
 CCTGCACCTCAGGGTTGCACGCTCTGGTTCCTCAAGCCCCGGCCGCTGGCTTATGCAAATCACTTAGGTACATGCAA
 AAGTATCCCTTCTCCCGGAGCGCCATTGGCCCCGGGAGGTCTCGAGCTCATTACTATGCAGAGAGGAGAGCCGCCAT
 TGGCCAAGAGGAGGACCAGAGGGCGGTGTTCTCGGGCAAAATGGATCTCCTAAATTGGATGACCTGGGCTGAAAGA
 CAACCTAAAGACCCCCAGAAAACCTCTGGTTTTATAGATAAGAAATCTGAGGCTCGAGAGAGAGTGTGTTCTGCCCAA
 CATCATCACGGAACAGCTCCTGGGCTCCTGGCTCCTAATCTGTCTCATCGCTGTCTGGAACAGCGATGACTCGATCGCG
 AGATCAGGAAGGTGGCCGAGTGTGTGCGCGCGCCATCAGGCACCTTCTCCTTCTGCCCCTTGATGAAGAAGGATGT
 GTTTGCTTCCCTTGTGCCATGATTGTAAATTTCTGAGGCTCCTCAGCCCTGCAGAACTGGGGTTATAGCCATGT
 GACTGATCTTCGTCCAAGAATATGTAAAGAAAAGTGTGAGTTGGCTTTTAGGGCTAGAGCAATGTATCTTAGGCT
 CACTTAAGGAAGCTGTAGAGATGAGCCCAAGGAGGGAACAGAAAGAGCCCCCAGGCTCACCAGTTGTTTGTGTTGGC
 TCCCTACAAACATGTCATTCAGTGGCTAATCTTACAACAGCACAAATTCATCTAACCAGAAAGAGAAGAGGAGGCT
 CCAAAGGCACTTGACTACTGAGCATCACCTGGACGTGTACAAGTCTGCGTCCTTATTGTTTTCTTCATTGGGCCGA
 ACTTCTGGTCTCATCCAACAGCTCTTCTATCACGTGTTGAAAGTGTGAGCAATGATGTCAAGCATCTTGAACC
 TGCCCTGGGCCCCATTACGCTCTCCAGAGTCCCATGGGTCCGCACACCTGGAGATACTCTATTATAGCAAAGAAGAA
 AGATAATTTTCATTGAGCCATCCTGTTTTACAGTATTGAATTATTACCACAAGGTACCAACCATATATGCATACCTAA
 TAGGGTATTTTGTCAAAACTATGTCATGAAGGTCATTTGTTGATTAGTGTGAGAACATTTTCCCGTGAGAGATCTCAT
 TGGGCAATTGAAACAGAACACATGCTCTTCAGACCAGCAACCGCGACTACCAATACTCCTCTGTCAACTCTACTTG
 AGTAAGAACGCTTTCAATTAAGGCCTAAGTGTCAACATGCCCTTAAAAAAAATCGTGGTGACACAAAATCTTTCTTT
 TTAGACCCCAACAGAAATCCCTTCAAAGCCTCGTGGTCTGACACCTATGCTACGTGACTTGTGACCCATCCATTTGT
 CATGTTCTTCGGGAATGTGGCTAAGGGGCTAAGATGTGACTTGAAAAGAAAGGTAGAACAAGATCATCTCAAATTTA
 TTATCAAGGAATAGTTCAGAAAACGACTTCAGACCACAGAGACAGCAGAACAGATGGTCCGGCATGGATAGAGCATC
 AGACACTCACAGACTGTGCCAACAAGAGCCATCGAGTCAAAACAGCCAAAGGAAGGAGGGTATGGAATGGGTTCTC
 TCACACCAAACTGATGCCAGAGGCCCTCAGCATGAATAACAAAGGCAACCCAGACCCACAAGCCATACTGAGTGGAT
 ACAAACCTATACCTAGGCTGACATCCCAAATGTGTGTGGCAAGTTAGATGATGATGGCACAAAAGACAGAACACCT

TGCTTCTGGCCATTGTCAGCTCTTGGAAGAGAGCACACTTTTAGAGGAGCAGCTGCAAGGAGCCTGAGAACAAAAC
GGAAATGTCTGTTATGAAAGCCTTCACAGGAAATCTGCAAGTGGCAACGTGGGTCCATTCCGTGTGTGTCAC TAGA
GCTGGCGCAAGCCCATGGCCATGGTGAGGCAGCGTTTCCACTGGAAC TAATCTGATACCTGCACCAACTCTTGCAAC
TGTGCAGTGTTCCCACTGCAAACTACGGATGGGGTAAAAGACTGCTCACCTCCTATTTCTCATCTAATCTCACACAC
TCTGTTTGATGAGGCTATGGAGAAACAGGTCTTCTCATACTAAAGGTGGGAGTACAAACAATTCAAGCCCTGTGC
AGGACAATTAGGCAATACCTATCAAAATTATACATGATTTTTCCTGCTGACCCAGCAATTCCACTTTTGGGAATAAT
TGACAGATATAGGTGCATATGTACAAAATGATGGAAAGCTCTCTGGTATATATTAGTAAGTGATAAAACAAGGTGTG
TGTATATATGGCTACTACCTTTTGTTTTAAAAATGGGGGAAAAATGGTGGAGCTTGCGGTGAGCCGAGATCGTGCCAC
TGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAAACAGGGTGGGGTGGGGGGGAAATAATAGTA
CATACTCATATTTACCTGTATCTATATAAAACACACTATCAAGGATTCACAAGAACTAATACAAATGATCCCCTTA
TAGATGGTATGTATTGGGGGATACTGAGGTGAGCAGGGTATAAGTGGGGCAAGACTTTTCAGTGTAACCTTCTTTTA
AATTTTATTTGATTTTGAATAATGTAAATTAAGTGTCAAATAATTAAATTAAAAATAACCAATTTATTAACAAA
AAAAAAAAAAAAAAAAATA

FIGURE 4

Sequence ID	Sequence
SEQ ID NO:3	C**T**T*G*A*A*T*T*G*T*T*T*+G**T**+A
SEQ ID NO:4	A**G**+T*T*G*C*A*A*G*A*G*T**+T**+G**+G
SEQ ID NO:5	A**+T**+C*T*G*T*T*C*T*G*C*T**+G**+T**+C
SEQ ID NO:6	C**+A**+T*A*T*T*C*T*T*G*G*A**+C**+G**+A
SEQ ID NO:7	T**+G**+T*G*C*T*G*T*T*G*T*A**+A**+G**+A
SEQ ID NO:8	T**+G**+A*C*A*G*A*G*G*A*G*T**+A**+T**+T

FIGURE 5

Sequence ID	Sequence
SEQ ID NO:9	GCACACCTGGAGATACTCTATTATA
SEQ ID NO:10	CCTGCAGAATGGCCTGGAATTACAA

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 61152132 A [0001]
- WO 9801573 A [0003]
- WO 2006072005 A [0003]
- US 5432272 A, Benner [0038] [0157]
- US 5013830 A [0138]
- US 5149797 A [0138]
- US 5220007 A [0138]
- US 5256775 A [0138]
- US 5366878 A [0138]
- US 5403711 A [0138]
- US 5491133 A [0138]
- US 5565350 A [0138]
- US 5623065 A [0138]
- US 5652355 A [0138]
- US 5652356 A [0138]
- US 5700922 A [0138]
- US 5034506 A [0140] [0150] [0152]
- US 5138045 A [0142] [0160] [0179]
- US 5218105 A [0142] [0160] [0179]
- US 5459255 A [0142] [0157]
- US 3687808 A [0148] [0156] [0157]
- US 4469863 A [0148]
- US 4476301 A [0148]
- US 5023243 A [0148]
- US 5177196 A [0148]
- US 5188897 A [0148]
- US 5264423 A [0148]
- US 5276019 A [0148]
- US 5278302 A [0148]
- US 5286717 A [0148]
- US 5321131 A [0148]
- US 5399676 A [0148]
- US 5405939 A [0148]
- US 5453496 A [0148]
- US 5455233 A [0148]
- US 5466677 A [0148] [0150]
- US 5476925 A [0148]
- US 5519126 A [0148]
- US 5536821 A [0148]
- US 5541306 A [0148]
- US 5550111 A [0148]
- US 5563253 A [0148]
- US 5571799 A [0148]
- US 5587361 A [0148]
- US 5625050 A [0148]
- US 5166315 A [0150]
- US 5185444 A [0150]
- US 5214134 A [0150]
- US 5216141 A [0150]
- US 5235033 A [0150]
- US 5264562 A [0150]
- US 5264564 A [0150]
- US 5405938 A [0150]
- US 5434257 A [0150]
- US 5470967 A [0150]
- US 5489677 A [0150] [0152]
- US 5541307 A [0150]
- US 5561225 A [0150]
- US 5596086 A [0150]
- US 5602240 A [0150] [0152]
- US 5610289 A [0150]
- US 5608046 A [0150] [0160] [0179]
- US 5618704 A [0150]
- US 5623070 A [0150]
- US 5663312 A [0150]
- US 5633360 A [0150]
- US 5677437 A [0150]
- US 5677439 A [0150]
- US 5539082 A [0151]
- US 5714331 A [0151]
- US 5719262 A [0151]
- US 4981957 A [0154]
- US 5118800 A [0154]
- US 5319080 A [0154]
- US 5359044 A [0154]
- US 5393878 A [0154]
- US 5446137 A [0154]
- US 5466786 A [0154]
- US 5514785 A [0154] [0160] [0179]
- US 5519134 A [0154]
- US 5567811 A [0154]
- US 5576427 A [0154]
- US 5591722 A [0154]
- US 5597909 A [0154]
- US 5610300 A [0154]
- US 5627053 A [0154]
- US 5639873 A [0154]
- US 5646265 A [0154]
- US 5658873 A [0154]
- US 5670633 A [0154]
- US 5700920 A [0154]
- US 4845205 A [0157]
- US 5130302 A [0157]
- US 5134066 A [0157]
- US 5175273 A [0157]
- US 5367066 A [0157]
- US 5457187 A [0157]
- US 5484908 A [0157]

- US 5502177 A [0157]
- US 5525711 A [0157]
- US 5552540 A [0157]
- US 5587469 A [0157]
- US 5596091 A [0157]
- US 5614617 A [0157]
- US 5750692 A [0157]
- US 5681941 A [0157]
- US 4828979 A [0160] [0179]
- US 4948882 A [0160] [0179]
- US 5525465 A [0160] [0179]
- US 5541313 A [0160] [0179]
- US 5545730 A [0160] [0179]
- US 5552538 A [0160] [0179]
- US 5578717 A [0160] [0179]
- US 5580731 A [0160] [0179]
- US 5591584 A [0160] [0179]
- US 5109124 A [0160] [0179]
- US 5118802 A [0160] [0179]
- US 5414077 A [0160] [0179]
- US 5486603 A [0160] [0179]
- US 5512439 A [0160] [0179]
- US 5578718 A [0160] [0179]
- US 4587044 A [0160] [0179]
- US 4605735 A [0160] [0179]
- US 4667025 A [0160] [0179]
- US 4762779 A [0160] [0179]
- US 4789737 A [0160] [0179]
- US 4824941 A [0160] [0179]
- US 4835263 A [0160] [0179]
- US 4876335 A [0160] [0179]
- US 4904582 A [0160] [0179]
- US 4958013 A [0160] [0179]
- US 5082830 A [0160] [0179]
- US 5112963 A [0160] [0179]
- US 5214136 A [0160] [0179]
- US 5245022 A [0160] [0179]
- US 5254469 A [0160] [0179]
- US 5258506 A [0160] [0179]
- US 5262536 A [0160] [0179]
- US 5272250 A [0160] [0179]
- US 5292873 A [0160] [0179]
- US 5317098 A [0160] [0179]
- US 5371241 A [0160] [0179]
- US 5391723 A [0160] [0179]
- US 5416203 A [0160] [0179]
- US 5451463 A [0160] [0179]
- US 5510475 A [0160] [0179]
- US 5512667 A [0160] [0179]
- US 5565552 A [0160] [0179]
- US 5567810 A [0160] [0179]
- US 5574142 A [0160] [0179]
- US 5585481 A [0160] [0179]
- US 5587371 A [0160] [0179]
- US 5595726 A [0160] [0179]
- US 5597696 A [0160] [0179]
- US 5599923 A [0160] [0179]
- US 5599928 A [0160] [0179]
- US 5688941 A [0160] [0179]
- US 9209196 W [0178]
- US 6287860 B [0178] [0186] [0195] [0197] [0198] [0199] [0202] [0203]
- US 5108921 A [0180]
- US 5354844 A [0180]
- US 5416016 A [0180]
- US 5459127 A [0180]
- US 5521291 A [0180]
- US 5543165 A [0180]
- US 5547932 A [0180]
- US 5583020 A [0180]
- US 5591721 A [0180]
- US 4426330 A [0180]
- US 4534899 A [0180]
- US 5013556 A [0180]
- US 5213804 A [0180]
- US 5227170 A [0180]
- US 5264221 A [0180]
- US 5356633 A [0180]
- US 5395619 A [0180]
- US 5417978 A [0180]
- US 5462854 A [0180]
- US 5469854 A [0180]
- US 5512295 A [0180]
- US 5527528 A [0180]
- US 5534259 A [0180]
- US 5543152 A [0180]
- US 5556948 A [0180]
- US 5580575 A [0180]
- US 5595756 A [0180]
- US 2007011772 A [0188]
- US 6632427 B [0189]
- US 6756523 B [0189]
- US 4866042 A [0189]
- US 6294520 B [0189]
- US 6936589 B [0189]
- US 7563884 B [0207]
- US 6310048 B [0229] [0231]

Non-patent literature cited in the description

- **PRUUNSILD et al.** *Genomics*, 2007, vol. 90 (3), 397-406 [0003]
- **BEITER et al.** *Cellular and Molecular Life Sciences*, 2008, vol. 66 (1), 94-112 [0003]
- **LIU et al.** *Brain Research*, 2006, vol. 1067 (1), 1-12 [0003]
- **QING-RONG LIU et al.** *American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics*, 2005, vol. 134B (1), 93-103 [0003]

- LIU et al. *International Journal of Developmental Neuroscience*, 2006, vol. 24 (8), 559 [0003]
- EGUCHI et al. *Ann. Rev. Biochem.*, 1991, vol. 60, 631-652 [0025]
- CAPLEN, N. J. et al. *Proc. Natl. Acad. Sci. USA*, 2001, vol. 98, 9742-9747 [0033]
- BERNSTEIN, E. et al. *Nature*, 2001, vol. 409, 363-366 [0033]
- BOUTLA, A. et al. *Curr. Biol.*, 2001, vol. 11, 1776-1780 [0033]
- CECH. *J. American. Med. Assoc.*, 1988, vol. 260, 3030-3035 [0035]
- SULLENGER et al. *Cell*, 1990, vol. 63, 601-608 [0036]
- KORNBERG ; BAKER. *DNA Replication*. Freeman, 1992 [0038]
- SCHEIT. *Nucleotide Analogs*. John Wiley, 1980 [0039]
- FREIER ; ALTMANN. *Nucl. Acid. Res.*, 1997, vol. 25 (22), 4429-4443 [0039]
- TOULMÉ, J.J. *Nature Biotechnology*, 2001, vol. 19, 17-18 [0039]
- MANOHARAN M. *Biochemica et Biophysica Acta*, 1999, vol. 1489, 117-139 [0039]
- FREIER S. M. *Nucleic Acid Research*, 1997, vol. 25, 4429-4443 [0039]
- UHLMAN, E. *Drug Discovery & Development*, 2000, vol. 3, 203-213 [0039]
- HERDEWIN P. *Antisense & Nucleic Acid Drug Dev.*, 2000, vol. 10, 297-310 [0039]
- N.K CHRISTIENSEN. et al. *J. Am. Chem. Soc.*, 1998, vol. 120, 5458-5463 [0039]
- PRAKASH TP ; BHAT B. *Curr Top Med Chem*, 2007, vol. 7 (7), 641-9 [0039]
- CHO EJ et al. *Annual Review of Analytical Chemistry*, 2009, vol. 2, 241-264 [0039]
- ALTSCHUL et al. *J. Mol. Biol.*, 1990, vol. 215, 403-410 [0044]
- ZHANG ; MADDEN. *Genome Res.*, 1997, vol. 7, 649-656 [0044]
- SMITH ; WATERMAN. *Adv. Appl. Math.*, 1981, vol. 2, 482-489 [0044]
- KORSCHING. *J. Neurosci.*, 1993, vol. 13, 2739 [0056]
- LEIBROCK. et al. *Nature*, 1989, vol. 341, 149 [0056]
- IDE. *Neurosci. Res.*, 1996, vol. 25, 101 [0056]
- DISTEFANO. et al. *Neuron*, 1992, vol. 8, 983 [0056]
- OPPENHEIM. et al. *Nature*, 1992, vol. 360, 755 [0056]
- YAN. et al. *Nature*, 1992, vol. 360, 753 [0056]
- MEYER. et al. *J. Cell Biol.*, 1992, vol. 119, 45 [0056]
- NONOMURA et al. *Brain Res.*, 1995, vol. 683, 129 [0056]
- CHENG, J. et al. *Science*, 2005, vol. 308 (5725), 1149-1154 [0094]
- KAPRANOV, P. et al. *Genome Res*, 2005, vol. 15 (7), 987-997 [0094]
- FIRE et al. *Nature*, 1998, vol. 391, 806-811 [0106]
- TIMMONS ; FIRE. *Nature*, 1998, vol. 395, 854 [0106]
- TIMMONS et al. *Gene*, 2001, vol. 263, 103-112 [0106]
- TABARA et al. *Science*, 1998, vol. 282, 430-431 [0106]
- MONTGOMERY et al. *Proc. Natl. Acad. Sci. USA*, 1998, vol. 95, 15502-15507 [0106]
- TUSCHL et al. *Genes Dev.*, 1999, vol. 13, 3191-3197 [0106]
- ELBASHIR et al. *Nature*, 2001, vol. 411, 494-498 [0106]
- ELBASHIR et al. *Genes Dev.*, 2001, vol. 15, 188-200 [0106]
- TIJSTERMAN et al. *Science*, 2002, vol. 295, 694-697 [0106]
- ZAUG et al. *Nature*, 1986, vol. 324, 429 [0119]
- CECH. *JAMA*, 1988, vol. 260, 3030 [0119]
- JEFFERIES et al. *Nucleic Acids Research*, 1989, vol. 17, 1371 [0119]
- USMAN ; MCSWIGGEN. *Ann. Rep. Med. Chem*, 1995, vol. 30, 285-294 [0120]
- CHRISTOFFERSEN ; MARR. *J. Med. Chem.*, 1995, vol. 38, 2023-2037 [0120]
- ORGEL. *Proc. R. Soc. London*, 1979, vol. B 205, 435 [0122]
- JOYCE. *Gene*, 1989, vol. 82, 83-87 [0122]
- BEAUDRY et al. *Science*, 1992, vol. 257, 635-641 [0122]
- JOYCE. *Scientific American*, 1992, vol. 267, 90-97 [0122]
- BREAKER et al. *TIBTECH*, 1994, vol. 12, 268 [0122]
- BARTEL et al. *Science*, 1993, vol. 261, 1411-1418 [0122]
- SZOSTAK. *TIBS*, 1993, vol. 17, 89-93 [0122]
- KUMAR et al. *FASEB J.*, 1995, vol. 9, 1183 [0122]
- BREAKER. *Curr. Op. Biotech.*, 1996, vol. 7, 442 [0122]
- UHLENBECK, O. C. *Nature*, 1987, vol. 328, 596-600 [0124] [0125]
- HASELOFF ; GERLACH. *Nature*, 1988, vol. 334, 585 [0125]
- WALBOT ; BRUENING. *Nature*, 1988, vol. 334, 196 [0125]
- KOIZUMI, M. et al. *FEBS Lett*, 1988, vol. 228, 228-230 [0125]
- HAMMOND et al. *Nat. Rev. Genet.*, 1991, vol. 2, 110-119 [0128]
- MATZKE et al. *Curr. Opin. Genet. Dev.*, 2001, vol. 11, 221-227 [0128]
- SHARP. *Genes Dev.*, 2001, vol. 15, 485-490 [0128]
- DE MESMAEKER et al. *Acc. Chem. Res.*, 1995, vol. 28, 366-374 [0139]
- DE MESMAEKER et al. *Acc. Chem. Res.*, 1995, vol. 28, 366-374 [0140]
- NIELSEN et al. *Science*, 1991, vol. 254, 1497 [0140]
- MARTIN et al. *Helv. Chim. Acta*, 1995, vol. 78, 486 [0140]

- **KORNBERG, A.** DNA Replication. W. H. Freeman & Co, 1980, 75-77 [0141]
- **GEBEYEHU, G. et al.** *Nucl. Acids Res.*, 1987, vol. 15, 4513 [0141]
- **SANGHVI, Y. S.** Antisense Research and Applications. CRC Press, 1993, 276-278 [0141]
- **LETSINGER et al.** *Proc. Natl. Acad. Sci. USA*, 1989, vol. 86, 6553 [0142]
- **MANOHARAN et al.** *Bioorg. Med. Chem. Lett.*, 1994, vol. 4, 1053 [0142]
- **MANOHARAN et al.** *Ann. N.Y. Acad. Sci.*, 1992, vol. 660, 306 [0142]
- **MANOHARAN et al.** *Bioorg. Med. Chem. Lett.*, 1993, vol. 3, 2765 [0142]
- **OBERHAUSER et al.** *Nucl. Acids Res.*, 1992, vol. 20, 533 [0142]
- **SAISON-BEHMOARAS et al.** *EMBO J.*, 1991, vol. 10, 111 [0142]
- **KABANOV et al.** *FEBS Lett.*, 1990, vol. 259, 327 [0142]
- **SVINARCHUK et al.** *Biochimie*, 1993, vol. 75, 49 [0142]
- **MANOHARAN et al.** *Tetrahedron Lett.*, 1995, vol. 36, 3651 [0142]
- **SHEA et al.** *Nucl. Acids Res.*, 1990, vol. 18, 3777 [0142]
- **MANOHARAN et al.** *Nucleosides & Nucleotides*, 1995, vol. 14, 969 [0142]
- **UHLMAN et al.** *Current Opinions in Drug Discovery & Development*, 2000, vol. 3 (2 [0146]
- **NIELSEN et al.** *Science*, 1991, vol. 254, 1497-1500 [0151]
- **MARTIN et al.** *Helv. Chim. Acta*, 1995, vol. 78, 486-504 [0153]
- The Concise Encyclopedia of Polymer Science And Engineering. John Wiley & Sons, 1990, 858-859 [0156]
- **ENGLISCH et al.** *Angewandte Chemie, International Edition*, 1991, vol. 30, 613 [0156]
- **SANGHVI, Y.S. ; CROOKE, S.T. ; LEBLEU, B. EA.** Antisense Research and Applications. CRC Press, 1993, 289-302 [0156]
- Antisense Research and Applications. CRC Press, 1993, 276-278 [0156]
- **LETSINGER et al.** *Proc. Natl. Acad. Sci. USA*, 1989, vol. 86, 6553-6556 [0159]
- **MANOHARAN et al.** *Bioorg. Med. Chem. Lett.*, 1994, vol. 4, 1053-1060 [0159]
- **MANOHARAN et al.** *Ann. N. Y. Acad. Sci.*, 1992, vol. 660, 306-309 [0159]
- **MANOHARAN et al.** *Bioorg. Med. Chem. Lett.*, 1993, vol. 3, 2765-2770 [0159]
- **OBERHAUSER et al.** *Nucl. Acids Res.*, 1992, vol. 20, 533-538 [0159]
- **KABANOV et al.** *FEBS Lett.*, 1990, vol. 259, 327-330 [0159]
- **SVINARCHUK et al.** *Biochimie*, 1993, vol. 75, 49-54 [0159]
- **MANOHARAN et al.** *Tetrahedron Lett.*, 1995, vol. 36, 3651-3654 [0159]
- **SHEA et al.** *Nucl. Acids Res.*, 1990, vol. 18, 3777-3783 [0159]
- **MANCHARAN et al.** *Nucleosides & Nucleotides*, 1995, vol. 14, 969-973 [0159]
- **MISHRA et al.** *Biochim. Biophys. Acta*, 1995, vol. 1264, 229-237 [0159]
- **CROOKE et al.** *J. Pharmacol. Exp. Ther.*, 1996, vol. 277, 923-937 [0159]
- **BRAZMA ; VILO.** *FEBS Lett.*, 2000, vol. 480, 17-24 [0171]
- **CELIS et al.** *FEBS Lett.*, 2000, vol. 480, 2-16 [0171]
- **MADDEN et al.** *Drug Discov. Today*, 2000, vol. 5, 415-425 [0171]
- **PRASHAR ; WEISSMAN.** *Methods Enzymol*, 1999, vol. 303, 258-72 [0171]
- **SUTCLIFFE et al.** *Proc. Natl. Acad. Sci. U.S.A.*, 2000, vol. 97, 1976-81 [0171]
- **JUNGBLUT et al.** *Electrophoresis*, 1999, vol. 20, 2100-10 [0171]
- **LARSSON et al.** *J. Biotechnol.*, 2000, vol. 80, 143-57 [0171]
- **FUCHS et al.** *Anal. Biochem.*, 2000, vol. 286, 91-98 [0171]
- **LARSON et al.** *Cytometry*, 2000, vol. 41, 203-208 [0171]
- **JURECIC ; BELMONT.** *Curr. Opin. Microbiol*, 2000, vol. 3, 316-21 [0171]
- **CARULLI et al.** *J. Cell Biochem.*, 1998, vol. 31, 286-96 [0171]
- **GOING ; GUSTERSON.** *Eur. J. Cancer*, 1999, vol. 35, 1895-904 [0171]
- **TO, COMB.** *Chem. High Throughput Screen*, 2000, vol. 3, 235-41 [0171]
- **GELLER, A.I. et al.** *J. Neurochem*, 1995, vol. 64, 487 [0184]
- **LIM, F. et al.** DNA Cloning: Mammalian Systems. Oxford Univ. Press, 1995 [0184]
- **GELLER, A.I. et al.** *Proc Natl. Acad. Sci.: U.S.A.*, 1993, vol. 90, 7603 [0184]
- **GELLER, A.I. et al.** *Proc Natl. Acad. Sci USA*, 1990, vol. 87, 1149 [0184]
- **LEGAL LASALLE et al.** *Science*, 1993, vol. 259, 988 [0184]
- **DAVIDSON et al.** *Nat. Genet.*, 1993, vol. 3, 219 [0184]
- **YANG et al.** *J. Virol.*, 1995, vol. 69, 2004 [0184]
- **KAPLITT, M.G. et al.** *Nat. Genet.*, 1994, vol. 8, 148 [0184]
- **NAGAHARA et al.** Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. *Nature Medicine*, 2009, vol. 15 (3), 331-337 [0228]
- **FLOOD et al.** *Physiology & Behavior*, 1995, vol. 58, 819-822 [0231]
- **FLOOD et al.** *Neurobiology of Aging*, 1993, vol. 14, 159-166 [0231]

AGYI EREDETŰ NEUOTRÓF FAKTORRAL (BRAIN-DERIVED NEUOTROPHIC FACTOR, BDNF) ÖSSZEFÜGGŐ BETEGSÉGEK KEZELÉSE A BDNF-FEL KAPCSOLATOS TERMÉSZETES ANTISZENZ TRANSZKRIPTUMOK GÁTLÁSA RÉVÉN

Igénypontok

1. Antiszensz oligonukleotid, amely agyi eredetű neurotróf faktor (BDNF) természetes antiszensz transzkriptumot vesz célba terápiás vegyületként történő alkalmazásra, ahol a BDNF természetes antiszensz transzkriptum egyben BDNFOS transzkriptum, és ahol az antiszensz oligonukleotid növeli az agyi eredetű neurotróf faktor (BDNF) expresszióját.
2. Antiszensz oligonukleotid, amely agyi eredetű neurotróf faktor (BDNF) természetes antiszensz transzkriptumot vesz célba, ahol a BDNF természetes antiszensz transzkriptum egyben BDNFOS transzkriptum, agyi eredetű neurotróf faktorral (BDNF) kapcsolatos betegség vagy rendellenesség megelőzésekor vagy kezelésakor történő alkalmazásra, ahol az említett antiszensz oligonukleotid növeli az agyi eredetű neurotróf faktor (BDNF) expresszióját, ahol a betegség vagy rendellenesség a következőkből álló csoportból kerül kiválasztásra: neuro-otológiai betegség vagy rendellenesség, hallásvesztés, Rett-szindróma, Alzheimer-kór, skizofrénia, Huntington-kór, gerincvelő-sérülés, depresszió, kognitív károsodás, bipoláris zavar, WAGR szindróma és elhízás.
3. Olyan antiszensz oligonukleotid alkalmazása, amely agyi eredetű neurotróf faktor (BDNF) természetes antiszensz transzkriptumot vesz célba, ahol a BDNF természetes antiszensz transzkriptum egyben BDNFOS transzkriptum agyi eredetű neurotróf faktorral (BDNF) kapcsolatos betegség vagy rendellenesség megelőzését vagy kezelését célzó gyógyszer előállítására, ahol az említett antiszensz oligonukleotid növeli az agyi eredetű neurotróf faktor (BDNF) expresszióját, ahol a betegség vagy rendellenesség a következőkből álló csoportból kerül kiválasztásra: neuro-otológiai betegség vagy rendellenesség, hallásvesztés, Rett-szindróma, Alzheimer-kór, skizofrénia, Huntington-kór, gerincvelő-sérülés, depresszió, kognitív károsodás, bipoláris zavar, WAGR szindróma és elhízás.
4. *In vitro* módszer az agyi eredetű neurotróf faktor (BDNF) expressziójának fokozására páciensek sejtjeiben vagy szöveteiben, amely a következőket foglalja magában: az említett sejtek vagy szövetek érintkeztetése olyan antiszensz oligonukleotiddal, amely agyi eredet neurotróf faktor (BDNF) természetes antiszensz transzkriptumot vesz célba, ahol a BDNF természetes

antiszensz transzkriptum egyben BDNFOS transzkriptum, ezáltal növeli az agyi eredetű neurotróf faktor (BDNF) expresszióját.

5. A 3. igénypont szerinti alkalmazás vagy az 1. illetve 2. igénypont szerint alkalmazandó antiszensz oligonukleotid vagy a 4. igénypont szerinti módszer, ahol a természetes antiszensz transzkriptum nukleinsav-szekvenciáját a 2. azonosító számú szekvencia (SEQ. ID. NO: 2) írja le.
6. A 3. vagy az 5. igénypont szerinti alkalmazás, illetve az 1, 2 vagy 5 igénypontok bármelyike szerint alkalmazandó antiszensz oligonukleotid, illetve a 4. vagy 5. igénypont szerinti módszer, ahol az antiszensz oligonukleotid egyszálú, vagy ahol az antiszensz oligonukleotid siRNA vegyület.
7. A 3., 5. vagy 6. igénypontok bármelyike szerinti alkalmazás illetve az 1., 2., 5. vagy 6. igénypontok bármelyike szerint alkalmazandó antiszensz oligonukleotid vagy a 4-6. igénypontok bármelyike szerinti módszer, ahol az antiszensz oligonukleotid a 3., 5., 6., 7. vagy 8. azonosító számú (SEQ. ID. NO.) szekvenciák egyikéből áll.
8. A 3., 5 - 7. igénypontok bármelyike szerinti alkalmazás vagy az 1., 2., 5 - 7. igénypontok bármelyike szerint alkalmazandó antiszensz oligonukleotid vagy a 4-7. igénypontok bármelyike szerinti módszer, ahol az agyi eredetű neurotróf faktor (BDNF) expressziója legalább 10%-kal nő.
9. A 3., 5 - 8. igénypontok bármelyike szerinti alkalmazás vagy az 1., 2., 5 - 8. igénypontok bármelyike szerint alkalmazandó antiszensz oligonukleotid vagy a 4-8. igénypontok bármelyike szerinti módszer, ahol az antiszensz oligonukleotid az alábbiakban felsorolt egy vagy több módosítást is magában foglalja:

a. legalább egy módosított internukleozid kötés, a következők közül kiválasztva: foszforotioát, alkil-foszfónát, foszforoditioát, alkil-foszforotioát, foszforamidát, karbamát, karbonát, foszfát-triészter, acetamidát, karboxi-metil-észter és ezek kombinációja;

b. legalább egy módosított nukleotid, a következők közül kiválasztva: peptid-nukleinsav (PNA), zárt nukleinsav (LNA), arabino-nukleinsav (FANA), valamint utóbbiak analogonja, származéka és azok kombinációi; vagy

c. legalább egy módosított cukor-molekularész, a következők közül kiválasztva: 2'-O metoxi-etil módosított cukor molekularész, 2'-fluor módosított cukor molekularész, 2'-metoxi módosított cukor molekularész, 2'-O-alkil módosított cukor molekularész, biciklusos cukor molekularész és ezek kombinációi.

10. Antiszensz oligonukleotid, amely agyi eredetű neurotróf faktor (BDNF) természetes antiszensz transzkriptumot vesz célba, ahol a BDNF természetes antiszensz transzkriptum egyben BDNFOS transzkriptum, ahol az antiszensz oligonukleotid növeli az agyi eredetű neurotróf faktor (BDNF) expresszióját, ahol az antiszensz oligonukleotid siRNS vegyület.
11. Antiszensz oligonukleotid, amely agyi eredetű neurotróf faktor (BDNF) természetes antiszensz transzkriptumot vesz célba, ahol a BDNF természetes antiszensz transzkriptum egyben BDNFOS transzkriptum, ahol az antiszensz oligonukleotid növeli az agyi eredetű neurotróf faktor (BDNF) expresszióját, ahol az antiszensz oligonukleotid a 3., 5. 6. 7. vagy 8. azonosító számú (SEQ. ID. NO.) szekvenciák egyikéből áll.
12. A 10. vagy a 11. igénypont szerinti antiszensz oligonukleotid, ahol a BDNFOS transzkriptum nukleinsav-szekvenciáját a 2. szekvenciaazonosító (SEQ. ID. NO: 2) szemlélteti.
13. A 11. vagy 12. igénypont szerinti antiszensz oligonukleotid, ahol az antiszensz oligonukleotid egyszálú vagy ahol az antiszensz oligonukleotid siRNS vegyület.
14. A 10-13. igénypontok bármelyike szerinti antiszensz oligonukleotid, ahol az agyi eredetű neurotróf faktor (BDNF) expressziója legalább 10%-kal nő.
15. A 10-14. igénypontok bármelyike szerinti antiszensz oligonukleotid, ahol az antiszensz oligonukleotid az alábbiakból álló egy vagy több módosítást is magában foglalja:
 - a. legalább egy módosított internukleotid kötés, a következők közül kiválasztva: foszforotioát, alkil-foszfónát, foszforoditioát, alkil-foszforotioát, foszforamidát, karbamát, karbonát, foszfát-triészter, acetamidát, karboxi-metil-észter és ezek kombinációja;
 - b. legalább egy módosított nukleotid, a következők közül kiválasztva: peptid-nukleinsav (PNA), zárt nukleinsav (LNA), arabino-nukleinsav (FANA), valamint utóbbiak analogonja, származéka és azok kombinációi; vagy

c. legalább egy módosított cukor-molekularész, a következők közül kiválasztva: 2'-O metoxi-etil módosított cukor molekularész, 2'-fluor módosított cukor molekularész, 2'-metoxi módosított cukor molekularész, 2'-O-alkil módosított cukor molekularész, biciklusos cukor molekularész és ezek kombinációi.

16. A 10., 12-15. igénypontok bármelyike szerinti antiszensz oligonukleotid, ahol az antiszensz oligonukleotid 10 - 30 nukleotid hosszúságú.
17. A 10., 12-16. igénypontok bármelyike szerinti antiszensz oligonukleotid, ahol az antiszensz oligonukleotid legalább 90%-os szekvencia-komplementaritást mutat a BDNFOS transzkriptumhoz viszonyítva.
18. Gyógyászati készítmény, amely legalább egy antiszensz oligonukleotidot tartalmaz a 10-17. igénypontok bármelyike szerint, valamint egy gyógyászatilag elfogadható segédanyag.